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Schizophrenia is a group of severe mental disorders, often with unknown pathological 
mechanisms. Genetic studies implied a connection between schizophrenia and 
Neuregulin-1 (NRG1) signaling, which might become an important drug target. A 
mutation has been identified within the NRG1 gene, which impairs its intracellular 
cleavage. The aim of this study is to find potential substances or compounds that could 
modulate the intracellular cleavage of NRG1. The NRG1 cleavage assay was developed 
from live cell assays into 96-well format and finally into 384-well format using robotics. 
The drug library for screening was the NIH Clinical Collection, of which all compounds 
are already approved by the American Food and Drug Administration (FDA). These 
drugs have passed clinical trials, so it may accelerate clinical application of validated 
hits. In this study, promising compounds were identified that have been used in the 
treatment of psychiatric diseases, such as Citalopram as an activator, or Ifenprodil, 
Perphenazine, Pamelor, Annoyltin as inhibitors of NRG1 cleavage. Additional 
validation of these compounds will be conducted, and once all critical controls are 
performed, the compounds may be applied in mouse models of schizophrenia and even 
clinical studies. 
Abstract 
Schizophrenie ist eine Gruppe von schweren psychischen Störungen, oft mit 
unbekannten pathologischen Mechanismen. Genetische Studien ließen auf eine 
Verbindung zwischen Schizophrenie und Neuregulin-1 (NRG1) schließen, die ein 
wichtiges Drug-Target werden könnte. Eine Mutation wurde im NRG1-Gen identifiziert, 
welche seine intrazelluläre Spaltung beeinträchtigt. Das Ziel dieser Studie ist, 
potentielle Substanzen oder Compounds zu finden, die die intrazelluläre Spaltung von 
NRG1 modulieren können. Der NRG1 Spaltungs-Assay wurde vom Lebendzell-Assays 
in 96-Well-Platten und schließlich in 384-Well-Platten für automatisiertes Screening 
adaptiert. Die Medikamentendatenbank „NIH Clinical Collection“ enthält Substanzen, 
von denen alle bereits von der amerikanischen Food and Drug Administration (FDA) 
zugelassen sind. Diese Compounds haben klinische Studien durchlaufen, so dass 
eventuelle klinische Applikation von wirksamen Substanzen beschleunigt werden kann. 
In dieser Studie werden vielversprechende Hits identifiziert, die schon bei der 
Behandlung von psychiatrischen Erkrankungen verwendet werden, wie zum Beispiel 
Citalopram als Aktivator, oder Ifenprodil, Perphenazine, Pamelor, Annoyltin als 
Inhibitoren der NRG1-Spaltung. Zusätzliche Validierungen dieser Compounds sind 
notwendig, um diese dann in Mausmodellen der Schizophrenie und schlussendlich in 






Schizophrenia is a complex mental disorder that causes a range of different 
psychological symptoms, including positive symptoms, negative symptoms, and 
cognitive dysfunction (Tandon et al. 2013). Positive symptoms represent a change in 
behavior or thoughts such as hallucinations, delusions, or other reality distortions 
(Tandon, Nasrallah, and Keshavan 2009). Negative symptoms involve a withdrawal or 
lack of affective function so that people with schizophrenia often appears emotionless, 
flat, and apathetic (Tandon, Nasrallah, and Keshavan 2009). Cognitive dysfunction 
describes deficits in global intellectual performance or in cognitive abilities, such as 
learning disorder or memory impairment (Hegde et al. 2013; Aquila and Citrome 2015). 
The diagnostic criteria for schizophrenia are based on the clinical manifestation, since 
there is no known pathognomonic biological marker (Tandon et al. 2013). Clinicians 
and researchers use the Diagnostic and Statistical Manual of Mental Disorder (DSM) as 
a manual to diagnose and classify mental illness (Table 1). In DSM-5, schizophrenia 
subtypes (paranoid, disorganized, catatonic, undifferentiated, and residual) no longer 
belong to the diagnostic criteria.  
The causes of schizophrenia are multifactorial, involving neurobiological, psychological, 
social, environmental, and genetic factors (Paul J. Harrison and Owen 2003; Kuswanto 
et al. 2015). These exemplary factors, such as prenatal health issues (prenatal stress, 
prenatal infection, intrauterine malnutrition, brain hypoxia), infections, drugs (cannabis, 
hallucinogens, alcohol), smoking, and many other factors are shown to contribute to 
development of schizophrenia (Ameri 1999; Stathopoulou, Beratis, and Beratis 2013; 
Nielsen, Meyer, and Mortensen 2016). Evidence also supports elevated prenatal and 
family environmental disruptions in families with a first-degree relative with 
schizophrenia (Walder et al. 2014).  
Genetics also play a significant role in the development of schizophrenia. Some studies 
suggested that several susceptibility genes have been identified, including neuregulin 
(NRG), dysbindin, ERBB4, COMT, DISC1, RGS4, GRM3, and DAO (Chumakov et al. 
2002, 30; Williams et al. 2003; Stefansson et al. 2004; P. J. Harrison and Weinberger 
2005; D. Li and He 2007, 30; Lu et al. 2010). Recently, a mutation has been found in 




2010). The identification of this mutation has provided a useful starting point to learn 
more about the pathological mechanism of schizophrenia (Mei and Xiong 2008).  
Identification of risk loci that associated with schizophrenia is done with genome-wide 
association study (GWAS). In this case, GWAS examines the genetic variants (e.g. 
single-nucleotide polymorphism) and its connection with schizophrenia by comparing 
the DNA of two groups of different individuals. The participants in this study are the 
patients with schizophrenia and the healthy ones for control. If the genetic variant is 
more frequent in patients, then that variant might be associated with the disease. 
Research of these associated genes may lead to better understanding of the 
pathophysiological and etiological of the disease and the development of more effective 
treatments (Bergen and Petryshen 2012; Bush and Moore 2012; Ripke et al. 2014; Paul 
J Harrison 2015). 
A genome-wide scan in Icelandic population provided the first genetic evidence, 
suggesting a linkage of schizophrenia to NRG1 (Stefansson et al. 2002). The affected 
individuals were estimated to have 2.2 times the risk, as compared to controls 
(Stefansson et al. 2002). There is also a strong correlation between NRG1 and 
schizophrenia in Chinese population (Tang et al. 2003; Yang et al. 2003). However, the 
follow-up studies in different population, such as Scotland and Wales, showed lower 
ratio than that in Iceland (Stefansson et al. 2003; Williams et al. 2003). It was also 
confirmed that in Japanese population, there was no association between NRG1 and 
schizophrenia (Iwata et al. 2003). This highlights the fact that NRG1 is not necessarily 
related to all cases of schizophrenia. There are also other numerous genes that 
contribute in this complex disease (Corfas, Roy, and Buxbaum 2004). 
Mutation of these genes results in disruption or dysregulation of the following pathways. 
Impaired NRG1-ERBB4 signaling affects both excitatory and inhibitory synaptic 
transmission in the adult brain (Mei and Xiong 2008; Mei and Nave 2014). The 
resulting abnormalities of altered neurotransmission and cortical function may cause  
psychotic symptoms and cognitive impairments during development, which can be 
observed in mouse models (Rimer et al. 2005; Arguello and Gogos 2006; Bjarnadottir et 






Table 1. Diagnostic criteria for schizophrenia from DSM-5. Modified from (Tandon et al. 2013). 
   
2.2 Neuregulins and ERBB4 
2.2.1 Neuregulin 
Neuregulins (NRGs) are signaling proteins that comprise a family of epidermal growth 
factor (EGF)-like proteins (Mei and Nave 2014). The encoding gene for NRG1 is 
located on the short arm of chromosome 8 (Falls 2003). Neuregulins have multiple 
biological functions, which are essential for embryogenesis (Burden and Yarden 1997). 
Together with its receptors ERBB3-4, neuregulins play a role in the cardiac 
development by helping with the formation of the heart trabeculae (Gassmann et al. 
1995; Burden and Yarden 1997). Neuregulins also influence the differentiation of 
Schwann cells and oligodendrocytes in the myelination of neurons (Vartanian, 
Fischbach, and Miller 1999). Furthermore, neuregulins contribute in neuromuscular 
synapse formation by stimulating the transcription of acetylcholine receptor (AchR) 




Two (or more) of the following, each present for a significant portion of time during a 1-month period (or less if 
successfully treated). 
At least one of these should include 1-3 
1. Delusions 
2. Hallucinations 
3. Disorganized speech 
4. Grossly disorganized or catatonic behavior 
5. Negative symptoms (i.e., diminished emotional expression or abolition) 
Criterion B 
Social/occupational dysfunction 
For a significant portion of the time since the onset of the disturbance, one or more major areas of functioning, 
such as work, interpersonal relations, or self-care, are markedly below the level achieved prior to the onset (or 
when the onset is in childhood or adolescence, failure to achieve expected level of interpersonal, academic, or 
occupational achievement). 
Criterion C  
Duration of 6 months 
Continuous signs of the disturbance persist for at least 6 months. This 6-month period must include at least 1 
month of symptoms (or less if successfully treated) that meet Criterion A (i.e., active-phase symptoms) and may 
include periods of prodromal or residual symptoms. During these prodromal or residual periods, the signs of the 
disturbance may be manifested by only negative symptoms or by two or more symptoms listed in Criterion A 
present in an attenuated form (e.g., odd beliefs, unusual perceptual experiences). 
Criterion D 
Schizoaffective and mood disorder exclusion 
Schizoaffective disorder and depressive or bipolar disorder with psychotic features have been ruled out because 
either (1) no major depressive or manic episodes have occurred concurrently with the active phase symptoms; or 
(2) if mood episodes have occurred during active-phase symptoms, their total duration has been brief relative to 
the duration of the active and residual periods. 
Criterion E  
Substance/general mood condition exclusion 
Substance/general medical condition exclusion: The disturbance is not attributed to the direct physiological 
effects of a substance (e.g., a drug of abuse, a medication) or another medical condition. 
Criterion F 
Relationship to Global Developmental Delay or Autism Spectrum Disorder 
 
If there is a history of autism spectrum disorder or other communication disorder of childhood onset, the addition-
al diagnosis of schizophrenia is made only if prominent delusions or hallucinations are also present for at least 1 




The neuregulin family has four members: NRG1, NRG2, NRG3, and NRG4 (Falls 
2003). NRG1 is the best characterized among these. Each NRG gene produces multiple 
isoforms by differential splicing and the use of alternative promoters and transcriptional 
start sites. For example, NRG1 generates more than 30 different proteins (Mei and 
Xiong 2008) (Figure 1). Each type of NRG1 isoform has an EGF-like domain that 
activates ERBB receptor tyrosine kinases (Falls 2003).  
Fully synthesized NRG1 isoforms are called pro-NRG1s. Most of them are single 
transmembrane proteins, with the EGF-like domain located in the extracellular region. 
NRG1 Type III is unique among other NRG1 proteins because it has not only one but 
two transmembrane domains, forming a so-called hairpin. Both its N- and C-terminal 
regions are located intracellular. NRG1 Type III also has a cysteine-rich domain (CRD), 
whose hydrophobic segment serves as the second transmembrane domain (N- terminal 
transmembrane domain) (Falls 2003). 
When pro-NRG1s undergo proteolytic cleavage, a mature NRG1 (Ecto-NRG1) is 
released that contains the EGF-like domain and is soluble, except in the case of NRG1 
Type III. Because of its hairpin nature, the EGF-like domain is still membrane-tethered 
with the N-terminal fragment of NRG1 Type III (NRG1-NTF) (Falls 2003). It was later 
revealed that the EGF-like domain of NRG1 Type III can be released from its NRG1-






Figure 1: Different types of NRG1 isoforms. (a) The six types of NRG1 isoforms are classified 
according to their distinct amino-terminal sequences. Every single isoform has EGF-like domain. Type III 
NRG1 has a transmembrane domain within the cysteine-rich domain (CRD). Type I, II, IV, and V have 
immunoglobulin-like domain (Ig), with or without the spacer region (S). (b) Most NRG1 isoforms are 
synthesized as a transmembrane protein (pro-NRG1s) with the EGF-like domain located extracellular. 
Type III has both its N- and C-terminal fragment located intracellular. Extracellular cleavage by tumor 
necrosis factor-α converting enzyme (TACE) or β-site amyloid precursor protein cleaving enzyme 1 
(BACE1) (indicated by the lightning arrow) generates a soluble mature NRG1, except for NRG1 Type III. 
The processing of NRG1 Type IV, V, and VI is still unclear, but is thought to resemble that of Type I and 










2.2.2    ERBB4 
ERBB proteins belong to the superfamily of receptor tyrosine kinases (RTKs). ERBB 
receptor is structurally similar to its founding member, epidermal growth factor receptor 
(EGFR), also known as ERBB1. ERBB family of proteins in humans includes HER1 
(EGFR, ERBB1), HER2 (NEU, ERBB2), HER3 (ERBB3), and HER4 (ERBB4). Each 
member of the family has an extracellular ligand-binding domain, a single 
transmembrane region, and a cytoplasmic protein tyrosine kinase domain (Cho and 
Leahy 2002; Mei and Xiong 2008).   
After ligands of the EGF family bind the extracellular domain of ERBB receptors, the 
ERBB proteins dimerize to form homo- or heterodimers. ERBB1 does not bind to 
NRG1, but can form a heterodimer with ERBB4. ERBB2 also does not bind to NRG1, 
but can form heterodimer with all other ERBBs. ERBB3 can bind to NRG1 but has 
impaired kinase activity, so it needs to form a heterodimer either with ERBB2 or 
ERBB4 in order to be functional. Only ERBB4 can bind to NRG1 as a homodimer. 
Dimerization triggers autophosphorylation of specific tyrosine residue in the 
cytoplasmic domain. The intracellular signaling cascade begins eventually (Olayioye 
2000; Bublil and Yarden 2007; Mei and Xiong 2008). Figure 2 refers to the domain 
structure and proteolytic processing (that is very similar to the cleavage of NRG1) of 
ERBB4. 
Among NRG1s receptors, ERBB4 is of particular interest due to its crucial role in 
neurodevelopment (Anton et al. 2004). Research has also found an association between 
a particular single nucleotide polymorphism (SNP) in the ERBB4 gene and 
schizophrenia (Lu et al. 2010).  
Loss of ERBB proteins results in embryonic or perinatal lethality in mice, depending on 
its type. It also contributes to cardiac, sexual, and neuronal development (Olayioye 
2000). Overexpression of ERBB receptors, especially ERBB2/HER2, is found in many 
human cancers, especially in breast cancer. A monoclonal antibody against 
ERBB2/HER2 receptor, called Trastuzumab (Herceptin), is a choice of treatment for 





Figure 2: Domain structures of ERBB4. (a) Exon numbers are displayed above the domain structures. 
Inclusion of exon 26 generates CYT-1. Exclusion of it generates CYT-2. The extracellular juxtamembrane 
region is encoded either by exon 15 or exon 16 to produce JMb or JMa respectively. This combination 
makes four possible isoforms of ERBB4. (b) CYT-1 has the ability to bind to phosphoinositide 3-kinase 
(PI3K) and activates the signaling pathway (Junttila et al. 2000). Both JMa and JMb can be activated by 
NRG1, but only JMa can be cleaved by tumor necrosis factor-α converting enzyme (TACE) (indicated by 
the lightning arrow) (Rio et al. 2000). The cleavage produces a soluble Ecto-ERBB4 and a membrane-
anchored C-terminal fragment of ERBB4 (ERBB4-CTF). CRD, cysteine-rich domain; TM, 











2.3   NRG1 signaling 
NRG1/ERBB4 signaling plays a critical role in neural development. Impairment of this 
signaling network has been thought to be connected to psychiatric diseases such as 
schizophrenia (Hahn et al. 2006). Studies also showed that abnormal NRG1/ERBB4 
signaling is detected in postmortem brains of patients with schizophrenia (Hahn et al. 
2006). There are three types of NRG1 signaling: canonical forward signaling, non-
canonical forward signaling, and backward signaling. Therefore, signaling between 
NRG1 and ERBBs (and perhaps between RTKs and their ligands in general) should be 
considered as bidirectional. 
2.3.1    Canonical forward signaling 
The soluble Ecto-NRG1 contains the EGF-like domain, which is necessary for the 
activation of ERBB receptor tyrosine kinases. Upon stimulation by NRGs, the ERBB 
proteins form homo- or heterodimer (see above). The activation of the tyrosine kinase 
domains leads to phosphorylation of the intracellular domain, resulting in the initiation 
of signaling pathways. The main signaling cascades downstream of NRG1-ERBB4 are 
the mitogen-activated protein kinase (MAPK) pathways (e.g. via Raf-MEK-ERK) and 
the phosphoinositide 3-kinase (PI3K)/Protein Kinase B (PKB, also known as AKT) 
pathway (Earp et al. 1995; Y. Liu et al. 2007). 
2.3.2    Non-canonical forward signaling 
The extracellular cleavage of ERBB4 can be induced by binding with NRG1 as its 
ligand, or by protein kinase C (PKC) activation (Vecchi and Carpenter 1997; Ni et al. 
2001). The cleavage requires a metalloprotease called tumor necrosis factor-α 
converting enzyme (TACE, or ADAM 17). It is an enzyme that belongs to the ‘a 
disintegrin and metalloprotease’ family (ADAM) (Rio et al. 2000). Only the 
extracellular juxtamembrane-a (JMa) isoform of ERBB4, not the juxtamembrane-b 
(JMb) isoform, can be cleaved by TACE (Rio et al. 2000). ERBB4 protein, cleaved by 
TACE, produces Ecto-ERBB4, which is soluble, and ERBB4-CTF, which is still 
membrane-anchored. The C-terminal fragment of ERBB4 (ERBB4-CTF) is further 
cleaved by an enzyme called γ-secretase in its transmembrane domain, leaving ERBB4-
β and ERBB4-ICD. The soluble intracellular domain of ERBB4 (ERBB4-ICD) can 
translocate into the nucleus and regulate transcription (Ni et al. 2001; Sardi et al. 2006). 




a number of proteins such as amyloid precursor protein (APP), voltage-gated sodium 
channel (VGSC) β, Interleukin-1 Receptor II (IL-1R2), and NRG1 (see below) (Wong et 
al. 2005; Kuhn et al. 2007). 
2.3.3    Backward signaling 
The pro-NRG1s undergo a similar proteolytic processing as the ERBBs (Mei and Xiong 
2008). After the cleavage of the extracellular domain of pro-NRG1, the remaining 
membrane-anchored region (NRG1-CTF) can be further cleaved by γ-secretase to 
release the intracellular domain of NRG1 (NRG1-ICD) from the membrane. These 
proteolytic cleavages can also be stimulated by ERBB4 binding or neuronal membrane 
depolarization. Considering that the transmembrane isoforms of pro-NRG1 are 
bidirectional signaling function, the pro-NRG1 can act as a receptor for the ERBB4 
ligand, either as a soluble Ecto-ERBB4 or as a transmembrane form (Bao et al. 2003; 
Mei and Xiong 2008; Canetta et al. 2011). Afterwards, the NRG1-ICD translocates to 
the nucleus to regulate gene expression (Bao et al. 2003; Mei and Xiong 2008) (Figure 
3). 
Signaling via the NRG1-ICD has not been fully characterized. There is some evidence 
that NRG1-ICD contributes to neural and cardiac development (X. Liu et al. 1998). 
Research also supports the signaling function of NRG1-ICD (Chong et al. 2008). Once 
in the nucleus, the NRG1-ICD represses expression of several regulators of apoptosis 
(Weinstein and Leder 2000; Bao et al. 2003). NRG1-ICD also forms specific complexes 
with cytoplasmic proteins, in particular with Lin11, Isl-1, & Mec-3 (LIM) kinase 1, 
which helps in controlling the organization of actin filaments (Wang et al. 1998; 
Sparrow et al. 2012). Another publication indicates that NRG1-ICD enhances the 
transcriptional activity of the PSD 95 promoter by binding to a zinc finger transcription 





Figure 3: NRG1-ERBB4 signaling. In canonical forward signaling (bottom cell, left-hand pathway), 
binding of a mature NRG1 activates ErbB4 tyrosine kinase receptor to form a homodimer. The 
subsequent autophosphorylation of intracellular domain leads to signaling pathways, such as extracellular 
signal-regulated kinase (ERK) pathway or phosphoinositide 3-kinase (PI3K) pathway. In non-canonical 
forward signaling (bottom cell, right-hand pathway), ErbB4 is cleaved by TACE and produces soluble 
Ecto-ERBB4 and ERBB4-CTF. ERBB4-CTF is further cleaved by γ-secretase to generate ERBB4-β and 
ERBB4-ICD, which translocates to the nucleus to regulate gene expression. Backward signaling (top cell) 
by pro-NRG1 can proceed through enzymatic cleavage (left-hand pathway) and can be stimulated by 
ERBB4 binding (right-hand pathway). The released NRG1-ICD from NRG1-CTF relocates to the nucleus 
and regulates gene transcription. The cytoplasmic tail of pro-NRG1 can also interact with the protein 








2.4    NRG1 cleavage 
The pro-NRG1 can be extracellularly cleaved by β-site amyloid precursor protein 
cleaving enzyme 1 (BACE1), ADAM10, or TACE (ADAM17) (Fleck et al. 2012, 2013). 
BACE1 is a protease that plays a role in Alzheimer’s disease. BACE1 cleaves 
extracellularly the amyloid precursor protein (APP), generating a soluble extracellular 
fragment and a membrane bound fragment. The γ-secretase cleaves at its 
transmembrane domain, releasing the intracellular domain of APP and amyloid-β 
peptide (Aβ). This accumulation of amyloid-β peptides are found in the brain of 
Alzheimer’s patient. Considering the relationship of Aβ and BACE1, the inhibition of 
BACE1 should reduce the level of Aβ generation, which can be used as a treatment for 
patients of Alzheimer’s disease (Cui et al. 2015; Hu et al. 2016). However, the side-
effects due to many other substrates of BACE1 must be taken into account. 
NRG1 has also been identified as BACE1 substrate, besides APP, type II α-2,6-
sialyltransferase (ST6Gal-1), platelet selectin glycoprotein ligand-1 (PSGL-1), and 
interleukin receptor type II (Kitazume et al. 2001; Lichtenthaler et al. 2003; Hu et al. 
2006; Willem, Lammich, and Haass 2009). Together, BACE1 and NRG1 are essential in 
cardiac and neuronal development. BACE1 is required for peripheral nerve myelination 
through NRG1 Type III processing (Hu et al. 2006; Willem et al. 2006). Because of this 
physiological function of BACE1, therapeutic enzyme inhibition as a therapy for 
Alzheimer’s patient must be done with extreme caution.  
Most of the NRG1 isoforms release a soluble Ecto-NRG1, which contain the EGF-like 
domain to stimulate paracrine signaling, and leaving a membrane-anchored domain 
called NRG1-CTF (C-terminal fragment). In the case of NRG1 type III, both the N-
terminal fragment and the C-terminal fragment are still membrane bound after the 
extracellular cleavage because of its hairpin form, suggesting signaling in a juxtacrine 
(direct-contact) manner, whereas the other types of NRG1 are specialized in paracrine 
signaling (Falls 2003). Recent studies have shown that a dual cleavage by BACE1 and 
TACE liberates the EGF-like domain of NRG1 type III from the membrane anchor and 
also allows paracrine signaling (Fleck et al. 2013). 
The NRG1-CTF is further cleaved by γ-secretase in its transmembrane domain, starting 
at the ε-like site and ending at the γ-site. This intramembrane cleavage creates NRG1-
ICD, which is involved in backward signaling, and a NRG1-β peptide (Fleck et al. 





Figure 4: Cleavage processing of NRG1 Type III. Extracellular cleavage by ADAM10/17 generates 
NRG1-NTF (N-terminal fragment) and NRG1-CTF (C-terminal fragment). NRG1-NTF can be further 
cleaved by ADAM17 and BACE1 to liberate EGF-like domain from membrane-tethered NRG1-NTF. 
NRG1-CTF is cleaved by γ-secretase in the transmembrane domain and releases NRG1-β and NRG1-ICD. 
Modified from (Fleck et al. 2016).   
 
Figure 5: Identified cleavage sites of NRG1 Type III. (a) Cleavage sites by respective proteases are 
marked by arrows. (b) Intramembrane cleavage sites by γ-secretase at ε-like site (blue arrow) and at γ-like 
sites (green arrows). A single nucleotide polymorphism (Valine to Leucine) in the transmembrane domain 
is also represented (yellow arrow). CRD, cysteine-rich domain; EGF, epidermal growth factor; TMD, 





2.5    NRG1 mutation in schizophrenia 
NRG1 has been identified as a susceptibility gene for schizophrenia in several 
populations (Stefansson et al. 2002, 2003). Research has found that there is a mutation 
within the transmembrane domain of NRG1 Type III. A particular  SNP causes an amino 
acid change from valine to leucine at residue 321(Walss-Bass et al. 2006; Y. Chen et al. 
2010). This valine-to-leucine substitution is associated with increased risk of 
schizophrenia in humans (Walss-Bass et al. 2006; Y. Chen et al. 2010). The mutation 
results in an accumulation of NRG1-CTF, suggesting that the γ-secretase cleavage is 
compromised (Fleck et al. 2016). Moreover, this mutation does not only reduce the 
generation of NRG1-ICD, but also affects the cleavage precision of γ-secretase (Fleck et 
al. 2016). The following defective backward signaling might impair a subset of NRG1 
functions in cortical development and contribute to abnormal neuroconnectivity 
involved in schizophrenia (Y. Chen et al. 2010).  
There are several reports indicating that overexpression of NRG1 in mice may 
contribute to the development of schizophrenia (Deakin et al. 2009; Weickert et al. 
2012). Elevated level of NRG1-ICD protein is also found in the brain of schizophrenic 
patients (Chong et al. 2008). Other reports state that a decreased expression of NRG1 
Type III may lead to hypomyelination in several brain regions (Taveggia et al. 2008; 
Makinodan et al. 2012) and some behavioral alterations that are also connected to 
schizophrenia (Y.-J. J. Chen et al. 2008).  In behavioral studies, hypomorphic NRG1 
mutant mice displayed hyperactivity in multiple tests, which can be suppressed by 
clozapine, an antipsychotic drug used to treat schizophrenia (Gerlai, Pisacane, and 
Erickson 2000; Stefansson et al. 2002). Another study said hypomorphic ErbB4 mutant 
mice showed hypoactivity syndrome (Golub, Germann, and Lloyd 2004). These results 
suggested an inverted U-shaped effect, in which both over- and under-expressing mice 
showed suspicious behavior related to schizophrenia (Deakin et al. 2009). This inverted 
U-shaped model has also been hypothesized for NRG1 signaling in relation to synaptic 








2.6    NRG1 cleavage assay 
NRG1 cleavage assay is focused on the backward signaling of NRG1, using a 
luciferase-based reporter gene assay. Reporter gene assays are used to analyze the 
NRG1 cleavage indirectly through luciferase expression (Figure 6). Luciferase is an 
enzyme that catalyzes a reaction with its substrate luciferin to produce bioluminescence. 
This luminescence can be measured using existing equipment. 
The assay was established in a rat adrenal pheochromocytoma cell line called PC12 
(Greene and Tischler 1976). The intracellular domain of NRG1 type I and type III is 
tagged with the Gal4-VP16 (GV) transcriptional activator. Gal4-VP16 is a hybrid 
protein that combines a DNA-binding fragment of the yeast activator (Gal4) and herpes 
simplex virus protein VP16 (also known as Vmw65) (Sadowski et al. 1988, 4). After the 
γ-secretase cleavage, the NRG1-ICD-GV will translocate to the nucleus and bind 
specifically to the clustered upstream activating sequence (UAS) (Duffy 2002). The 
UAS is fused with the reporter gene luciferase, activating its transcription (Webster et al. 
1988) (Figure 6).  
The luciferase activity was first measured in living cells with a LumiCycle 32-channel 
Luminometer (Actimetrics). The luciferase induction kinetics provided some crucial 
information, such as timing of optimal NRG1 cleavage and conditions of cleavage 
stimulation or inhibition. The assay was also adapted in both 96-well and 384-well 
microplates and could be measured using a microplate reader (Berthold Technologies). 
Potential constructs or compounds that were identified during the experiments were 
added as controls for the screen. The drug screen was then performed to find the 






Figure 6: NRG1 cleavage assay. An example of NRG1 Type III construct. The cytoplasmic tail is fused 
with GV. After the γ-secretase cleavage, NRG1-ICD is released and translocate into the nucleus. GV 
binds specifically to UAS, eventually resulting in activation of the luciferase expression. The luciferase 
activity will be measured with LumiCycle or a microplate reader. CRD, cysteine-rich domain; EGF, 
epidermal growth factor; GV, Gal4-VP16; ICD, intracellular domain; UAS, upstream activating sequence. 




















3 Aim of the study 
Schizophrenia is a psychiatric disorder that seriously affects the lives of the patients. 
Medication that can alleviate positive symptoms and cognitive deficits has yet to be 
found. Genetic studies contribute towards researching the pathophysiological 
mechanisms of schizophrenia. NRG1 and ERBB4 have been identified as susceptibility 
genes. Association of defective NRG1-ERBB4 signaling and neurological dysfunction 
implicated in schizophrenia has been confirmed by many studies. These findings signify 
the importance of this mechanism, which might eventually lead to new drug 
developments and therapeutics for patients with de-regulated NRG1-ERBB4 signaling. 
The aim of this study was to establish a robust and sensitive NRG1 intracellular 
cleavage assay in a plate format suitable for high-throughput screening (HTS). The 
assay was first tested with different constructs and compounds to find precise conditions 
in which the cleavage is stimulated or inhibited. The protocols were adapted to both 96-
well and 384-well format, and a small molecule screen was performed including 
previously identified positive and negative controls. 
As compound library, the National Institutes of Health (NIH) clinical collection was 
used, which consists of 727 small molecules. The screen was performed to find 
potential modulators of NRG1 processing from the compound library, both as activators 
and inhibitors. Once potential hits have been identified, they will undergo several 
secondary assays for validation. Since the Food and Drug Administration (FDA)-
approved drugs from the compound library have already passed the preclinical and 
clinical trials, the validated compounds can be quickly tested on animal models and 
eventually on human. Moreover, these compounds might have a new potential that 











4 Materials and Methods  
4.1 Materials 
4.1.1 Chemicals and reagents  









Coelenterazin  PJK 
Coenzyme A PJK 
DAPT Enzo Life Sciences 
Dialyzed FBS Life Technologies 
D-Luciferin PJK 
DMEM, 1 g/L Glucose, 500 ml Lonza 
DMSO Merck 
DNA Ladders (100 bp, 1kb) Thermo Scientific 
DTT PJK 
EDTA Sigma 
Ethanol  Sigma 
EtOH Merck 
GlutaMAX Life Technologies 
HCl Merck 




Lipofectamine 2000 Life Technologies 





Opti-MEM Life Technologies 
Passive Lysis Buffer (PLB) Promega 
PBS Biochrom 
Penicillin Sigma 
Poly-L-lysine Hydrobromide Sigma-Aldrich 
Streptomycin Sigma 
TAPI-1 Sigma Aldrich 
Tricine Merck 
Trypan blue Sigma 
Trypsin 2,5 % (10X) Life Technologies 




4.1.2 Laboratory equipment 
Table 3. List of laboratory equipment used 
 
4.1.3 Plasmids 
Table 4. List of plasmids used 
 
4.1.4 Restriction enzymes 







Centrifuge 5810 R Eppendorf 
Delfia Plate shake Wallac 
Microscope Primovert Zeiss 
Finnpipette F1 Multichannel-pipette Thermo Scientific 
Heraeus Megafuge 16 Centrifuge Thermo Scientific 
Heracell 240i CO2 incubator Thermo Scientific 
LumiCycle 32-channel Luminometer Actimetrics 
BioPhotometer 6131 Eppendorf 
Safe 2020 Class II Biological Safety Cabinets Thermo Scientific 
Picodrop Picodrop 
Automated liquid handling system Microlab STAR Line Hamilton Robotics 
Luminometer  Berthold Technologies 








pcDNA3.1  pcDNA 
TK Renilla TC35 TK Renilla 
Enzyme Sequence Supplied NEBuffer 
BsrGI T/GTACA NEBuffer 2.1 
HindIII-HF A/AGCTT CutSmart Buffer 
HpaI GTT/AAC CutSmart Buffer 
NcoI C/CATGG NEBuffer 3.1 
PstI-HF CTGCA/G CutSmart Buffer 




4.1.5 Ready-made systems (Kits) 
Table 6. List of kits used 
 
4.1.6    Mammalian cell lines 
PC12 rat adrenal medulla pheochromocytoma cell line 
 
4.1.7    Solutions and buffers 
4.1.7.1    Solutions for cell culture 
PC12 growth medium 
DMEM (1g/L Glucose)    500 ml 
FBS       10 % 
Horse Serum      5 % 
GlutaMAX      1 % 
Penicillin/Streptomycin    1 % 
 
PC12 antibiotic free medium 
DMEM (1g/L Glucose)    500 ml 
FBS       10 % 
GlutaMAX      1 % 
 
PBS (1x) 
PBS powder      9.55 g 
ddH2O      1 L 
Adjust to pH 7.2 with 1 M NaOH 
 
PLL (0.02 mg/ml) 
Dilute PLL with ddH2O to a concentration of 5 mg/ml 
Aliquot in 1 ml volumes and freeze at -20°C 
To create working solutions (0.02 mg/ml) dilute the aliquots 1:250 with ddH2O 
Store in 50 ml falcons at -20°C 
 
Name Manufacturer 
NucleoBond Xtra Midi EF Macherey-Nagel 




Trypsin-EDTA (10x, 100 ml) 
Trypsin      5 g 
EDTA       6.85 mM 
Dilute Trypsin-EDTA 1:10 with PBS 
Store in 50 ml aliquots at -20°C 
 
4.1.7.2    Solutions for luciferase assay 
Firefly Luciferase Assay buffer (according to (Gaunitz and Papke 1998))  
 
for 500 ml for 1500 ml  
Tricine      20 mM  1792 mg  5376 mg  
(MgCO3)4*Mg(OH)2*5H2O    1.07 mM  260 mg  780 mg  
(Magnesiumcarbonate-Hydroxide-Pentahydrate)  
MgSO4      2.67 mM  329 mg  987 mg  
EDTA      0.1 mM  100 μl (0.5 M) 300 μl  
DTT       33.3 mM  2570 mg  7710 mg  
Coenzyme A      270 μM  105 mg  315 mg  
D-Luciferin, free acid    470 μM 66 mg   198 mg  
ATP       530 μM  146 mg  438 mg  
 
To solve (MgCO3)4*Mg(OH)2*5H2O, adjust the pH value using HCl (37%, ~1.5 ml for 
1.5 l) until the solution becomes clear. Afterwards, adjust the pH value to 7.8 using 5M 
NaOH (~10 ml for 1.5 l).  
Add D-Luciferin and Coenzyme A afterwards, and then check pH. 
Store buffers at -20°C without light, thaw at room temperature for use.  
 
Renilla Luciferase Assay buffer  
 
for 500 ml   for 1500 ml  
NaCl      1.1 M   32.15 g   96.45 g  
Na2-EDTA     2.2 mM  2.2 ml (0.5 M)  6.6 ml   
KxPO4 (pH 5.1)    0.22 M  110 ml 1 M KH2PO4 330ml  
BSA      0.44 mg/ml  220 mg   660 mg  
NaN3      1.3 mM  42.25 mg   126.75 mg  
Coelenterazin (solved in EtOH)  1.43 mM  300 μl Stock  900 μl  
 
KxPO4 (pH 5.1): 1M KH2PO4, adjust the pH value to 5.1 using 2 M KOH (~20 ml for 
1.5 l).  
Adjust the pH value to 5.0. 
Add Coelenterazin afterwards.  
Coelenterazin stock: 1mg/ml in EtOH, store at -20°C.  
Store buffers at -20°C without light, thaw at room temperature for use. 
Lysis Buffer 
Passive lysis buffer (5x)  





4.2    Methods 
4.2.1    Molecular biological techniques 
4.2.1.1    Transformation of bacteria 
Chemically competent bacteria (i.e. XL1 blue or DH5α) are stored in a -80°C laboratory 
freezer. The aliquot was thawed on ice and the ThermoMixer was set to 42°C. The LB 
medium (without antibiotic) was warmed up to 37°C in a water bath. The LB plates 
containing the appropriate antibiotic were placed in the incubator.  100-200 ng plasmid 
DNA was pipetted into an Eppendorf tube and was placed on ice. 15 µl of competent 
bacteria was added to plasmid tube and the mixture was incubated on ice for 15 minutes. 
The tube was heat shocked for 30-35 seconds at 42°C in the ThermoMixer and 
incubated for 2 minutes on ice directly afterwards. 600 µl of pre-warmed LB medium 
was added into the tube and mixed. The mixture was incubated at 37°C while gently 
shaking it (450 rpm) for 20 minutes in the ThermoMixer. Using a plate spreader, 200 µl 
of the bacteria was evenly distributed onto agar plates containing appropriate antibiotics. 
The plate was wrapped with parafilm and incubated overnight at 32°C. 
4.2.1.2   Preparation of plasmids 
4 ml of LB medium containing the appropriate antibiotics was prepared in a 15 ml 
round bottom tube. A single round large colony of bacteria was transferred using a 
micropipette into the tube with LB medium. The tube was capped and placed into the 
shaking incubator that was set at 37°C and 200 rpm for 6 hours. For Midi preparation, 
an Erlenmeyer flask was prepared with 150 ml of LB medium with appropriate 
antibiotics. After 6 hours of incubation, 500 µl of bacterial culture was transferred into 
the flask and incubated overnight in a shaking incubator (200 rpm, 37°C). 
4.2.1.3   Plasmid purification 
Plasmid DNA was done according to the manufacturer’s instructions using NucleoSpin 
Plasmid Kit (Macherey-Nagel) or NucleoBond Xtra Midi EF Kit (Macherey-Nagel), 
depending on the amounts of plasmid DNA needed. The basic principle is based on 






4.2.1.3.1   Plasmid DNA Mini 
The bacterial culture was transferred into a 2 ml Eppendorf tube and centrifuged for 30 
seconds at 11,000 x g. Supernatant was discarded and the cell pellet was resuspended 
completely with 250 µl Buffer A1. 250 µl Buffer A2 was mixed into the tube for lysis 
and incubated for 5 minutes at room temperature. For neutralizing the lysate, 300 µl 
Buffer A3 was added and mixed to create the appropriate conditions for binding the 
plasmid DNA to the silica membrane of the NucleoSpin Plasmid. The tube was 
centrifuged for 5 minutes at 11,000 x g at room temperature. A NucleoSpin Plasmid 
Column was placed inside a 2 ml Collection Tube. The supernatant was loaded onto the 
column. The tube, along with the column, was centrifuged for 1 minute at 11,000 x g, so 
that the DNA bound to the silica membrane. The membrane was washed with 600 µl 
Buffer A4 and centrifuged for 1 minute at 11,000 x g. The membrane was dehydrated by 
centrifuge for 2 minutes at 11,000 x g. The column with the membrane was placed in a 
1.5 ml Eppendorf tube. 50 µl Buffer AE was then added to elute the DNA. The 50 µl 
Buffer AE was incubated at room temperature for a minute afterwards. Finally, the tube 
was centrifuged for 1 minute at 11,000 x g.  
4.2.1.3.2   Plasmid DNA Midi   
First, the bacterial culture from the flask was transferred into a 50 ml Falcon tube. Using 
centrifuge at 2500 rpm for 15 minutes at 4°C, the bacterial cells were cultivated and 
harvested. The bacterial cells were resuspended using 8 ml RES-EF until no clumps 
were visible. 8 ml LYS-EF was then added into the mixture to lyse the cells. The tube 
was inverted 5 times and incubated at room temperature for 5 minutes. The NucleoBond 
Xtra Column and Filter was prepared with 15 ml EQU-EF for equilibration. For 
neutralization, 8 ml NEU-EF was added into the tube and then mixed by inverting the 
tube 10-15 times. The lysate was loaded on the filter by gravity flow and then was 
cleansed with 5 ml FIL-EF buffer. The plasmid DNA is bound to the NucleoBond Xtra 
Silica Resin. The filter was then discarded from the column and the column was washed 
2 times with 35 ml ENDO-EF and 15 ml WASH-EF buffer to remove endotoxins 
completely. The plasmid DNA was eluted with 5 ml ELU-EF and the eluate was 
collected in a 50 ml Falcon tube. 3.5 ml Isopropanol was added for precipitation of the 
eluted plasmid DNA. The tube was centrifuged at 4°C, 11,000 rpm for 30 minutes. The 
supernatant was carefully discarded. The pellet was washed with 2 ml of 70% ethanol 




room temperature with 11,000 rpm for 20 minutes. Ethanol was carefully removed and 
the pellet was left to dry at room temperature. The DNA pellet was finally dissolved 
using 200 µl TE-EF. Therefore, the concentration of plasmid DNA can be measured 
with a photometer. 
4.2.1.4   Restriction Digest 
The plasmid DNA produced by the purification from the previous process can be 
analyzed by DNA restriction digests using Type II restriction endonucleases. The Type 
II enzymes cut the DNA at a certain position within their recognition sequences. The 
total volume of the DNA sample was 25 µl, containing 1 µl of plasmid DNA, 0.5 µl of 
its respective enzyme, 2.5 µl of its respective buffer, and 21 µl ddH2O. The sample was 
incubated at room temperature for 30-45 minutes. The agarose gel electrophoresis was 
then prepared to separate the DNA fragments. 3 µl 6x Loading Dye was added into the 
sample. A marker was prepared with 9 µl of GeneRuler 1kb DNA ladders and 1 µl 6x 
Loading Dye. 12 µl of the sample and 10µl of marker were added into the agarose gel. 
The electrophoresis of the agarose gel was set at 70 Volt for 40 minutes. The separated 
DNA fragments can be visualized under ultraviolet light by using a gel documentation 
system. 
4.2.2   Cell Culture  
4.2.2.1   Basics 
4.2.2.1.1   Coating 
Coating the culture dishes is necessary for the differentiation of certain cell line, such as 
PC12 cell line. The cultivated cells will adhere to the dishes, so that the higher chance 
of survival (Reid and Rojkind 1979; Balda and Matter 2003). For coating of 15 cm petri 
dish, 10 ml of poly-L-lysine (PLL) solution with a concentration of 0.02 mg/ml was 
placed and the dish was gently swirled until the solution was equally distributed 
throughout the surface of the petri dish. The dish was incubated at 37 °C for 30 minutes. 
Afterwards the solution was removed. The dish was washed twice, each with 10 ml 
ddH2O. The dish was left to dry in the safety cabinet. As soon as the dish dried out, it 
can be kept in a refrigerator. The same procedure was also done for the coating of 3.5 




Coating of 96-well plates was done manually with multichannel-pipette using 50 µl PLL 
0.02 mg/ml per well. The plate was also incubated at 37°C for 30 minutes and washed 
twice as well, each with 100 µl ddH2O per well. The coating can also be achieved with 
the assistance of a liquid handling system (Hamilton Robotics). 30 µl PLL 0.02 mg/ml 
was pipetted into each well and incubated for at least 20 minutes. The wells were 
washed twice with ddH2O and dried out thereafter. 
For the coating of 384-well plates, PLL solution (0.02 mg/ml) was diluted 1: 3 with 
ddH2O. 20 µl of this solution was used to coat each well using multichannel-pipette. 
The plate was left to dry overnight inside the safety cabinet with UV light. 
 
4.2.2.1.2    Passaging  
A new PC12 cell line in a vial was thawed and collected from a nitrogen tank. The cells 
were centrifuged together with 30 ml of PC12 complete medium in a 50 ml Falcon tube 
for 5 minutes at room temperature (1200 rpm). The pellet was resuspended with 1 ml of 
growth medium and then plated in a coated 15 cm petri dish with 15 ml growth medium. 
The cells were passaged every 3-5 days depending on the dilution. 
Passaging is used to dilute the cells in a new culture dish after reaching maximum 
density. If the cell density is too high, the proliferation rate will drop significantly and 
the culture will deteriorate. With passaging, the amount of subculture and passage 
number increases by one.  
If the culture was already 80-90% confluent, they should be subcultured. The medium 
was removed from the petri dish. The cells were washed with 10 ml PBS to remove the 
serum residue, which contains Trypsin-Inhibitor. 5 ml Trypsin was gradually added 
dropwise. 3 ml Trypsin was then removed immediately. Trypsin detached the cells from 
the cultured surface. After waiting for 2-3 minutes, 10 ml of growth medium was added 
to petri dish. The cells that are mixed with the medium were carefully pipetted into a 
new 50 ml Falcon tube. Afterwards, the appropriate amount of cell suspension was 
added into a new petri dish. For example, a dilution 1:3 would mean 10 ml of growth 







4.2.2.1.3    Transfection 
Cells were transfected by means of lipofection using Lipofectamine 2000 (L2000). 
Lipofectamine reagents encase the DNA plasmid in a synthetic cationic liposome. This 
complex can fuse with the anionic cell membrane by endocytosis. The DNA plasmids 
will be released into the cytoplasm to reach the nucleus and begin their transcription. 
4.2.2.2   Assays 
4.2.2.2.1    Assay with LumiCycle 
On the first day, the cells were transfected with the plasmid DNA and then seeded into 
the wells of a coated 3.5 cm culture dish. There were two replicates (two dishes) for 
each condition. In this experiment, 1.4 x 10
6
 cells per dish in 1.5 ml growth medium is 
needed for the assay to work. The materials, such as the growth medium, antibiotic free 
medium, OptiMEM, PBS, and Trypsin were placed in a 37° C water bath. The DNA for 
each condition was prepared in their respective 1.5 ml Eppendorf tube (Table 7). 
Afterwards, 100 µl OptiMEM and 4.2 µl L2000 (3 x DNA amount) were added into a 
different empty tubes, vortexed for 5 seconds, and incubated for 5 minutes. Meanwhile, 
100 µl of OptiMEM was added into each DNA tube and incubated for another 5 minutes. 
After 5 minutes, the DNA/OMEM-tube was mixed into its corresponding 
OMEM/L2000-tube, and incubated for 20 minutes at room temperature. In the 
meantime, the cells were split using antibiotic free medium and counted using Neubauer 
hemocytometer. The formula is: cell number on 4 corner squares / 4 * 10 (dilution factor 




 (volume factor in one corner square). Assuming the 
amount of cells was 3,000,000 per ml and approximately 2,800,000 cells were needed 
for each condition, about 1 ml of cells (the amount of cells per ml divided by the 
amount of cells needed per condition) was pipetted each into another four empty falcon 
tubes. After 20 minutes, each DNA/L2000 mixture was added into its respective falcon 
tubes filled with cells. The tubes were inverted three times and incubated for 5 hours at 
37°C lying flat. After 5 hours, each tube was resuspended with the appropriate amount 
of growth medium until the desired volume was achieved (Final volume – cells volume 
– total volume of DNA/L2000/OMEM). The substrate luciferin (3 µl) was then added 
into each falcon tube (1: 1000) and 3 µl of DAPT (1:1000) was added into the second 




dish. The dishes were wrapped with parafilm to prevent the evaporation of the liquid 
and were eventually placed into the LumiCycle for about two days. The progress of the 
induction kinetics can be observed through software program connected with the 
machine. The evaluation was performed using a LumiCycle Analysis program and 
Microsoft Excel. 





















DNA N1-III-GV 300 ng  * 2 
dishes = 600 
ng 
300 ng  * 2 
dishes = 600 
ng 
300 ng  * 2 
dishes = 600 
ng 
300 ng  * 2 




300 ng  * 2 
dishes = 600 
ng 
300 ng  * 2 
dishes = 600 
ng 
300 ng  * 2 
dishes = 600 
ng 
300 ng  * 2 
dishes = 600 
ng 
 pcDNA 100 ng * 2 
dishes = 200 
ng 
100 ng * 2 
dishes = 200 
ng 
  
 mERBB4-F   100 ng * 2 
dishes = 200 
ng 
 
 BACE1    100 ng * 2 




 1400 ng 1400 ng 1400 ng 1400 ng 
      
OptiMEM 
x2 
 100 µl 100 µl 100 µl 100 µl 
L2000  4.2 µl 4.2 µl 4.2 µl 4.2 µl 
Split cells      
Add cells      
5h incubator      
Resuspend  Until 3 ml Until 3 ml Until 3 ml Until 3 ml 
Luciferin  3 µl 3 µl 3 µl 3 µl 
Additional 
compound 





4.2.2.2.2    Assay with 96-well plate 
On the first day, the growth medium, transfection, OptiMEM, PBS, and Trypsin were 
first warmed up in a water bath. The DNAs for each condition were prepared according 
to the Table 8. In 96-well plate, one well contained 70,000 cells with a volume of 200 µl. 
In the example above, there were 4 conditions. Each condition had 24 replicates (wells), 
but 30 replicates were made in case there was a need of more. The ideal amount for 
OptiMEM is 250 µl for 6,000 ng DNA. Using rule of three: 250 µl x 1,050 ng / 6,000 
ng = 43.75 μl OptiMEM. The amount of L2000 was roughly estimated: 3 x 1.05 µg 
DNA amount = 3.15 µl. About 43.75 µl OptiMEM and 3.15 µl L2000 were mixed in 
another Eppendorf tube. Another 43.75 µl OptiMEM was added in the DNA tube. After 
5 minutes, both tubes were mixed together on a vortex mixer for 5 seconds. The tubes 
were incubated at room temperature for 20 minutes. Meanwhile, the cells were 
subcultured using antibiotic free medium. About 2,100,000 cells were needed for each 
condition. Assuming the amount of cells was 3,000,000 per ml, 1.43 ml cells had to be 
transferred into a new 50 ml falcon tube for each condition. After 20 minutes, the 
contents from DNA tube were pipetted into the corresponding falcon tube with the cells. 
The mixture was inverted three times. The falcon tubes were incubated for 2-3 hours 
lying flat. After 2-3 hours, each falcon tube was resuspended with the growth medium 
until 6 ml. For the second tube, 6 µl of DAPT (1:1000) was added. After mixing it well, 
the cells were placed in a labelled reservoir for each condition. The cells were pipetted 
into their respective wells through the usage of a multichannel-pipette (200 µl) (Figure 
7). The 96-well plate was incubated for 24 hours at 37°C. 
On the second day, the growth medium was removed from the plate. 35 µl Passive Lysis 
Buffer (PLB) was applied into each well. The plate was incubated on a plate shaker for 
about 20 minutes at room temperature. If the clear plate was used, the cells had to be 
transferred into the white plate for measurement. After 20 minutes, the plate was 
measured using a microplate reader (Berthold). The MicroWin 2000 software program 
was opened on PC: 
- Open data : DLR_disp_FF15min_1sec_RN_2sec-byWell 
- Click the ‘Plate picture’  → mark the wells which are used in the assay → pay 
attention to Inject 2 (blue = RN) and Inject 3 (red=FF)  




- Put the RN and FF hose into the falcon tube with ddH2O 
- Instrument → Wash 50 Cycle → Injector 2 and 3 in ddH2O → OK 
- Put the hose now into each respective substrates (Renilla Luciferase and Firefly 
Luciferase) 
- Instrument → Prime → Injector 2 and 3 → Next (Repeat one more time) 
- Instrument → Unload Plate → Put the white plate inside 
- Write the data name and click ‘Start’ 
- The results are automatically transferred on the desktop within the folder: ‘Ver-
knupfung mit Transfer’   
- Termination: Instrument → Wash → Injector 2 and 3 in ddH2O → 50 Cycle → 
Next 
- Instrument → Wash → Injector 2 and 3 in Ethanol → 50 Cycle → Next 
- Instrument → Wash → Injector 2 and 3 in ddH2O → 50 Cycle → Next 
- Instrument → Unload Injector → 15 Cycle → Next 
- Close the program 
The data obtained from the program was processed and analyzed with Microsoft Excel. 
 

































DNA N1-III-GV 15 ng * ~30 
wells = 450 
ng 
15 ng * ~30 
wells = 450 
ng 
15 ng * ~30 
wells = 450 
ng 
15 ng * ~30 




15 ng * ~30 
wells = 450 
ng 
15 ng * ~30 
wells = 450 
ng 
15 ng * ~30 
wells = 450 
ng 
15 ng * ~30 
wells = 450 
ng 
 pcDNA 5 ng * ~30 
wells = 150 
ng 
5 ng * ~30 
wells = 150 
ng 
  
 mERBB4-F   5 ng * ~30 
wells = 150 
ng 
 
 BACE1    5 ng * ~30 




 1050 ng 1050 ng 1050 ng 1050 ng 
      
OptiMEM 
x2 
 43.75 µl 43.75 µl 43.75 µl 43.75 µl 
L2000  3.15 µl 3.15 µl 3.15 µl 3.15 µl 
Split cells      
Add cells      
2h incubator      
Resuspend  Until 6 ml Until 6 ml Until 6 ml Until 6 ml 
Additional 
compound 




4.2.2.2.3    Assay with 384-well plate 
Once the assay has been successfully tested in 96-well plate, the same method was 
applied in 384-well plate with a few adjustments. The suitable amount of cells per well 
is 20,000 cells with a volume of 90 µl. Each condition had 96 replicates/wells (rounded 
up to 100 wells). The DNA plasmids were prepared in 1.5 ml Eppendorf tubes 
according to the Table 9. 105 µl of OptiMEM and 7.5 µl of L2000 were mixed in other 
tubes and incubated for 5 minutes. Another 105 µl of OptiMEM was inserted into each 
DNA tube and incubated for 5 minutes. Both tubes were mixed together and incubated 
for 20 minutes at room temperature. Meanwhile, the cells were split using antibiotic free 
medium and counted with the hemocytometer. Assuming the cell number was 2,000,000 
cells per ml, 1 ml cell was pipetted into a new falcon tube for each condition. After 20 
minutes, the DNA was transferred into the respective falcon tubes that contain the cells. 
The tubes were incubated lying flat at 37°C for 2-3 hours. After 2-3 hours, each tube 
was resuspended with growth medium until its volume reached 9 ml. The cells were 
applied into corresponding wells in 384-well plate using multichannel-pipette (90 µl) 
(Figure 8). The plate was incubated at 37°C for 24 hours. 
On the following day, the medium was completely removed from the plate using a 
centrifuge (700 g for one minute). The plate was placed upside down with a reservoir 
under it to catch the medium. 15 µl PLB was applied into each well for lysis. The plate 
was placed on a plate shaker for 20 minutes at room temperature. The cells needed to be 
transferred into a white plate if a clear plate was used beforehand. Afterwards the plate 
was measured using microplate reader (Berthold). 
- Open program MicroWin 2000 → Data : DLR_disp_FF15min_1sec_RN_2sec-
384 byWell 
- Click the ‘Plate picture’  → mark the wells which are used in the assay → pay 
attention to Inject 2 (blue = RN) and Inject 3 (red=FF)  
- Next → OK 
- Put the RN and FF hose into the falcon tube with ddH2O 
- Instrument → Wash 50 Cycle → Injector 2 and 3 in ddH2O → OK 
- Put the hose now into each respective substrates (Renilla Luciferase and Firefly 
Luciferase) 
- Instrument → Prime → Injector 2 and 3 → Next (Repeat one more time) 
- Instrument → Unload Plate → Put the white plate inside 




- The results are automatically transferred on the desktop within the folder: ‘Ver-
knupfung mit Transfer’   
- Termination: Instrument → Wash → Injector 2 and 3 in ddH2O → 50 Cycle → 
Next 
- Instrument → Wash → Injector 2 and 3 in Ethanol → 50 Cycle → Next 
- Instrument → Wash → Injector 2 and 3 in ddH2O → 50 Cycle → Next 
- Instrument → Unload Injector → 15 Cycle → Next 
- Close the program 
The data obtained from the program was processed and analyzed with Microsoft Excel. 
 












Table 9. Protocol for NRG1 cleavage assay using 384-well plate 
 
4.2.2.2.4   NRG1 cleavage screening 
4.2.2.2.4.1   NIH Clinical Collection 
The NIH Clinical Collection (NCC) is a plated array of 281 (NCC 201) and 445 (NCC 
003) small molecules. The National Institutes of Health (NIH) assembled the collection 
through the Molecular Libraries Roadmap Initiative so that the compounds could be 
used in high throughput screening in biomedical research. These clinically tested 
compounds with already known safety profiles may offer an excellent starting point for 


















DNA N1-III-GV 10 ng * ~100 
wells = 1000 
ng 
10 ng * ~100 
wells = 1000 
ng 
10 ng * ~100 
wells = 1000 
ng 
10 ng * ~100 




10 ng * ~100 
wells = 1000 
ng 
10 ng * ~100 
wells = 1000 
ng 
10 ng * ~100 
wells = 1000 
ng 
10 ng * ~100 
wells = 1000 
ng 
 pcDNA 5 ng * ~100 
wells = 500 
ng 
5 ng * ~100 
wells = 500 
ng 
  
 mERBB4-F   5 ng * ~100 
wells = 500 
ng 
 
 BACE1    5 ng * ~100 




 2500 ng 2500 ng 2500 ng 2500 ng 
      
OptiMEM 
x2 
 105 µl 105 µl 105 µl 105 µl 
L2000  7.5 µl 7.5 µl 7.5 µl 7.5 µl 
Split cells      
Add cells      
2h incubator      
Resuspend  Until 9 ml Until 9 ml Until 9 ml Until 9 ml 
Additional 
compound 




4.2.2.2.4.2   Plate layout  
 
 
Figure 9: Plate layout for NRG1 cleavage assay screen. (a) Compound plate in 96-well plate. (b) Assay 
plate in 384-well plate. A compound in 1 well in compound plate was transferred to 4 wells in assay plate 
to create 4 replicates of said compound. 
 
There were 727 compounds to be tested. A compound plate (96-well plate) consisted of 
80 compounds from NIH clinical collection diluted in DMSO in the middle, two 
negative controls (DAPT and TAPI-1) at column 1 which also have been diluted in 
DMSO, and growth medium for the baseline at column 1 and positive controls at 
column 12. Each of these wells will be transferred equally into 4 wells of a 384-well 
plate (assay plate). For example, compound X, located at 2A in compound plate, was 






4.2.2.2.4.3   Preparation of the compound plates 
A working stock contained all 727 compounds from NIH was already prepared in a sum 
of 10 of 96-well plates. Each compound had originally 5 µl as its volume and 10 mM as 
its concentration. For the screening, the final concentration of the compounds should be 
10 µM. The compounds were first diluted 1:10 with DMSO (addition of 45 µl DMSO) 
to make a concentration of 1 mM.  Ten other 96-well plates were prepared with 54 µl 
growth medium per well. 6 µl of the compounds were transferred onto the plate with the 
medium. The compounds were diluted 1:10 with the medium and had a total of 60 µl 
and 100 µM. Each well in 96-well plate that contained one compound was transferred 
onto four wells of 384-well plate (assay plate) to create four replicates of the 
corresponding compounds. 90 µl of PC12 cells were prepared in each well of 384-plate. 
10 µl of the same compound (100 µM) were transferred into the four respective wells of 
384-well plate containing 90 µl cells. Eventually, each well of 384-well plate had a 
volume of 100 µl and 10 µM compound. All transferring were done with the assistance 
of liquid handling system (Hamilton Robotics). 
 
4.2.2.2.4.4   Screen protocol 
A sum of ten 96-well plates for compound plate ten 384-well plates for assay plate was 
prepared. There were 12 transfection tubes in total. The first ten were used for the 
baseline, the negative controls (DAPT and TAPI-1), and the compounds. The 
transfection was prepared about 5,000 wells, which was then divided into 10 tubes. The 
first positive control was a co-transfection with mERBB4-F and the second was a co-
transfection with BACE1. The DNAs were put into each respective tube and mixed with 
the appropriate number of OMEM shown in Table 10. Another amount of OMEM and 
L2000 was placed into different Eppendorf tubes, vortex and wait for 5 minutes. Put the 
OMEM/L2000 mix into DNA tubes, vortex and wait for 20 minutes. During the 20 
minutes of anticipation, the PC12 cells were subcultured using antibiotic free medium. 
Assuming the cell number was 3,000,000 per ml, put 3.33 ml cells in the first ten tubes 
and insert 2 ml cells in the both tubes for positive controls. After 20 minutes, the 
DNA/L2000 was mixed into the cell tubes and incubated for 2 hours at 37°C. After 2 
hours, each tube was resuspended with growth medium until the desired volume had 
been achieved. All ten tubes containing the same DNA were mixed together into a 500 




cells from the bottle were transferred into the column 1-22 in assay plate. 90 µl cells 
from the first positive control (mERBB4-F) were transferred into wells 23/24 A-H and 
90 µl cells from the second positive control (BACE1) were transferred into wells 23/24 
I-P (Figure 9). 10 µl of compounds or medium from the compound plate were then 
transferred into the assay plate according to the explanation above. After having a total 
of 100 µl and 10 µM for each well, the assay plates were incubated for 24 hours at 37°C.  
The robot has been programmed to do the assay systematically. After 24 hours, the 
medium was removed from the plates completely using a centrifuge (700g, 1 minute). 
20 µl PLB was put and the plate was shaken for about 20 minutes. Then, 30 µl of 
Firefly substrate was added into each well and the plate was incubated for 10 minutes. 
Afterwards, the plate was measured in microplate reader (Berthold). The analysis was 
done using cellHTS2 software program. 
Table 10. Protocol for NRG1 cleavage assay screen in 384-well plate 
 















DNA N1-III-GV 10 ng * 500 
wells = 5000 
ng 
50,000 ng 10 ng * 300 
wells = 3000 
ng 
10 ng * 300 




10 ng * 500 
wells = 5000 
ng 
50,000 ng 10 ng * 300 
wells = 3000 
ng 
10 ng * 300 
wells = 3000 
ng 
 pcDNA 5 ng * 500 
wells = 2500 
ng 
25,000 ng   
 mERBB4-F   5 ng * 300 
wells = 1500 
ng 
 
 BACE1    5 ng * 300 




 12,500 ng  7500 ng 7500 ng 
      
OptiMEM 
x2 
 520.83 µl  312.5 µl 312.5 µl 
L2000  37.5 µl  22.5 µl 22.5 µl 
Split cells      
Add cells      
2h incubator      
Resuspend  Until 45 ml  Until 27 ml Until 27 ml 
Additional 
compound 





5.1 Promoter tests 
 
Figure 10: Result of LumiCycle measurement comparing G5-luc, G10-MLP-luc, and G10-CMV-luc. 
X-Axis: time after transfection [h]. Y-Axis: luciferase activity [cpm]. 
 
This assay was performed using LumiCycle method as explained above. The assay used 
three conditions with two replicas for each condition. Five hours after on plate 
transfection, the dishes were put into the LumiCycle and the activity was monitored. 
This line chart shows the comparison of using different available reporter genes. The 
black lines represent the use of G5-luc, the yellow lines show the G10-MLP-luc, and the 
blue lines are for the G10-CMV-luc. In the first hours, each condition increased steadily 
at its own pace and achieved its highest activity approximately 24 hours after the 
transfection. After reaching the peak, the luciferase activities fell down on the following 
hours. G5-luc has the least luciferase activity in comparison to other reporter genes. 
G10-CMV-luc shows a 3-fold increase in activity from G5-luc. G10-MLP-luc appeared 
to be the most optimal reporter gene in this experiment, resulting in almost 7-fold higher 



























time after transfection [h] 
Promoter Test 
N1-I-GV + G5-luc 1












5.2 ERBB4 amount optimization 
 
Figure 11: Result of LumiCycle measurement comparing different amount of ERBB4-F stimulation. 
X-Axis: time after transfection [h]. Y-Axis: luciferase activity [cpm]. 
 
This assay was made to define which amount of the positive control, ERBB4-F, would 
be optimal for the screening.  The amount of N1-III-GV and G10-MLP-luc in this assay 
was always constant, which was 300 ng per dish. The amount of ERBB4-F being tested 
were 100 ng, 200 ng, 300 ng, and 400 ng. Therefore, five conditions were prepared, 
each with two replicas. Each line represents the average activity of two respective 
dishes. The black line is the condition for the cells transfected with only N1-III-GV and 
G10-MLP-luc, without any stimulation. The red line shows the activity with 100 ng 
ERBB4-F transfection, the green one is for 200 ng ERBB4-F, the blue one is for 300 ng 
ERBB4-F, and the yellow one is for 400 ng ERBB4-F. The baseline rose up and reached 
its peak at 1250000 cpm around 25 hours post transfection. All the conditions with the 
ERBB4-F stimulation grew up higher than the baseline with its peak around 28 hours 
post transfection. Relatively small difference can be seen between the red, green, and 
blue line, whose activities are twice as much as the baseline. The red line with 100 ng 
ERBB4-F has the highest level of activity, followed by 200 ng ERBB4-F, and lastly the 
300 ng ERBB4-F. The yellow line with 400 ng ERBB4-F has the smallest level of 
























time after transfection [h] 
ERBB4 Test 
N1-III-GV +G10-MLP-luc
+ 100 ng ERBB4-F
+ 200 ng ERBB4-F
+ 300 ng ERBB4-F




5.3 Control tests   
 
Figure 12: Result of LumiCycle measurement showing an assay with a positive and a negative 
control. X-Axis: time after transfection [h]. Y-Axis: luciferase activity [cpm]. 
 
This chart shows NRG1 cleavage assay with a positive and a negative control. Three 
conditions were prepared, each with two replicas. The black lines are the baseline, using 
only NRG1-III-GV and G10-MLP-luc. The blue lines represent the positive control, 
using co-transfection of ERBB4-F as stimulation for the assay. The red lines are the 
negative control, using 10 µM DAPT, a γ-secretase inhibitor, to inhibit the cleavage 
activity. They reached their own highest level of activity at approximately 25 hours post 
transfection. The positive control is twice as high compared to the baseline. Meanwhile, 




























time after transfection [h] 
Control Test 1 
N1-III-GV 1
N1-III-GV 2
N1-III-GV + E4-F 1








Figure 13: Result of LumiCycle measurement with two positive controls, ERBB4-F and BACE1, 
and a negative control, DAPT. X-Axis: time after transfection [h]. Y-Axis: luciferase activity [cpm]. 
 
This chart shows an assay with two positive controls and a negative control. The 
baseline is the black lines, which represent transfection of N1-III-GV and G10-MLP-luc. 
The first positive control is the yellow line, a co-transfection with ERBB4-F. The 
second positive control is also a co-transfection with BACE1, which illustrated by the 
blue lines. Lastly, the red lines show the negative control, which is DAPT. All the 
conditions have their peak at approximately 25 hours post transfection. As seen above, 
co-transfection with BACE1 stimulates the luciferase activity much better than with 
ERBB4-F. It is over four times higher than the baseline, whereas the co-transfection 
with ERBB4-F only twice as much. The negative control showed half of the activity 
































time after transfection [h]  
Control Test 2 
N1-III-GV 1
N1-III-GV 2
N1-III-GV + DAPT 1
N1-III-GV + DAPT 2
N1-III-GV + mErbB4-F 1
N1-III-GV + mErbB4-F 2
N1-III-GV + BACE1 1




5.4 Assay results in 96-well plate 
 
Figure 14: Chart representation of assay result in 96-well plate. ERBB4-F and BACE1 were positive 
controls and DAPT was negative control. n: baseline. Y-Axis: luciferase activity (normalized to baseline). 
 
This chart represents the assay with the positive and negative controls, applied in 96- 
well plate format. The assay was measured around 25 hours after transfection using a 
microplate reader (Berthold Technologies). The result is nearly the same as the 
LumiCycle. DAPT, as a γ-secretase inhibitor, shows less than half as much activity as 
the baseline. The first positive control, ERBB4-F, had roughly 2.3 times higher activity 
than the baseline. The second positive control, BACE1, had almost 4 times increase in 



































Figure 15: Inhibitor test result in 96-well plate. DAPT and TAPI-1 were tested in final concentration of 
10 µM. LY2811376 and BACE1 Inhibitor IV were tested in final concentration of 60 µM. n: baseline. Y-
Axis: luciferase activity (normalized to baseline). 
 
This chart shows an assay comparing different negative controls. The negative controls 
being tested were DAPT, a γ-secretase inhibitor, TAPI-1, a TACE inhibitor, LY2811376, 
a BACE1 inhibitor, and β-secretase Inhibitor IV, also another BACE1 inhibitor. Using 
dose-response assay (not shown), the optimal amount of each negative control was 
determined. The final concentration of DAPT and TAPI-1 is 10 µM and the final 
concentration of LY2811376 and β-secretase Inhibitor IV is 60 µM. The assay was done 
in 96-well plate format and measured around 25 hours after the transfection using a 
microplate reader (Berthold Technologies). Each column represents 6 replicas. The 
luciferase activity of the cells with DAPT showed a decrease of about 50 per cent 
compared to the baseline (n). TAPI-1 had a 40 per cent activity reduction from baseline. 
LY2811376 inhibited the cleavage activity by 40 per cent and β-secretase Inhibitor IV 
blocked at the same level as DAPT. Considering the amount of compounds and its 

















































5.5 Assay results in 384-well plate 
 
Figure 16: Chart representation of assay result in 384-well plate. ERBB4-F and BACE1 were positive 
controls and DAPT was negative control. n: baseline. Y-Axis: luciferase activity (normalized to baseline). 
 
This assay was performed in 384-well format using a liquid handling system (Hamilton 
Robotics) and measured with microplate reader (Berthold Technologies). Each column 
represents 4 replicas of representative condition. As seen from the chart above, ERBB4-
F stimulation showed only a 1.5-fold increase from baseline (n) compared to previous 
experiment with 96-well format. On the other hand, BACE1 stimulation still showed 
about four to five-fold increase in the level of activity from the baseline. DAPT 

















































































5.6 Screen report 
5.6.1   Plate configuration  
 
Figure 17: A graphical representation of plate configurations. The location of baseline, positive and 
negative controls, as well as the samples are indicated by the colour coding. 
 
The samples from NCC 201, which consists of 281 compounds, were placed into Plate 
1 – 4. The 446 samples from NCC 003 were placed into Plate 5 – 10.  
 
 
5.6.2 Plate summary 
Figure 18 and Figure 19 show a set of diagnostic plots which provide an overview of 
the general screen quality. Figure 18 represents each boxplots of raw and normalized 
values of each replicated samples for every plate. The normalization of the data was 
intended to adjust the values for some inevitable technical abnormalities in the signal. 
As can be seen in Figure 18, the signal intensities between plates could vary between 
one another due to different time points of measurement. Thus, a more significant 
measure of the effect is the signal relative to a typical value per plate, such as the plate 
median. CellHTS2 calculated the plate median normalization by dividing the raw 
intensity with its corresponding plate median only from the sample of each replicate to 









𝑥(𝑎)𝑃𝑅 is the raw intensity of compound 𝑎 in plate P and replicate R. The median is 
calculated among the wells annotated as sample in plate P and replicate R.  𝑦(𝑎)𝑃𝑅 is its 
normalized intensity. 
Standard scores or z-scores were also calculated by cellHTS2 software. This scoring is 
important as a measure of evidence for a generated phenotype. Compounds with top z-
scores will be identified as candidate modifiers and selected as ‘hits’ of the screen. First, 





𝑦(𝑎)𝑃𝑅 is the normalized intensity of compound 𝑎 from plate P and replicate R, 𝜇(𝑠)𝑃𝑅 
is the mean value of sample wells from replicate R in plate P,  𝜎(𝑠)𝑃𝑅 is the standard 
deviation of sample wells from replicate R in plate P, and 𝑧(𝑎)𝑃𝑅  is the normalized 
value of compound 𝑎 from replicate R in plate P. Instead of using 𝜎 and 𝜇, more robust 
estimators were applied in the cellHTS2 software, like median absolute deviation 
(MAD) and median, respectively (Leys et al. 2013). Finally, the z-score of compound 𝑎 
is calculated by the median of the normalized values of all its 4 replicates. The raw 
values and the normalized values of all controls and samples, as well as the z-scores, 
can be found in Table 14 and 15. Compounds with a positive z-score indicate a strong 
increase in signal and can be identified as activators, whereas compounds with a 
negative z-score indicate a decrease in signal and thus, inhibitors. Several compounds 
with highest or lowest z-score were chosen to be further validated. Figure 19 represents 
the distribution of the normalized values of the positive and negative controls in the 












Figure 18: Plate normalization. Left: Box plots of raw values of samples only, grouped by plate for each 
replicate. Right: Box plots of normalized values of samples only, grouped by plate for each replicate. X-








5.6.2.2 Control plot 
 
Figure 19: Controls plot. Left: Normalized values of positive and negative controls plotted against the 
plate number for each replicate. Red dot: BACE1. Yellow dot: ERBB4-F. Blue dot: DAPT and TAPI-1. 
X-Axis: plate number. Y-Axis: normalized values. Right: Distribution of positive and negative controls 
across the plates, represented by density estimates. Red line: BACE1. Yellow line: ERBB4-F. Blue line: 







CellHTS2 calculated Z´-factor, which is a parameter to evaluate the quality or 
performance of the assay itself, without any intervention of test compounds (Zhang, 
Chung, and Oldenburg 1999). The Z´-factor also plays a significant role for the assay 
development and optimization. 




𝜎𝑝𝑜𝑠 and 𝜎𝑛𝑒𝑔 are the standard deviations of the positive and negative controls, whereas 
𝜇𝑝𝑜𝑠 and 𝜇𝑛𝑒𝑔 are their mean values. Z´-factor value is classified as following: Z´ = 1, 
an ideal assay; 1 > Z´ ≥ 0.5, an excellent assay; 0.5 > Z´ > 0, a double assay; Z´= 0, a 
“yes/no” type assay; Z´< 0 indicates that the assay conditions still need to be optimized. 
In the cellHTS2 software, robust estimators median and MAD were used instead 𝜇 and 
𝜎, respectively. Because there were 2 positive controls, cellHTS2 calculated the Z´-
factor between each of the positive controls and the negative control. 
 












Replicate Z´-factor (BACE1) Z´-factor (mERBB4-F) 
1 -0.74 -1.02 
2 -0.37 -0.42 
3 -0.3 -1.31 




5.6.3   Screen summary 
5.6.3.1   Screen-wide image plot of the scored values 
 
Figure 20: Image plot of assay scores (z-scores), stratified by plates. The scored values for each plate 
are indicated by colour coding on a rectangular grid.  
 
The plates were arranged consecutively from left to right. The controls and the samples 
were organized as in Figure 17. The baseline and the negative controls were placed at 
the left side of each plate. The positive controls were placed at the right side of each 
plate. The blue colors indicate negative z-score. Therefore, compounds that have a blue 
color act as inhibitors of the cleavage. On the other hand, compounds that have a red 












5.6.3.2   Q-Q Plot 
 
Figure 21: Normal Q-Q plot of assay scores. X-Axis: Theoretical quantiles. Y-Axis: Sample quantiles. 
 
The samples were distributed based on their quantiles, increasing from left to right. 
Sample quantiles refer to assay scores. The samples that are above the first or below the 
second dashed lines are the outliers, which might be the potential activators or inhibitors 
of the assay. The highest score of the samples was 7.4, illustrated by Irsogladine maleate 







Figure 22: Q-Q plot with all samples and controls. X-Axis: Theoretical quantiles. Y-Axis: Data 
quantiles. 
 
The data were distributed based on their quantiles, increasing from left to right. Data 
quantiles refer to the assay scores of all 10 plates. 727 samples are represented by the 
blue diamonds. 30 baselines are represented by black triangles. 30 DAPT are 
represented by red squares. 20 TAPI-1 are represented by yellow circles. 40 mERBB4-F 
are represented by green crosses. 40 BACE1 are represented by orange squares.  
 









5.6.5   Potential hits 
5.6.5.1   Activators 
Table 12. List of potential activators 
5.6.5.2   Inhibitors 
Table 13. List of potential inhibitors 
plate well score GeneID Uses & Effects 
7 B02 7.4 IRSOGLADINE MALEATE Phosphodiesterase inhibitor, gastroprotective 
8 A02 5.21 NITRENDIPINE 
Dihydropyridine calcium channel blocker, 
antihypertensive 
9 A02 3.41 BESTATIN 
Reversible protease inhibitor, adjuvant therapy 
for AML, CML, and lung cancer 
4 G04 3.15 
4-(AMINOMETHYL) 
BENZENESULFONAMIDE ACETATE 
Sulfonamide, topical anti-infective, burn therapy 
4 F06 3.05 Allegra Antihistamine drug, for seasonal allergic rhinitis 
9 F09 3.04 Zolmitriptan 
Selective serotonin receptor agonist of the 1B 
and 1D subtypes, anti-migraine 
1 B02 2.96 DIPYRIDAMOLE 
Phosphodiesterase inhibitor, platelet aggregation 
inhibitor 
4 F03 2.96 RIFAPENTINE Antimycobacterial, for pulmonary tuberculosis 
4 G02 2.84 NALTREXONE HYDROCHLORIDE 
Antagonists at the μ-opioid receptor (MOR), the 
κ-opioid receptor (KOR), management of opiate 
cessation 
4 A05 2.78 Citalopram 
Antidepressant drug of the selective serotonin 
reuptake inhibitor (SSRI) 
3 A03 2.75 Albendazole 
Anthelminthic, inhibiting the formation of 
microtubules from tubulin 
plate well score GeneID Uses & Effects 
5 F09 -3.72 Ifenprodil NMDA receptor inhibitor 
6 H08 -3.64 IDARUBICIN_HCl Anthracycline, flagged 
7 A10 -3.29 Doxorubicin_Hydrochloride Anthracycline, flagged 
7 H06 -3.29 EPIRUBICIN_HYDROCHLORIDE Anthracycline, flagged 
7 G07 -3.27 TRIPTOLIDE Antineoplastic agent, flagged 
5 E05 -3.05 diphenylcyclopropenone Allergic contact synthetizer, flagged 
1 D06 -3.01 Spironolactone 
Diuretic/antihypertensive, Mineralocorticoid 
receptor (MR) antagonist 
3 B04 -3 MITOXANTRONE Topoisomerase Inhibitor, flagged 
1 B05 -2.84 PERPHENAZINE 
Dopamine antagonist with antiemetic and  
antipsychotic properties 
7 A04 -2.76 TOPOTECAN_HCL 
Topoisomerase inhibitor, treatment of ovarian 
cancer 
9 H09 -2.71 DACTINOMYCIN 
Actinomycin D, inhibits transcription, treatment of 
Wilms’ tumour, Ewing’s sarcoma, metastatic 
nonseminomatous testicular cancer 
9 C11 -2.7 HOMOHARRINGTONINE Antineoplastic, flagged 
1 D11 -2.65 Pamelor second-generation tricyclic antidepressant (TCA) 
1 C08 -2.6 Annoyltin Amitriptyline, antidepressant 
7 H08 -2.57 MOSAPRIDE_CITRATE Serotonin receptor agonist, gastroprokinetic agent 
9 B11 -2.27 Cyproheptadine-Hydrochloride 
Serotonin antagonist, Histamine H1 Antagonist, 
anti-allergic, antipruritic 
2 D10 -2.23 Thioridazine_Hydrochloride Antipsychotic, flagged 




5.6.5.3   Potential hits from NCC 201 
 
Figure 23: Graphical representation of top hits from NCC 201. n: baseline. Negative controls: DAPT 
and TAPI1. Positive controls: E4 (ERBB4-F) and BACE1.  
 
The selected hits were represented in a column chart with the baseline, positive, and 
negative controls from the corresponding plates. Plate 2 was excluded from the 
selection because none of its compound carried any significant score. Top activators 
from NCC 201 were Dipyridamole, Albendazole, Naltrexone, Rifapentine, 4-
(aminomethyl) benzensulfonamide acetate, Citalopram, and Allegra. Top inhibitors from 
















































































































































































































5.6.5.4   Potential hits from NCC 003 
 
Figure 24: Graphical representation of top hits from NCC 003. n: baseline. Negative controls: DAPT 
and TAPI1. Positive controls: E4 (ERBB4-F) and BACE1. 
 
The selected hits were represented in a column chart with the baseline, positive, and 
negative controls from the corresponding plates. Plate 6 and 10 were excluded from the 
selection because none of its compound carried any significant score. Top activators 
from NCC 003 were Irsogladine maleate, Nitrendipine, Bestatin, and Zolmitriptan. Top 
inhibitors from NCC 003 were CGS 15943, Ifenprodil, Topotecan, Mosapride citrate, 



















































































































































































































6.1 Establishment of the assay and controls 
The use of bioluminescent assays has been commonly used for drug discovery by means 
of HTS. In HTS applications, luciferase has been well known as a reporter gene, which 
can be used to detect changes in assay regulation. This knowledge was implemented in 
the cleavage assay. The cleaved NRG1-ICD-GV binds to the UAS, which drives the 
reporter gene luciferase. The luciferase induction kinetics, which can be measured with 
a luminometer, will also determine whether the intracellular cleavage of NRG1 was 
stimulated or inhibited by the compounds. 
NRG1 cleavage assay was first performed in living cells, using 3.5 cm culture dishes in 
a 32-channel luminometer (LumiCycle). The advantage of using LumiCycle is the 
‘online’ measurement function, which helps in monitoring the progress of the assay in 
real time. The peak of luciferase activity was crucial for the measurement in 96- and 
384-well plates, which is around 24-26 hour after transfection. The adaptation to 96-
well plate was in accordance with the existing protocol. The amount of cells was 
optimized to 70,000 cells per well for better results.  
The protocol for 384-well plate had to be established from the beginning. After many 
experiments and consultations with other colleagues, 20,000 PC12 cells in a well were 
found to be the most favorable amount. All other amounts have also been adjusted for 
robust results.  
At first, all the pipetting had to be done manually using a multi-channel pipette. When 
transferring the assay to the robot (Hamilton Robotics), some issues arose that needed 
better adjustments, for instance the correct tips, dispense velocity, etc. Other issues such 
as coating or medium removal have all been resolved.  
A new transfection method was being developed by other colleagues. It was called ‘in 
solution transfection’. Until then, ‘on plate transfection’ was always the method of 
transfection. The idea of on plate transfection is to seed the cells on plates/dishes 
beforehand on the first day and further continue the DNA transfection into the seeded 
cells on plate on the next day. The concept of ‘in solution transfection’ is to directly 
transfect the DNA into the cells first, and then seed the DNA-transfected cells into the 
plate on the same day. The benefit of using ‘in solution transfection’ is that it is efficient 




experiments to compare the results adequately, it was concluded that the results from ‘in 
solution transfection’ were slightly better. Moreover, ‘on plate transfection’ can be 
hardly done on 384-well plate. Therefore, ‘in solution transfection’ was used for the 
screen. 
As can be seen from Figure 10, it was shown that both G10-MLP-luc and G10-CMV-luc 
had better results than G5-luc. The existence of promoters influences the luciferase 
expression. A test conducted by colleagues also displayed a better induction using 
10xUAS instead of 5xUAS. However, a report indicated that a high methylation status 
inhibits the binding of Gal4 to the UAS. It was suggested, that by reducing the number 
of repeated UAS sequences, the tendency of them being methylated might be reduced 
(Gälweiler et al. 2000; Engineer et al. 2005). Another publication has also studied the 
comparison of activity between MLP and CMV promoter (Goossens et al. 2000). In 
contrast to this study, the results showed that MLP promoter induces higher gene 
expression than CMV promoter. 
NRG1 type III used in the screen due to its relevance to schizophrenia. A lot of studies 
have explained its significance in neuroconnectivity, myelination, and cognitive 
functions. Furthermore, the mutation and cleavage processing of NRG1 type III have 
also been well examined. Nevertheless, validation assays with NRG1 type I should also 
be performed. 
The search for positive control compounds that stimulate NRG1 cleavage was not 
successful. Therefore, ERBB4 and BACE1 overexpression were chosen as the positive 
controls of the screen. 
The interaction with ERBB4 can activate the translocation of NRG1-ICD into the 
nucleus (Mei and Xiong 2008). Regardless, it is not known exactly how the mechanism 
of this stimulation works as it is still unexplained, whether the binding with ERBB4 
could also stimulate the extracellular cleavage, or just the intracellular cleavage. 
According to the result, a lower amount of ERBB4-F proved to have a better outcome 
than a higher amount (Figure 11). The secretory system of the cells might be plugged 
due to the artificially overexpression of ERBB4, so that less ERBB4 could reach the 
plasma membrane. Additional experiments, such as two-cell assay or 
immunofluorescence still need to be done. As stated above, an optimal amount of 
ERBB4 can increase the cleavage activity by ~2.5-fold from the baseline. Hence, less 




NRG1 belongs to the physiological substrates of β-secretase (BACE1) (Fleck et al. 2013, 
2016). BACE1 is an enzyme that can cleave NRG1 extracellularly, leaving a membrane-
bound NRG1-CTF (Figure 4 and 5). NRG1-CTF will be further intracellularly cleaved 
by γ-secretase to release NRG1-ICD. Experiments with BACE1 showed an outstanding 
result, with an increase of ~400 per cent from baseline (Figure 13). The extracellular 
cleavage of NRG1 could be essential for the processing of intracellular cleavage. With 
the additional source of BACE1, NRG1 could be cleaved extracellularly much faster 
and γ-secretase could do its work more effectively. A comparison with overexpressed γ-
secretase would provide an interesting result. 
As explained above, pro-NRG1 can be cleaved by these known enzymes: γ-secretase, 
TACE, and BACE1. The controls for successful inhibition of cleavage for the screen 
were inhibitors of these enzymes.  
DAPT is a γ-secretase inhibitor and it can indirectly inhibit Notch signaling that is 
involved in many diseases, such as cancers or atherosclerosis (Micchelli et al. 2003; L.-
C. Li et al. 2014; Qin et al. 2016). It can also reduce the Aβ peptides levels in the 
transgenic mouse which might be useful for Alzheimer’s disease study (Dovey et al. 
2001; Lanz et al. 2003). DAPT targets the C-terminal fragment of presenilin, a catalytic 
subunit of the γ-secretase intramembrane protease complex, by synthesizing a 
photoactivable DAPT derivative (Morohashi et al. 2006). By inhibiting the γ-secretase, 
the intracellular cleavage of NRG1 will be reduced. Thus, less NRG1-ICD will be 
released. In the assay, DAPT inhibited the activity as expected by ~50 per cent from 
baseline (Figure 14). Therefore, it is suitable for the screen.  
TAPI-1 is a potent inhibitor of matrix metalloproteinases and TACE (Sun et al. 2015). 
TAPI-1 also reduced muscarinic receptor-stimulated sAPP α (soluble N-terminal 
fragment of APP) release in HEK-293 cells (Slack, Ma, and Seah 2001; Doedens, 
Mahimkar, and Black 2003). Like BACE1, TACE can also cleave NRG1 extracellularly, 
but on different positions (Figure 5). At a final concentration of 10 µM, TAPI-1 showed 








As mentioned above, BACE1 is responsible for the extracellular cleavage. Two BACE1 
inhibitors were tested, namely LY2811376 and β-secretase Inhibitor IV. LY2811376 is a 
BACE1 Inhibitor with marked Aβ-lowering effects in animal models (May et al. 2010, 
2011; Portelius et al. 2014). β-secretase Inhibitor IV is a cell-permeable inhibitor that 
binds to BACE-1 active site and blocks its proteolytic activity (Potter and Dressler 
2000; Stachel et al. 2004). After some dose response assays, both LY2811376 and β-
secretase IV did not make any convincing inhibition unless used at high concentrations 
(60-80 µM). Both of them only showed a 20 per cent reduction from baseline at a final 
concentration of 10 µM (Figure 15), thus BACE1 inhibitors were not used as controls.  
DAPT worked presumably the best because it inhibits directly the intracellular cleavage 
of NRG1-ICD from the rest of NRG1. Because the intracellular cleavage is blocked by 
DAPT, NRG1-ICD cannot be released, despite the event of the extracellular cleavage. 
Even though the extracellular cleavage is blocked (by TAPI-1, LY2811376, or β-
secretase Inhibitor IV), NRG1-ICD can still be intracellularly cleaved by γ-secretase. 
This could still result in the occurrence of intracellular cleavage despite the extracellular 
cleavage being blocked.  
Both BACE1 inhibitors need to have a higher concentration to be at the same level as 
TACE inhibitor. Unfortunately, it is still unknown, exactly how the mechanism of action 
of these inhibitors works. LY2811376 and β-secretase Inhibitor IV at the final 
concentration of 60 µM have the same result as TAPI-1 at 10 µM. DAPT and TAPI-1 












6.2 Screen and hits 
The compounds used for the screen were supplied from NIH Clinical Collection. 
Additionally, all compounds have already been clinically tested and approved by FDA 
with its known safety profile. Therefore, the upcoming hits could be directly tested on 
animals and in clinical trials. Many drugs still have undiscovered therapeutic efficacy 
aside from its original indication. This screen can help to find drugs that could provide 
some insight in relevance to NRG1 back signaling and perhaps schizophrenia.  
The screen was planned to be done in 384-well plate instead of 96-well plate after 
considering time and cost efficiency, and also the high amount of plates for replicates. 
The tests that were carried out between 4 replicates and 8 replicates beforehand in order 
to correlate the results appear to be nearly identical. Four replicates were then selected 
for each compound. In order to create 4 replicates of all 727 compounds, only 10 384-
well plates were needed instead of 40 96-well plates. Renilla luciferase was not used for 
the screen due to its inconstant value in the 384-well plate. The discovered hits should 
be then individually validated with Renilla luciferase or other secondary assays to 
investigate their toxicity.  
After the assay was robust enough to be done in 384-well plates, the screen was ready to 
be performed as well. The protocol was carefully planned and all the materials needed 
for the screen were prepared beforehand. During the course of the screen, there were 
some new ideas for improvements. Two hours after transfection, ten 50 ml Falcon tubes 
containing the cells with the same transfected DNA should be first mixed together as 
one before pouring them into the reservoir, instead of pouring them one by one. The 
chance for every well to have the same amount of cells might be better.  The method of 
using a centrifuge to remove the medium from the plates could also be improved.  
However, there were also some problems throughout the screen. The cells were not 
evenly distributed for each well on some plates. There were wells that had more volume 
than the others. There was only one microplate reader (Berthold), so the other following 
plates had to wait in a queue. Consequently, the exact time of measurement for the other 
plates would also be delayed. The robot also unknowingly stopped functioning as it 
pipetted the Firefly buffer onto plate 7, so the application had to be done manually. 
Some problems in replicate performances were also observed. After looking at the raw 




the rows before, especially the positive controls. That suggests, either the first and the 
second replicates had lower values, or the third and fourth replicates’ value was too high. 
There could be many reasons behind this, such as volume differences in some wells due 
to pipetting error. Due to volume differences, the wells that had more volume might also 
have a higher value. Such event was also observed during the measurement. As the 
pipette tips passed into certain wells, the tip volume would also be added up into the 
mixture volume of PLB and Firefly buffer, so that the total volume would exceed the 
maximal well volume, which can result in the possible contamination to the nearby 
wells. Another explanation is the position of the wells on the screening plate, 
specifically on the outer rows and columns. The value on said rows and column would 
differ from wells in the interior plate. This phenomenon is called edge effects, which are 
caused by rapid evaporation at the corners and edges during the screen (Carralot et al. 
2012).  
The analysis of the screen was done by cellHTS2 software (Boutros, Brás, and Huber 
2006). CellHTS2 is a software program designed to analyze cell-based high-throughput 
screens. Raw data files need to be imported and the experimental outliers will be 
identified. It is also capable of normalizing data for systematic technical variations. 
After the phenotypes scoring and statistical summary, the complete analysis can be 
documented as a set of HTML pages. 
As shown in Figure 19, the normalized values of the negative controls have an average 
of about -1 and have a defined peak for each replicate. In contrast, the normalized 
values of the positive controls, especially BACE1, scatter overall. They are not dense 
enough to make a defined peak equivalent to the negative controls. Some technical 
errors, as explained above, are to be considered. Z´-factor is also the ratio of the 
separation between these two peaks to the assay dynamic range. Based on Table 11, all 
Z´-factors were smaller than 0. The activation from the positive controls was very 
strong but the replicate performance was not robust enough. The positive controls have 
to be optimized again, perhaps using a compound rather than a co-transfection. As an 
alternative, the position of the wells could be changed considering the edge effects.    
The following were the top activators of the screen: Irsogladine maleate, Nitrendipine, 
Bestatin, 4-(aminomethyl) benzensulfonamide acetate, Allegra, Zolmitriptan, 
Dipyridamole, Rifapentine, Naltrexone hydrochloride, Citalopram, and Albendazole. 




only Citalopram is known for its practice in psychiatric diseases.  
Citalopram belongs to selective serotonin reuptake inhibitor (SSRI), a class of 
antidepressant agents. SSRI increases the neurotransmitter serotonin-level in the blood 
by inhibiting its resorption into the presynaptic cell. Contrary to antipsychotics, they 
have little affinity for the dopamine D2 receptor (Baumann 1996; Mandrioli et al. 2012). 
The increase in serotonin-level may have an invigorating effect that might help relieve 
the negative symptoms of schizophrenia patients. Citalopram is indicated for depression, 
anxiety disorder, and obsessive-compulsive disorder. There was a recent clinical trial 
conducted to treat schizophrenia patients with antidepressant Citalopram. The result 
suggested that Citalopram had some effect on one of the negative symptoms, 
avolition/amotivation, although further investigation still needs to be done (Barnes et al. 
2016).  
The top inhibitors included: Ifenprodil, Idarubicin, Doxorubicin, Epirubicin, Triptolide, 
Diphenylcyclopropenone, Spironolactone, Mitoxantrone, Perphenazine, Topotecan, 
Dactinomycin, Homoharringtonine, Pamelor, Annoyltin, Mosapride citrate, 
Cyproheptadine hydrochloride, Thioridazine hydrochloride, and CGS 15943 (Table 13). 
Some of the inhibitors that were flagged (Idarubicin, Doxorubicin, Epirubicin, 
Triptolide, Diphenylcyclopropenone, Mitoxantrone, Homoharringtonine, and 
Thioridazine hydrochloride) are considered toxic because of the low level of Renilla 
luciferase during a previous screen performed by colleagues. Among the rest, there are 
some interesting compounds that have also been used for psychiatric disease treatments, 
like Ifenprodil, Perphenazine, Pamelor, and Annoyltin. 
Ifenprodil is an N-methyl-D-aspartate receptor (NMDAR) antagonist (Reynolds and 
Miller 1989). NMDA receptors are ionotropic glutamate receptors that play a critical 
role in synaptic plasticity and memory functions (F. Li and Tsien 2009). However, 
NMDA receptors are also involved in excitotoxicity, a condition by which the nerve 
cells are damaged due to overstimulation by neurotransmitters such as glutamate (Choi, 
Koh, and Peters 1988). Excitotoxicity might lead to some neurodegenerative diseases, 
such as Alzheimer’s disease or Huntington’s disease (Parsons and Raymond 2014). 
Preventing excessive excitotoxicity by using an NMDAR antagonist such as Ifenprodil 
might provide some therapeutic benefits. Furthermore, glutamate hypothesis of 
schizophrenia suggests that hypofunction of NMDA receptor signaling may contribute 




the side effects of NMDAR antagonist, which reproduce similar symptoms resembling 
psychosis, such as hallucinations, delusions, catatonia, and thought disorders (Aarts and 
Tymianski 2003; Erhardt et al. 2007).  
Perphenazine is classified as a typical antipsychotic drug. It is a dopamine (D2) 
antagonist with antiemetic properties and extrapyramidal side-effects (Sweet et al. 
2000). It blocks postsynaptic D2 receptors, which prevent dopamine excess in brain. 
Hyperactivity in brain dopamine systems was hypothesized to be the cause of 
schizophrenia (Howes and Kapur 2009). D2 receptor antagonist is used to reduce 
psychotic symptoms of schizophrenia, such as aggressions, hallucinations or delusions 
(Hartung, Sampson, and Leucht 2015). It was also suggested, that D2 receptor 
antagonist may hold promises against tauopathies and neurotoxicity (McCormick et al. 
2013).  
Pamelor and Annoyltin are the hydrochloride salt forms of Nortriptyline and 
Amitriptyline, respectively. Both of them are tricyclic antidepressant (TCA) drugs. 
Amitriptyline blocks norepinephrine and serotonin presynaptic receptors, thus inhibiting 
the reuptake and increasing norepinephrine and serotonin levels in synaptic clefts in the 
CNS, whereas Nortriptyline blocks selectively the norepinephrine reuptake (Tatsumi et 
al. 1997). They are used to treat psychological disorders, such as major depression or 
personality disorder, and are also used in pain management (Kevin Hicks et al. 2016). 
However, due to its anticholinergic side effects, the indication has to be considered 
carefully (Gray et al. 2015). A combination of antipsychotic Perphenazine and 
antidepressant Amitriptyline was more effective against depression form of 
schizophrenia than a monotherapy (Prusoff et al. 1979). 
It was interesting to see that drugs from antidepressant class can function both as 
activator (Citalopram) and also inhibitor (Pamelor, Annoyltin) of the assay. Both 
Citalopram and Annoyltin have the same mechanism of action, which resulting in a high 
level of serotonin in synaptic clefts in the CNS. There could be a connection between 
serotonin and NRG1 cleavage activity, as experiments with serotonin receptor can also 
be done in PC12 cells (Homma et al. 2006; Koizumi and Nakajima 2014). Animal 
studies proposed the involvement of NRG1 gene expression in the development of the 
serotonergic system (Dean et al. 2008). There might be another different mechanism of 
action of the drugs, which is still yet to be discovered. Other intriguing results from the 




might cause irregularity in glutamatergic signaling, as stated in the glutamate hypothesis 
of schizophrenia. Research done on animal models showed that defect on glutamatergic 
synapses might lead to behavioral abnormalities in ErbB2/B4-deficient mice (Barros et 
al. 2009). On the other hand, dopamine hypothesis of schizophrenia suggests 
hyperactivity of dopamine in brain might also lead to schizophrenia, which can be 
treated by Perphenazine, a dopamine receptor antagonist. Both hypotheses might 
complement each other, which result into both dopaminergic and glutamatergic 
abnormalities in CNS and eventually the symptom complex of schizophrenia. 
Nevertheless, all selected hits will go through further validation. 
 
6.3 Outlook 
Following the flow of drug discovery process, the identified hits will be further 
validated. The selected compounds will be individually tested again along with the 
positive and negative controls with LumiCycle live cell measurements and in 96-well 
plates for confirmation. Afterwards, the compounds will undergo 96-well plate methods 
with Renilla luciferase for toxicity tests. Technical control assays using CMV-GV also 
need to be done to check whether the compounds actually modify the NRG1 cleavage 
activity or rather they have more effects on the GV, the UAS promoter, or the Firefly 
luciferase. Dose response assays of the compounds will be established with the robot. 
After the qualified compounds passed the control tests, secondary assays and secondary 
targets using the compounds will be planned. To test whether the compounds also have 
an effect to ERBB4, ERBB4-PI3K split TEV assay will be done (Wehr et al. 2006). 
Another example would be a NRG1-LIMK1 split TEV assay to test whether the 
compounds have any effects on its interaction. Alternative targets for the compounds, 
such as APP or Notch which are similarly processed by BACE1, TACE, and γ-secretase 
(see above), could also be tested to see, whether the compounds inhibit/activate 
specifically the NRG1 cleavage or generally also the other targets which could cause 
some side effects. Additional testing, like orthogonal validation includes western blot, 
e.g. NRG1 cleavage products. The following step would be preclinical studies using 
mouse models to collect information regarding in vivo processing of NRG1 in the 
mouse brain and the first human dose. After being approved by the regulatory 
authorities, the drugs may advance to the clinical phase, where the drugs could be tested 






Schizophrenia is a developmental, long-term mental disorder that causes a number of 
different psychological symptoms, such as positive symptoms, negative symptoms, and 
cognitive deficits. The exact causes of schizophrenia are unknown, but research 
suggests that a combination of physical, genetic, psychological, and environmental 
factors might contribute to the development of schizophrenia. In recent years, genome-
wide association studies (GWAS) provided insights into possible etiological 
mechanisms of this symptom complex. Several genes have been associated with the 
disease, such as Neuregulin-1 (NRG1). This gene was identified as risk factor for 
schizophrenia in a certain population. Therefore, an improved understanding of NRG1 
signaling could eventually lead to the development of more effective therapies for 
certain forms of schizophrenia. 
A mutation within the transmembrane domain of NRG1 (V321L) was found to be 
associated with schizophrenia. It interferes with the intracellular cleavage of NRG1, 
which consecutively impairs the physiological NRG1 signaling, for instance in the 
development of cortical dendrite formation and neuroconnectivity. This so-called 
backward signaling of NRG1 is our main focus, in which the intracellular domain of 
NRG1 is crucial. Although there were already some hypotheses regarding its function as 
explained above, it is still unclear which signaling pathways it affects. Therefore, NRG1 
cleavage assay was established and then a high-throughput screening (HTS) approach 
was conducted to find potential modulators of NRG1 cleavage.  
The assay was first carried out in living cells to observe the NRG1 cleavage kinetics. 
After an ideal time point of the cleavage was determined, the assay was adapted to a 96-
well format and then to a 384-well format for robotics. Inhibitors for the enzymes that 
play important roles for the NRG1 processing (BACE1, TACE, and γ-secretase) were 
included in the screen as control for down-modulation. Controls for activation were co-
transfection with ERBB4 or BACE1 constructs, which stimulate the intracellular 






After the assay was robust enough in 384-well plates, the screen was performed using 
an automated liquid handling system assembled with a microplate reader. The NIH 
Clinical Collection (NCC) compound library consists of more than 700 drugs that have 
been FDA-approved. All these drugs have been tested on humans and their safety 
profiles are already known. Via this drug repurposing strategy, the costs and time for 
application of identified hits can be reduced significantly, so that validated hits could be 
tested in mouse models and clinical trials rapidly. 
Screen results revealed some promising modulators of NRG1 cleavage, mainly because 
of their history of use in psychiatric diseases. Citalopram, which has been used as 
antidepressant, was identified as a potential activator of NRG1 intracellular cleavage. 
Moreover, Pamelor and Annoyltin, which also belong to antidepressant class, were 
found to be potential cleavage inhibitors. Another interesting hit was Perphenazine, a 
dopamine receptor antagonist that has already been used for treatment of schizophrenia. 
The most potent inhibitor from the screen was Ifenprodil, an NMDA receptor antagonist, 
which has been linked with the glutamate hypothesis of schizophrenia. These substances 
should be further validated, e.g. in cellular toxicity tests, so-called counter assays to 
asses specificity, and dose response assays. After the selected compounds pass all the 
necessary criteria, the compounds would be evaluated in mouse models of 








Schizophrenie ist eine entwicklungsbedingte, langfristige psychische Störung, die eine 
Reihe von verschiedenen psychologischen Symptomen verursacht, wie zum Beispiel 
positive Symptome, negative Symptome, und kognitive Defizite. Die genauen Ursachen 
der Schizophrenie sind unbekannt, aber die Forschung lässt darauf schließen, dass eine 
Kombination von physischen, genetischen, psychologischen und Umweltfaktoren zur 
Entwicklung der Schizophrenie beiträgt. Sogenannte genome-wide association studies 
(GWAS) lieferten insbesondere einen Einblick in die möglichen ätiologischen 
Mechanismen dieser Erkrankung. Mehrere Gene wurden mit der Krankheit assoziiert, 
darunter Neuregulin-1 (NRG1). Dieses Gen wurde als Risikofaktor für Schizophrenie in 
einer bestimmten Population identifiziert. Daher könnte ein verbessertes Verständnis der 
NRG1-Signaltransduktion zur Entwicklung von wirksameren Therapien für bestimmte 
Formen der Schizophrenie führen. 
 
Es wurde ein Zusammenhang zwischen einer Mutation, die innerhalb der 
Transmembrandomäne von NRG1 lokalisiert (V321L), und Schizophrenie identifiziert. 
Diese Mutation interferiert mit der intrazellulären Spaltung von NRG1, was folglich die 
physiologische Funktion von NRG1 beeinträchtigt, zum Beispiel bei der Entwicklung 
der kortikalen Dendritbildung und der Neurokonnektivität. Diese 
„Rückwärtssignalisierung“ von NRG1 ist unser Schwerpunkt, bei der die intrazelluläre 
Domäne von NRG1 eine kritische Rolle übernimmt. Zwar gab es bereits einige 
Hypothesen über ihre Funktion, wie oben erläutert, aber es ist noch unklar, welche 
Signalwege sie im Detail beeinflusst. Daher wurde der NRG1 Spaltungs-Assay etabliert 
und anschließend ein Screening durchgeführt, um potentielle Modulatoren der NRG1-
Prozessierung zu finden. 
 
Der Assay wurde zuerst in lebenden Zellen durchgeführt, um die NRG1-Spaltkinetik zu 
untersuchen. Nachdem ein idealer Zeitpunkt der Spaltung bestimmt wurde, wurde der 
Assay in 96-Well-Platten und schließlich in 384-Well-Platten für das automatisierte 
Screening angepasst. Inhibitoren für Enzyme, die bei der NRG1-Verarbeitung (BACE1, 
TACE und γ-Sekretase) wichtige Rollen spielen, wurden als Kontrollen einbezogen. 
Kontrollen für Aktivatoren der NRG1-Spaltung waren die Co-Transfektion mit ERBB4- 





Nachdem der Assay in 384-Well-Platten robust etabliert wurde, konnte der Screen unter 
Verwendung eines Roboters durchgeführt werden. Die hier verwendete NIH Clinical 
Collection (NCC) Compound Bibliothek besteht aus mehr als 700 Medikamenten, die 
bereits FDA-zugelassen sind. Alle diese Medikamente wurden am Menschen getestet 
und ihre Sicherheitsprofile sind bereits bekannt. Durch diese „drug repurposing“-
Strategie können die Kosten und die Zeit für die weitere Entwicklung der identifizierten 
Hits deutlich verringert werden, so dass validierte Medikament-Kandidaten schnell in 
klinischen Studien eingesetzt werden können. 
 
Im Screen wurden einige vielversprechende Modulatoren der NRG1-Spaltung 
identifiziert, welche vor allem aufgrund ihrer Verwendung bei psychiatrischen 
Erkrankungen interessant sind. Citalopram, das als Antidepressivum verwendet wird, ist 
ein potentieller Aktivator der intrazellulären NRG1-Spaltung. Darüber hinaus wurden 
Pamelor und Annoyltin, ebenfalls Antidepressiva, als potenzielle Inhibitoren 
identifiziert. Ein weiterer interessanter Kandidat ist Perphenazin, ein Dopamin-
Rezeptor-Antagonist, der bereits zur Behandlung von Schizophrenie verwendet wird. 
Der potenteste Inhibitor aus dem Screen war Ifenprodil, ein NMDA-Rezeptor-
Antagonist, der mit der Glutamat-Hypothese der Schizophrenie assoziiert wird. Alle 
diese Substanzen müssen weiter validiert werden, z.B. in Toxizitätstests, sog. Counter-
Assays als Spezifitätskontrollen, und Dose-Response-Assays. Nachdem die 
ausgewählten Compounds alle notwendigen Kontrollen durchlaufen haben, können sie 











ADAM a disintegrin and metalloprotease 
APP amyloid precursor protein 
ATP Adenosine triphosphate 
BACE β-site amyloid precursor protein cleaving enzyme 
BSA Bovine Serum Albumin 
CNS Central nervous system 
cpm Counts per minute 
CRD Cysteine-rich domain 




DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DSM Diagnostic and Statistical Manual of Mental Disorders 
DTT 1,4-dithiothreitol 
e.g. For example/exempli gratia 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ERBB4/E4 Receptor tyrosine kinase family  
FBS Fetal bovine serum 
FDA Food and Drug Administration 
Fluc Firefly luciferase 
g gram, gradians 
GV Gal4-VP16 
GWAS Genome-wide association study 
h hour 
HER Human epidermal growth factor receptor 
HS Horse serum 
HTML Hypertext Markup Language 
HTS High-throughput screening 
ICD Intracellular domain 
Ig Immunoglobulin 
IL-1R2 Interleukin-1 Receptor II 
JMa Juxtamembrane region a 
JMb Juxtamembrane region b 
l liter 
L2000 Lipofectamine2000                                                                          
LB medium Lysogeny broth medium 
LIMK1 Lin11, Isl-1, & Mec-3 kinase 1 
M Molar 
MAD Median Absolute Deviation 
MAPK mitogen-activated protein kinase 















NCC NIH Clinical Collection 
NIH National Institutes of Health 
NMDAR N-Methyl-D-aspartate Receptor 
NRG Neuregulin 
NTF N-terminal fragment 
OMEM OptiMEM 
PBS Phosphate buffered saline 
PC12 Rat pheochromocytoma cell line 
PI3K phosphoinositide 3-kinase 
PKB Protein Kinase B 
PKC Protein Kinase C 
PLB Passive Lysis Buffer 
PLL Poly-L-lysine 
RLU Relative luciferase units 
rpm Revolution per minute 
RTK Receptor tyrosine kinase 
SNP Single nucleotide polymorphism 
SSRI Selective serotonin reuptake inhibitor 
TACE TNF-α converting enzyme 
TAPI-1 TNF-α protease inhibitor 1 
TCA Tricyclic Antidepressant 
TEV Tobacco etch virus 
TK Tyrosine kinase 
TMD Transmembrane domain 
TNF-α Tumor necrosis factor-α 
UAS Upstream activating sequence 
UV Ultraviolet 
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12.1   NCC 201 screen result  
























1 1 -1.35 A01 baseline 55360 48340 59570 82130 -0.696 -3.128 -1.711 -0.999 control 
1 13 0.24 B01 baseline 88180 89060 90840 81810 2.052 0.612 -0.131 -1.01 control 
1 25 0.65 C01 baseline 77120 66410 118400 115230 1.126 -1.468 1.262 0.173 control 
1 37 -1.91 D01 dapt 40980 47560 63140 56070 -1.9 -3.199 -1.53 -1.922 control 
1 49 -1.62 E01 dapt 55460 48400 61420 64710 -0.687 -3.122 -1.617 -1.616 control 
1 61 -1.92 F01 dapt 46940 41680 56170 55310 -1.401 -3.739 -1.883 -1.949 control 
1 73 -2.33 G01 tapi-1 35000 37980 48840 48840 -2.401 -4.079 -2.253 -2.178 control 
1 85 -1.76 H01 tapi-1 44150 60150 56010 65240 -1.635 -2.043 -1.891 -1.597 control 
1 2 -1.91 A02 sample 37820 53340 60810 79150 -2.165 -2.669 -1.648 -1.105 SAM002264608_DOXEPIN_HYDROCHLORIDE 
1 14 2.96 B02 sample 70570 116860 167870 187970 0.578 3.164 3.761 2.748 SAM002264609_DIPYRIDAMOLE 
1 26 0.4 C02 sample 84550 88120 90070 118330 1.748 0.525 -0.17 0.283 SAM002264610_Propofol 
1 38 -0.61 D02 sample 58540 82290 65400 87760 -0.43 -0.01 -1.416 -0.8 SAM002264611_ETHACRYNIC_ACID 
1 50 -0.02 E02 sample 68600 96010 84650 81550 0.413 1.25 -0.444 -1.02 SAM002264612_FLUTAMIDE 
1 62 0.35 F02 sample 82090 88700 95860 103630 1.542 0.579 0.123 -0.238 SAM002264613_FENOFIBRATE 
1 74 0.49 G02 sample 88670 100290 79720 91610 2.093 1.643 -0.693 -0.664 SAM002264614_FUROSEMIDE 
1 86 -1.96 H02 sample 31620 54510 66500 80110 -2.684 -2.561 -1.361 -1.071 SAM002264615_5-FLUOROURACIL 
1 3 0.19 A03 sample 65460 105830 98170 86510 0.15 2.152 0.239 -0.844 SAM002264616_Folic_acid 
1 15 1.43 B03 sample 72780 101050 125970 144770 0.763 1.713 1.644 1.219 SAM002264617_HYDROCORTISONE 
1 27 1.06 C03 sample 86360 103710 88320 116490 1.9 1.957 -0.258 0.217 SAM002264618_Cortell 






1 51 0.22 E03 sample 85460 91290 77780 99490 1.825 0.816 -0.791 -0.385 SAM002264620_KETOPROFEN 
1 63 0.58 F03 sample 72020 87490 107400 123230 0.699 0.467 0.706 0.456 
SAM002264621_MINOCYCLINE_HYDROCHLORI
DE 
1 75 0.99 G03 sample 79180 85350 122190 129700 1.299 0.271 1.453 0.685 SAM002264623_MICONAZOLE_NITRATE 
1 87 0.68 H03 sample 80970 87800 110370 113820 1.449 0.496 0.856 0.123 SAM002297829_METYRAPONE 
1 4 0.48 A04 sample 82780 80880 1e+05 127840 1.6 -0.14 0.332 0.619 SAM002264625_NORFLOXACIN 
1 16 0.31 B04 sample 68130 85170 113610 111790 0.373 0.254 1.02 0.051 SAM002264627_NADOLOL 
1 28 -0.24 C04 sample 53550 86470 76530 141280 -0.847 0.374 -0.854 1.095 SAM002264628_Disipal 
1 40 0.09 D04 sample 63720 86350 97010 100900 0.004 0.363 0.181 -0.335 SAM002264629_OFLOXACIN 
1 52 0.12 E04 sample 67250 82210 98450 110070 0.3 -0.017 0.254 -0.01 SAM002264631_PINDOLOL 
1 64 0.21 F04 sample 65290 83730 99170 136840 0.136 0.122 0.29 0.938 SAM002264632_PRAZIQUANTEL 
1 76 1.36 G04 sample 70470 111910 135820 119550 0.569 2.71 2.142 0.326 SAM002264634_Benzenebutanoic_Acid 
1 88 1.59 H04 sample 82300 86390 133760 156230 1.56 0.366 2.038 1.624 SAM002264635_PREDNISOLONE_ACETATE 
1 5 -1.64 A05 sample 37550 59440 72050 77120 -2.187 -2.108 -1.08 -1.177 SAM002264636_Phenergan 
1 17 -2.84 B05 sample 15870 39860 58310 102090 -4.003 -3.906 -1.774 -0.292 SAM002264637_PERPHENAZINE 
1 29 0.71 C05 sample 60500 101130 100860 139720 -0.265 1.72 0.375 1.04 SAM002264639_Prednisolone 
1 41 0.11 D05 sample 67090 81620 100800 101760 0.286 -0.072 0.372 -0.304 SAM002264640_PRILOCAINE_HYDROCHLORIDE 
1 53 -0.15 E05 sample 80500 79330 80210 109660 1.409 -0.282 -0.668 -0.024 SAM002264641_Prednisone 
1 65 -0.37 F05 sample 56550 78530 85890 103650 -0.596 -0.355 -0.381 -0.237 SAM002264642_DL-PENICILLAMINE 
1 77 1.33 G05 sample 94150 81930 116900 151990 2.552 -0.043 1.186 1.474 SAM002264643_PIPERACILLIN_SODIUM_SALT 
1 89 1.3 H05 sample 76700 95010 121860 160910 1.091 1.158 1.436 1.79 
SAM002264644_Quinidine_hydrochloride_monohydr
ate 
1 6 0.24 A06 sample 53900 81210 105040 133280 -0.818 -0.109 0.587 0.812 SAM002264645_Ranitidine_hydrochloride 
1 18 -0.39 B06 sample 63210 78900 76770 97260 -0.039 -0.321 -0.842 -0.463 SAM002264646_RIFAMPICIN 
1 30 -0.59 C06 sample 59790 75410 82920 82980 -0.325 -0.642 -0.531 -0.969 SAM002264647_Retinoic_acid 
1 42 -3.01 D06 sample 28950 41120 31850 36790 -2.907 -3.791 -3.111 -2.604 SAM002264648_Spironolactone 






1 66 1.3 F06 sample 80380 79610 117090 149780 1.399 -0.256 1.195 1.396 SAM002264650_Tyzine 
1 78 1.13 G06 sample 81490 90810 123150 115250 1.492 0.772 1.502 0.173 SAM002264651_L-THYROXINE 
1 90 0.03 H06 sample 55440 67650 158440 131410 -0.689 -1.354 3.285 0.746 SAM002264652_Artane 
1 7 0.1 A07 sample 64640 83760 79400 129970 0.081 0.125 -0.709 0.695 SAM002264653_URSODEOXYCHOLIC_ACID 
1 19 -0.86 B07 sample 44500 74930 72810 122970 -1.605 -0.686 -1.042 0.447 SAM002554879_Dapsone 
1 31 -0.11 C07 sample 70490 80410 88860 109140 0.571 -0.183 -0.231 -0.043 SAM002554881_Symmetrel 
1 43 1.75 D07 sample 63500 87780 166290 195300 -0.014 0.494 3.681 3.008 SAM002554882_WARFARIN_SODIUM 
1 55 0.05 E07 sample 63730 82090 95480 139020 0.005 -0.028 0.104 1.015 SAM002554883_Acetazolamide 
1 67 -0.46 F07 sample 59050 83840 82830 67590 -0.387 0.132 -0.536 -1.514 SAM002554884_Allopurinol 
1 79 0.07 G07 sample 63620 83360 100810 111900 -0.004 0.088 0.373 0.055 SAM002554885_ATROPINE 
1 91 0.47 H07 sample 83540 82510 111960 102620 1.664 0.01 0.936 -0.274 SAM002554914_Nalidixic_Acid 
1 8 -1.01 A08 sample 47930 73150 70320 100950 -1.318 -0.849 -1.168 -0.333 SAM003107539_3,5,3'-TRIIODOTHYRONINE 
1 20 -0.31 B08 sample 59680 65140 87790 108190 -0.334 -1.585 -0.285 -0.076 SAM002703134_HYDROFLUMETHIAZIDE 
1 32 -2.6 C08 sample 27390 49940 49510 87450 -3.038 -2.981 -2.219 -0.811 SAM002554886_Annoyltin 
1 44 -0.66 D08 sample 50510 71580 88300 100850 -1.102 -0.994 -0.259 -0.336 SAM002554887_Busulfan 
1 56 0.48 E08 sample 56200 83700 116410 134220 -0.626 0.119 1.161 0.845 SAM002554888_Chlorzoxazone 
1 68 -0.45 F08 sample 61430 79940 79950 88470 -0.188 -0.226 -0.681 -0.775 SAM002554891_Chlorothiazide 
1 80 -0.11 G08 sample 61000 82820 87760 110630 -0.224 0.039 -0.286 0.01 SAM002554892_Cimetidine 
1 92 -0.28 H08 sample 74710 78480 89490 89110 0.924 -0.36 -0.199 -0.752 SAM002554889_Carisoprodol 
1 9 -1.28 A09 sample 45640 65870 73100 80940 -1.51 -1.518 -1.027 -1.041 SAM002554890_Chlorpropamide 
1 21 -0.81 B09 sample 48920 65950 85750 167640 -1.235 -1.511 -0.388 2.028 SAM002554894_Bentyl 
1 33 -0.44 C09 sample 37980 73330 92480 117930 -2.151 -0.833 -0.048 0.268 SAM002554895_Chloroxine 
1 45 0.54 D09 sample 59610 77620 127800 150180 -0.34 -0.439 1.736 1.41 SAM002554896_Diflunisal 
1 57 1.3 E09 sample 49150 100160 130980 137990 -1.216 1.631 1.897 0.979 SAM002554898_Econazole_Nitrate 
1 69 -0.64 F09 sample 1780 73320 91000 97860 -5.182 -0.834 -0.123 -0.442 SAM002554899_Ethionamide 






1 93 0.45 H09 sample 62100 90590 96310 153260 -0.131 0.752 0.146 1.519 SAM002554901_Hydrochlorothiazide 
1 10 -0.67 A10 sample 64470 74820 80600 52600 0.067 -0.696 -0.648 -2.045 SAM002554902_Vistaril_Pamoate 
1 22 0.67 B10 sample 12490 88450 130680 132270 -4.286 0.556 1.882 0.776 SAM002554903_Hexachlorophene 
1 34 0.02 C10 sample 60680 76000 99300 122730 -0.25 -0.588 0.297 0.438 SAM002554904_Isoniazid 
1 46 0.52 D10 sample 55810 101480 94350 138620 -0.658 1.752 0.046 1.001 SAM002554905_Duvadilan 
1 58 -0.34 E10 sample 59580 77900 86890 124280 -0.342 -0.413 -0.33 0.493 SAM002554906_Isuprel 
1 70 0.87 F10 sample 67160 96150 102970 147960 0.292 1.263 0.482 1.332 SAM002554907_Triclosan 
1 82 0.23 G10 sample 67830 83580 120950 80720 0.348 0.108 1.39 -1.049 SAM002554908_Mefenamic_Acid 
1 94 0.51 H10 sample 88780 91680 96790 111330 2.103 0.852 0.17 0.035 SAM002554910_Cantil 
1 11 0.31 A11 sample 54340 92020 126820 102980 -0.781 0.883 1.687 -0.261 SAM002554911_Maxolon 
1 23 -0.09 B11 sample 65590 76360 92510 106830 0.161 -0.555 -0.046 -0.125 SAM002554912_Methyldopa 
1 35 -0.07 C11 sample 64740 75180 89260 112500 0.09 -0.663 -0.211 0.076 SAM002554913_NITROFURANTOIN 
1 47 -2.65 D11 sample 25230 44240 52400 80800 -3.219 -3.504 -2.073 -1.046 SAM002554915_Pamelor 
1 59 -0.41 E11 sample 58300 66190 87060 100080 -0.45 -1.489 -0.322 -0.364 SAM002554916_Albalon 
1 71 -0.35 F11 sample 67910 63340 81030 108280 0.355 -1.75 -0.626 -0.073 SAM002554917_Nicotinic_Acid 
1 83 -0.48 G11 sample 60190 58980 96270 91600 -0.291 -2.151 0.143 -0.664 SAM002554918_Norflex 
1 95 0.37 H11 sample 71550 90730 94900 78970 0.66 0.765 0.074 -1.111 SAM002554919_Oxytetracycline_hydrochloride 
1 12 4.73 A12 
merbb4
-f 
76960 366940 133820 319790 1.113 26.129 2.041 7.416 control 
1 24 8.65 B12 
merbb4
-f 
181620 353070 185390 319840 9.877 24.856 4.646 7.417 control 
1 36 6.29 C12 
merbb4
-f 
93400 298120 139440 395450 2.489 19.81 2.325 10.094 control 
1 48 8.08 D12 
merbb4
-f 
144040 369190 184830 376920 6.73 26.336 4.618 9.438 control 
1 60 26.56 E12 bace-1 442120 808230 442320 715700 31.69 66.653 17.627 21.433 control 
1 72 26.9 F12 bace-1 392690 612310 612870 662860 27.551 48.662 26.244 19.562 control 
1 84 25.78 G12 bace-1 451190 697410 471590 584970 32.449 56.476 19.106 16.805 control 






2 1 -0.32 A01 baseline 43170 50210 61700 74040 -0.299 -0.984 -0.348 -0.24 control 
2 13 -0.41 B01 baseline 46540 53600 52220 77330 -0.088 -0.74 -0.847 -0.06 control 
2 25 -0.21 C01 baseline 42700 62460 70920 72730 -0.328 -0.099 0.137 -0.312 control 
2 37 -1.75 D01 dapt 32670 30830 39550 42370 -0.957 -2.385 -1.514 -1.978 control 
2 49 -1.55 E01 dapt 31840 41350 38950 50060 -1.009 -1.625 -1.545 -1.556 control 
2 61 -1.41 F01 dapt 45370 47670 36890 34100 -0.161 -1.168 -1.654 -2.432 control 
2 73 -2.18 G01 tapi-1 26140 24280 31390 34370 -1.367 -2.858 -1.943 -2.418 control 
2 85 -1.61 H01 tapi-1 32000 41310 37640 49100 -0.999 -1.628 -1.614 -1.609 control 
2 2 -0.5 A02 sample 46780 49490 55980 72060 -0.073 -1.036 -0.649 -0.349 SAM002554920_Novocain 
2 14 -0.22 B02 sample 49100 63820 59850 60980 0.073 -0.001 -0.445 -0.957 SAM002554921_Pyrimethamine 
2 26 0.42 C02 sample 48020 86210 72090 90010 0.005 1.617 0.199 0.636 SAM002554922_Pro-Banthine 
2 38 -1.22 D02 sample 34810 55450 35790 48790 -0.823 -0.606 -1.712 -1.626 SAM002554923_Probenecid 
2 50 -0.66 E02 sample 42410 58330 50700 49210 -0.347 -0.398 -0.927 -1.603 
SAM002554924_PYRIDINE-2-
ALDOXIME_METHOCHLORIDE 
2 62 -0.4 F02 sample 40310 70670 51610 72470 -0.478 0.494 -0.879 -0.327 SAM002554925_Primidone 
2 74 -0.21 G02 sample 43600 67690 57670 75690 -0.272 0.279 -0.56 -0.15 SAM002554926_Propylthiouracil 
2 86 -0.18 H02 sample 54270 65530 59320 68410 0.397 0.122 -0.473 -0.549 SAM002554927_Pyrazinamide 
2 3 -0.2 A03 sample 47860 54940 84120 71380 -0.005 -0.643 0.832 -0.386 SAM002554928_Pronestyl 
2 15 -0.06 B03 sample 50080 76520 63550 67260 0.134 0.917 -0.251 -0.612 SAM002554929_Sulfisoxazole 
2 27 -0.43 C03 sample 38950 58430 60220 70510 -0.564 -0.391 -0.426 -0.434 SAM002554930_Sulfamethoxazole 
2 39 -0.39 D03 sample 43340 55330 68970 69610 -0.288 -0.615 0.035 -0.484 SAM002554931_Sulfacetamide 
2 51 0.02 E03 sample 49210 70940 67660 70720 0.08 0.513 -0.034 -0.423 SAM002554932_Sulfinpyrazone 
2 63 -0.41 F03 sample 38490 60690 56100 74100 -0.592 -0.227 -0.643 -0.237 SAM002554933_Sulindac 
2 75 0.76 G03 sample 55760 63850 96950 97080 0.49 0.001 1.507 1.024 SAM002554934_TETRACYCLINE 
2 87 -0.05 H03 sample 51800 58820 74690 72320 0.242 -0.362 0.336 -0.335 SAM002554935_Theophylline 






2 16 -1.33 B04 sample 36920 46490 41230 52640 -0.691 -1.253 -1.425 -1.415 SAM002554937_Triamterene 
2 28 -0.49 C04 sample 46010 72190 51920 59610 -0.121 0.604 -0.863 -1.032 SAM002554938_Intropin 
2 40 -1.22 D04 sample 26940 49060 47050 51560 -1.316 -1.068 -1.119 -1.474 SAM002564189_AMOXAPINE 
2 52 -1.26 E04 sample 33490 30940 41720 58010 -0.906 -2.377 -1.4 -1.12 SAM002564191_Adenine_9-beta 
2 64 0.99 F04 sample 57530 87580 82330 100900 0.601 1.716 0.738 1.234 SAM002564193_ATENOLOL 
2 76 -0.2 G04 sample 31810 72240 61140 77870 -1.011 0.607 -0.377 -0.03 SAM002703133_Tamoxifen 
2 88 0.96 H04 sample 53720 74390 90120 123410 0.362 0.763 1.148 2.469 SAM002564195_BUMETANIDE 
2 5 0.52 A05 sample 36880 50750 101080 122370 -0.693 -0.945 1.725 2.412 SAM002564250_CLOBETASOL_PROPIONATE 
2 17 -1.83 B05 sample 10060 32130 42420 70550 -2.375 -2.291 -1.363 -0.432 SAM002564196_Sonazine 
2 29 0.65 C05 sample 61680 69840 57400 94260 0.861 0.434 -0.574 0.869 SAM002564200_CEFAZOLIN_SODIUM_SALT 
2 41 -0.19 D05 sample 45110 60900 59590 91910 -0.177 -0.212 -0.459 0.74 SAM002564201_CAPTOPRIL 
2 53 -1.37 E05 sample 24720 43680 45990 54940 -1.456 -1.456 -1.175 -1.289 SAM002564202_CHLORAMBUCIL 
2 65 0.21 F05 sample 43440 54580 89570 91350 -0.282 -0.669 1.119 0.71 SAM002564251_CEFOXITIN_SODIUM_SALT 
2 77 1.49 G05 sample 69860 85990 125180 88400 1.374 1.601 2.993 0.548 SAM002564203_DANAZOL 
2 89 1.57 H05 sample 72150 86180 102340 96810 1.518 1.615 1.791 1.009 
SAM002564204_(+)-CIS-
DILTIAZEM_HYDROCHLORIDE 
2 6 -0.11 A06 sample 43910 70810 68750 72600 -0.253 0.504 0.023 -0.319 SAM002564205_DIGOXIN 
2 18 -0.08 B06 sample 43740 61410 68410 82300 -0.263 -0.175 0.005 0.213 
SAM002564206_17-BETA-ESTRADIOL_17-
VALERATE 
2 30 -0.22 C06 sample 42450 59260 66330 93390 -0.344 -0.331 -0.104 0.822 SAM002564207_EDROPHONIUM_CHLORIDE 
2 42 0.37 D06 sample 48660 80880 81610 70850 0.045 1.232 0.7 -0.415 SAM002564208_FLUOCINOLONE_ACETONIDE 
2 54 0.56 E06 sample 59310 69560 68570 117380 0.713 0.414 0.014 2.138 SAM002564209_Flurbiprofen 
2 66 0.79 F06 sample 65880 66990 77020 99720 1.125 0.228 0.458 1.169 SAM002564210_GLIPIZIDE 
2 78 2.08 G06 sample 87670 92480 107310 116550 2.49 2.07 2.053 2.093 SAM002564211_GEMFIBROZIL 
2 90 2.24 H06 sample 84520 88500 109850 137840 2.293 1.782 2.186 3.261 SAM002564212_Glyburide 
2 7 0.2 A07 sample 43970 52410 105500 90290 -0.249 -0.826 1.957 0.651 
SAM002564213_HYDROCORTISONE_HEMISUCCI
NATE 






2 31 -0.79 C07 sample 35460 51120 53070 81740 -0.782 -0.919 -0.802 0.182 
SAM002564215_IPRATROPIUM_BROMIDE_MON
OHYDRATE 
2 43 -1.19 D07 sample 24590 51220 34010 82590 -1.464 -0.911 -1.805 0.229 SAM002564216_Tofranil 
2 55 0.45 E07 sample 44710 75520 69190 119920 -0.202 0.844 0.046 2.278 SAM002564217_LABETALOL_HYDROCHLORIDE 
2 67 -0.82 F07 sample 25460 46200 67000 71740 -1.409 -1.274 -0.069 -0.367 SAM002564218_Imodium 
2 79 0.99 G07 sample 68070 73740 74950 120790 1.262 0.716 0.349 2.325 SAM002564219_Pro-Amatine 
2 91 1.69 H07 sample 68760 98880 104890 104780 1.305 2.532 1.925 1.447 SAM002564220_Medroxyprogesterone_17-acetate 
2 8 -0.86 A08 sample 23850 54420 49000 65710 -1.51 -0.68 -1.016 -0.698 SAM002564222_19-NORETHINDRONE_ACETATE 
2 20 -1.11 B08 sample 21250 45710 68210 61770 -1.673 -1.31 -0.005 -0.914 SAM002564223_19-Norethindrone 
2 32 -0.55 C08 sample 39110 52530 71560 68390 -0.554 -0.817 0.171 -0.55 SAM002564224_NICOTINE 
2 44 -0.16 D08 sample 29950 62200 83360 74890 -1.128 -0.118 0.792 -0.194 SAM002564254_Cardene 
2 56 1.24 E08 sample 61110 119480 89870 103000 0.826 4.021 1.135 1.349 SAM002564225_NABUMETONE 
2 68 1.13 F08 sample 61100 110440 95410 73000 0.825 3.367 1.426 -0.297 SAM002564226_OXYBUTYNIN_CHLORIDE 
2 80 -0.45 G08 sample 59200 62750 51670 63380 0.706 -0.078 -0.876 -0.825 SAM002564227_Mestinon 
2 92 0.42 H08 sample 55190 73470 62110 85510 0.454 0.696 -0.326 0.389 SAM002564228_Rythmol 
2 9 0.21 A09 sample 56010 62520 66450 92060 0.506 -0.095 -0.098 0.749 SAM002564229_Pfizerpen 
2 21 -0.69 B09 sample 35730 55750 56720 60990 -0.765 -0.584 -0.61 -0.957 SAM002564230_Valproic_Acid 
2 33 -0.72 C09 sample 30090 52070 57070 96560 -1.119 -0.85 -0.592 0.996 SAM002564231_Kemadrin 
2 45 0.54 D09 sample 51850 75390 83990 77280 0.245 0.835 0.825 -0.063 SAM002564232_Proxymetacaine 
2 57 1.22 E09 sample 66520 81410 102380 79020 1.165 1.27 1.793 0.033 SAM002703137_NALOXONE_HYDROCHLORIDE 
2 69 1.82 F09 sample 91760 84900 83810 117020 2.747 1.522 0.816 2.118 
SAM002564233_SPECTINOMYCIN_DIHYDROCH
LORIDE_PENTAHYDRATE 
2 81 0.57 G09 sample 62320 107460 67080 82940 0.901 3.152 -0.065 0.248 SAM002564235_TROPICAMIDE 
2 93 0.93 H09 sample 61880 94030 83420 96440 0.874 2.182 0.795 0.989 SAM002564236_TOLAZAMIDE 
2 10 0.48 A10 sample 43730 53170 99930 100800 -0.264 -0.771 1.664 1.228 SAM002564237_TRIAMCINOLONE_ACETONIDE 
2 22 1.07 B10 sample 54830 64110 100690 109970 0.432 0.02 1.704 1.732 SAM002564238_S(-)-Timolol_maleate 






2 46 -2.23 D10 sample 8550 15890 30330 51600 -2.469 -3.464 -1.999 -1.472 
SAM002564240_THIORIDAZINE_HYDROCHLORI
DE 
2 58 -0.02 E10 sample 43010 67760 67950 78070 -0.309 0.284 -0.019 -0.019 SAM002564241_Altretamine 
2 70 0.25 F10 sample 48330 73370 56320 87080 0.024 0.689 -0.631 0.475 SAM002564257_Phylloquinone 
2 82 -0.28 G10 sample 38420 68910 69100 67100 -0.597 0.367 0.042 -0.621 SAM002564242_Eryped 
2 94 -0.26 H10 sample 62300 62130 60740 70390 0.9 -0.123 -0.398 -0.441 SAM002564244_Dibenzyline 
2 11 0.06 A11 sample 33130 67300 65950 84030 -0.928 0.25 -0.124 0.308 
SAM002564258_6ALPHA-METHYL-11BETA-
HYDROXYPROGESTERONE 
2 23 0.68 B11 sample 54190 70710 84690 101000 0.392 0.497 0.862 1.239 SAM002564245_Thalidomide 
2 35 0.29 C11 sample 62400 59250 85490 72040 0.906 -0.331 0.904 -0.35 SAM002589919_Aminolevulinic_Acid 
2 47 0.49 D11 sample 63870 66840 76970 87970 0.999 0.217 0.456 0.524 SAM002589920_Carbinoxamine_Maleate 
2 59 0.06 E11 sample 58440 55520 61230 87280 0.658 -0.601 -0.373 0.486 SAM002589921_Demeclocycline 
2 71 0.47 F11 sample 65900 68700 79590 78770 1.126 0.352 0.594 0.019 SAM002589925_Westcort 
2 83 -0.16 G11 sample 56360 59230 68600 54640 0.528 -0.333 0.015 -1.305 SAM002589926_DEPRENALIN 
2 95 -0.1 H11 sample 53640 62370 66580 68970 0.357 -0.106 -0.091 -0.519 
SAM002589927_6-[2-ETHOXY-1-
NAPHTHAMIDO]-PENICILLIN_SODIUM_SALT 
2 12 8.37 A12 
merbb4
-f 
97820 252190 88100 331370 3.127 13.609 1.042 13.882 control 
2 24 9.02 B12 
merbb4
-f 
146840 287620 139360 294170 6.2 16.169 3.74 11.841 control 
2 36 6.92 C12 
merbb4
-f 
88660 289980 114250 284040 2.553 16.34 2.418 11.285 control 
2 48 8.13 D12 
merbb4
-f 
103850 257210 166540 280570 3.505 13.972 5.17 11.094 control 
2 60 19.02 E12 bace-1 262130 490570 296890 526930 13.427 30.833 12.031 24.615 control 
2 72 20.88 F12 bace-1 383110 397110 406010 456680 21.01 24.08 17.774 20.759 control 
2 84 23.3 G12 bace-1 398190 523670 444880 527340 21.955 33.225 19.82 24.637 control 
2 96 22.9 H12 bace-1 408230 525000 316740 501330 22.585 33.321 13.076 23.21 control 
3 1 -0.47 A01 baseline 34940 45170 40590 44260 -0.354 -0.386 -0.615 -0.549 control 
3 13 -0.33 B01 baseline 45290 46750 45040 47850 0.511 -0.287 -0.368 -0.389 control 






3 37 -1.15 D01 dapt 34200 38050 25130 23690 -0.416 -0.83 -1.474 -1.465 control 
3 49 -1.38 E01 dapt 27430 29710 20950 24730 -0.982 -1.351 -1.707 -1.418 control 
3 61 -1.02 F01 dapt 28970 27230 34610 31840 -0.853 -1.505 -0.947 -1.102 control 
3 73 -1.49 G01 tapi-1 21200 27750 20380 32650 -1.502 -1.473 -1.738 -1.066 control 
3 85 -0.9 H01 tapi-1 36110 30520 37040 34550 -0.256 -1.3 -0.812 -0.981 control 
3 2 -0.36 A02 sample 38030 42240 43590 50590 -0.096 -0.569 -0.448 -0.267 SAM002589929_Primaquine_Diphosphate 
3 14 -1.43 B02 sample 13660 20590 39600 35560 -2.133 -1.92 -0.67 -0.936 SAM002589930_Micropenin 
3 26 -0.5 C02 sample 33110 44270 42690 44280 -0.507 -0.442 -0.498 -0.548 SAM002589932_DOXYCYCLINE 
3 38 -0.83 D02 sample 29040 35920 48840 38420 -0.847 -0.963 -0.156 -0.809 SAM002699895_Beclomethasone_dipropionate 
3 50 -0.53 E02 sample 35610 36440 50200 39470 -0.298 -0.931 -0.081 -0.762 SAM002589934_Cromolyn_Sodium 
3 62 -0.65 F02 sample 40620 42830 37730 38290 0.121 -0.532 -0.774 -0.815 SAM002589935_Priscoline 
3 74 -0.45 G02 sample 32070 54650 37710 49850 -0.594 0.206 -0.775 -0.3 SAM002589937_Mercaptopurine 
3 86 -0.17 H02 sample 47700 51170 45740 46760 0.713 -0.012 -0.329 -0.437 SAM002589938_Azathioprine 
3 3 2.75 A03 sample 70590 90950 103320 138400 2.626 2.471 2.872 3.642 SAM002589939_Albendazole 
3 15 0.13 B03 sample 53860 43940 57410 55160 1.227 -0.463 0.32 -0.063 SAM002589940_Griseofulvin 
3 27 -0.35 C03 sample 38300 46900 44010 38100 -0.073 -0.278 -0.425 -0.823 SAM002589936_Lincomycin_hydrochloride 
3 39 0.1 D03 sample 40680 52630 56440 54450 0.126 0.08 0.266 -0.095 SAM002589943_Methazolamide 
3 51 0.26 E03 sample 42070 65930 56510 53390 0.242 0.909 0.27 -0.142 SAM002589944_Terbutaline_Sulfate 
3 63 0.07 F03 sample 39540 50770 60700 59170 0.031 -0.037 0.503 0.115 SAM002589979_Mupirocin 
3 75 0.97 G03 sample 50880 71200 68550 78340 0.978 1.238 0.939 0.969 
SAM002589945_FLUOCINOLONE_ACETONIDE_2
1-ACETATE 
3 87 -1.15 H03 sample 42510 28530 24730 36740 0.279 -1.424 -1.497 -0.884 SAM002699894_Mefloquine_hydrochloride 
3 4 -1.02 A04 sample 27470 31760 32550 45540 -0.978 -1.223 -1.062 -0.492 SAM002589947_Floxuridine 
3 16 -3 B04 sample 530 580 790 810 -3.23 -3.168 -2.827 -2.483 SAM002699896_MITOXANTRONE 
3 28 -0.64 C04 sample 30500 58820 41730 19100 -0.725 0.466 -0.552 -1.669 SAM002699897_ENALAPRIL_MALEATE 






3 52 1.22 E04 sample 45880 50570 111530 98880 0.56 -0.049 3.328 1.883 SAM002699899_RAMIPRIL 
3 64 1.18 F04 sample 52950 82770 73410 74920 1.151 1.96 1.209 0.816 SAM002699893_DEPO-MEDROL 
3 76 0.29 G04 sample 60490 57690 47000 60740 1.782 0.395 -0.259 0.185 
SAM002699901_(+/-)-
NOREPINEPHRINE_HYDROCHLORIDE 
3 88 2.23 H04 sample 58480 92880 93520 104690 1.614 2.591 2.327 2.142 SAM002699903_AMCINONIDE 
3 5 -1.06 A05 sample 16660 27350 40420 46390 -1.882 -1.498 -0.624 -0.454 SAM002699904_Clomid 
3 17 -0.95 B05 sample 26620 39430 27000 37430 -1.049 -0.744 -1.37 -0.853 SAM003107541_PHENTOLAMINE_HCL 
3 29 -0.68 C05 sample 33700 46890 22270 36330 -0.458 -0.279 -1.633 -0.902 SAM002548956_FLUDARABINE 
3 41 -1.55 D05 sample 14800 11590 37140 32550 -2.037 -2.481 -0.807 -1.07 SAM002548950_Testosterone 
3 53 0.45 E05 sample 44110 37890 66100 67610 0.412 -0.84 0.803 0.491 SAM002548955_Isotretinoin 
3 65 0.84 F05 sample 48730 65400 58860 77380 0.799 0.876 0.4 0.926 SAM002548951_Methimazole 
3 77 0.25 G05 sample 42030 68250 53710 62410 0.239 1.054 0.114 0.259 SAM002548957_Zonisamide 
3 89 0.95 H05 sample 52120 56770 90100 75070 1.082 0.338 2.137 0.823 SAM002548958_Brimonidine 
3 6 -0.07 A06 sample 14410 36250 67860 74710 -2.07 -0.942 0.901 0.807 SAM002548959_Mebendazole 
3 18 -2 B06 sample 7450 21070 13510 24460 -2.652 -1.89 -2.12 -1.43 SAM002548969_Duremesin 
3 30 -0.84 C06 sample 7000 42200 31720 45540 -2.689 -0.571 -1.108 -0.492 SAM002548968_Flecainide_Acetate 
3 42 0.67 D06 sample 28130 61260 64470 91980 -0.923 0.618 0.712 1.576 SAM002548966_Dilantin 
3 54 0.76 E06 sample 46440 65950 68420 69320 0.607 0.911 0.932 0.567 SAM002548945_Miochol 
3 66 0.09 F06 sample 33210 43710 77620 71470 -0.499 -0.477 1.443 0.663 SAM002703135_Dantrolene_sodium_salt 
3 78 1.16 G06 sample 53290 69490 73210 75710 1.18 1.132 1.198 0.851 SAM002548948_Dexamethasone 
3 90 1.13 H06 sample 50100 62480 83780 86710 0.913 0.694 1.786 1.341 SAM002548938_Cogentin_Mesylate 
3 7 -0.1 A07 sample 35200 54150 49140 55160 -0.332 0.174 -0.14 -0.063 SAM002548936_Ganciclovir 
3 19 -0.21 B07 sample 35100 50070 52560 44560 -0.341 -0.08 0.05 -0.535 SAM002548937_Mesna 
3 31 -0.13 C07 sample 31060 40940 62970 65130 -0.678 -0.65 0.629 0.38 SAM002548942_Meclomen 
3 43 -0.23 D07 sample 33130 44850 50650 79830 -0.505 -0.406 -0.056 1.035 SAM002589905_Fluconazole 






3 67 1.01 F07 sample 50190 88480 48040 81230 0.921 2.316 -0.201 1.097 SAM002548974_Methoxsalen 
3 79 0.31 G07 sample 29820 57600 55680 71160 -0.782 0.39 0.224 0.649 SAM002548963_Chloramphenicol 
3 91 1.25 H07 sample 58480 88240 67520 69810 1.614 2.301 0.882 0.589 SAM002548961_Tizanidine_hydrochloride 
3 8 -1.26 A08 sample 10760 33350 26480 53780 -2.375 -1.123 -1.399 -0.125 SAM002548935_Paroxetine 
3 20 -0.3 B08 sample 34000 45540 53340 51050 -0.433 -0.363 0.094 -0.246 SAM002548934_mirtazapine 
3 32 0.37 C08 sample 40970 61360 62120 59240 0.15 0.624 0.582 0.118 SAM002548930_Etomidate 
3 44 0.15 D08 sample 39570 49740 76650 62430 0.033 -0.101 1.389 0.26 SAM002548933_Moban 
3 56 -0.8 E08 sample 16790 36540 47540 41390 -1.871 -0.924 -0.229 -0.676 SAM002548940_fluvastatin 
3 68 0.6 F08 sample 48390 53350 79120 66290 0.77 0.124 1.527 0.432 SAM002548931_Urecholine 
3 80 -1.08 G08 sample 13660 30440 36310 41060 -2.133 -1.305 -0.853 -0.691 SAM002589901_Cefuroxime 
3 92 1.24 H08 sample 72800 65490 69630 89830 2.81 0.882 0.999 1.48 SAM002548983_Cytoxan 
3 9 0.33 A09 sample 42870 58070 47560 64290 0.309 0.419 -0.228 0.343 SAM002548982_Eszopiclone 
3 21 0.07 B09 sample 40610 57500 43020 57010 0.12 0.383 -0.48 0.019 SAM002264598_Bendrofluazide 
3 33 -0.52 C09 sample 30600 58480 39440 48360 -0.717 0.445 -0.679 -0.366 SAM002548975_Evista 
3 45 0.01 D09 sample 44170 52690 44580 55190 0.417 0.083 -0.393 -0.062 SAM002548971_zidovudine 
3 57 -0.38 E09 sample 21440 51870 37560 59050 -1.482 0.032 -0.783 0.11 SAM002548976_Clozapine 
3 69 -0.52 F09 sample 35750 39190 45360 40870 -0.286 -0.759 -0.35 -0.7 SAM002264590_Ampicillin_Sodium 
3 81 0.22 G09 sample 40650 61870 56210 60600 0.123 0.656 0.253 0.179 
SAM002264591_ACEBUTOLOL_HYDROCHLORI
DE 
3 93 1.39 H09 sample 59910 76580 73410 72260 1.733 1.574 1.209 0.698 SAM002264592_AMOXICILLIN_CRYSTALLINE 
3 10 -0.13 A10 sample 38810 47520 51260 51380 -0.031 -0.239 -0.022 -0.232 SAM002699891_(+/-)-Epinephrine_hydrochloride 
3 22 -0.08 B10 sample 12210 35650 69070 75100 -2.254 -0.98 0.968 0.824 SAM002264595_5-Azacytidine 
3 34 0.2 C10 sample 38320 51540 58510 70130 -0.071 0.012 0.381 0.603 SAM002264597_Buspar 
3 46 -0.46 D10 sample 35160 40160 41030 72380 -0.336 -0.699 -0.591 0.703 SAM002264596_Flumadine 
3 58 -1.5 E10 sample 20730 28130 26080 19770 -1.542 -1.449 -1.422 -1.639 SAM002548978_Podofilox 






3 82 -0.48 G10 sample 35390 41060 56290 41480 -0.316 -0.642 0.258 -0.672 SAM002264600_CORTISONE_ACETATE 
3 94 -1.55 H10 sample 29200 27500 16190 20460 -0.834 -1.488 -1.971 -1.608 SAM002264601_Anafranil 
3 11 0.43 A11 sample 41460 43550 100030 71810 0.191 -0.487 2.689 0.678 SAM002264603_Carbamazepine 
3 23 0.89 B11 sample 41660 64050 69470 80260 0.208 0.792 0.99 1.054 SAM002699890_Memantine_hydrochloride 
3 35 -0.06 C11 sample 38470 51720 42660 54990 -0.059 0.023 -0.5 -0.071 SAM002264605_Norpramin 
3 47 1.12 D11 sample 46850 76730 66310 88600 0.641 1.583 0.815 1.425 SAM002264606_Mexitil 
3 59 0.34 E11 sample 56100 59270 54250 60870 1.415 0.494 0.144 0.191 SAM002264607_Norpace 
3 71 0.27 F11 sample 42550 55400 69980 50050 0.282 0.252 1.019 -0.291 SAM002589948_STAVUDINE 
3 83 0.52 G11 sample 47200 66220 50550 64710 0.671 0.928 -0.061 0.362 SAM002589981_Doxazosin 
3 95 -0.68 H11 sample 35050 38360 40270 40180 -0.345 -0.811 -0.633 -0.73 SAM002589949_Minoxidil 
3 12 8.58 A12 
merbb4
-f 
136190 228830 152530 259920 8.109 11.074 5.607 9.053 control 
3 24 7.5 B12 
merbb4
-f 
140570 320320 125120 203330 8.475 16.782 4.083 6.533 control 
3 36 7.77 C12 
merbb4
-f 
139970 232140 90720 216590 8.424 11.28 2.171 7.124 control 
3 48 7.47 D12 
merbb4
-f 
120610 294220 164560 239250 6.806 15.154 6.276 8.132 control 
3 60 27.83 E12 bace-1 376670 611320 344260 673350 28.208 34.939 16.264 27.459 control 
3 72 25.42 F12 bace-1 337120 658520 486670 639210 24.902 37.884 24.179 25.939 control 
3 84 31.11 G12 bace-1 452170 701880 417580 678750 34.518 40.59 20.339 27.699 control 
3 96 22.75 H12 bace-1 280040 644090 296690 626310 20.132 36.984 13.62 25.365 control 
4 1 -0.79 A01 baseline 63166 67322 71040 88450 -0.357 -0.472 -1.225 -1.109 control 
4 13 0.29 B01 baseline 132015 133237 113450 151480 1.017 0.495 -0.34 0.085 control 
4 25 -0.21 C01 baseline 114841 119150 96060 109250 0.674 0.288 -0.703 -0.715 control 
4 37 -0.96 D01 dapt 73983 62982 63250 67920 -0.141 -0.536 -1.388 -1.499 control 
4 49 -0.68 E01 dapt 90730 68574 86260 72400 0.193 -0.454 -0.907 -1.414 control 
4 61 -0.99 F01 dapt 75053 51095 68810 68280 -0.12 -0.71 -1.272 -1.492 control 






4 85 -0.62 H01 tapi-1 86421 75145 87410 95510 0.107 -0.357 -0.883 -0.976 control 
4 2 -0.83 A02 sample 56809 62249 62640 87820 -0.484 -0.547 -1.401 -1.121 SAM002699889_Inderal 
4 14 -0.55 B02 sample 65244 70194 97420 104110 -0.316 -0.43 -0.674 -0.812 SAM002589951_Ribavirin 
4 26 -0.66 C02 sample 45961 57329 68270 117510 -0.701 -0.619 -1.283 -0.558 SAM002589982_Terazosin 
4 38 -0.48 D02 sample 56840 53539 106920 129290 -0.484 -0.674 -0.476 -0.335 SAM002589983_Chlorthalidone 
4 50 -0.23 E02 sample 64388 51278 123990 168370 -0.333 -0.708 -0.12 0.406 SAM002589984_METHYLPREDNISOLONE 
4 62 0.35 F02 sample 83976 88957 160870 185820 0.058 -0.155 0.65 0.736 SAM002589985_Phenelzine 
4 74 2.84 G02 sample 200589 265283 306460 318470 2.385 2.433 3.689 3.251 
SAM002589986_NALTREXONE_HYDROCHLORID
E 
4 86 0.2 H02 sample 69125 90027 163330 175740 -0.238 -0.139 0.701 0.545 SAM002589987_Glycopyrrolate 
4 3 -0.02 A03 sample 125781 112274 118520 118630 0.892 0.187 -0.234 -0.537 SAM002589988_Ethambutol 
4 15 -0.01 B03 sample 87613 99561 125220 145490 0.131 0.001 -0.094 -0.028 SAM002589989_Cetirizine 
4 27 -0.46 C03 sample 68452 105826 97090 111390 -0.252 0.093 -0.681 -0.674 SAM002589990_DICLOXACILLIN_SODIUM 
4 39 1.65 D03 sample 204440 177059 233540 185160 2.462 1.138 2.167 0.724 SAM002589991_Meloxicam 
4 51 -1.18 E03 sample 24019 16410 59740 124900 -1.139 -1.219 -1.461 -0.418 
SAM002589992_DAUNORUBICIN_HYDROCHLO
RIDE 
4 63 2.96 F03 sample 231179 216694 269430 380150 2.996 1.72 2.916 4.42 SAM002589953_RIFAPENTINE 
4 75 0.69 G03 sample 83579 154873 158950 188030 0.05 0.813 0.61 0.778 SAM002589954_Penicillin_V 
4 87 0.22 H03 sample 75267 92533 155420 190210 -0.116 -0.102 0.536 0.82 SAM002589955_Gatifloxacin 
4 4 -0.44 A04 sample 56565 68819 119060 124720 -0.489 -0.45 -0.223 -0.422 SAM002589956_clopidogrel 
4 16 -0.7 B04 sample 36426 35479 104950 150980 -0.891 -0.94 -0.517 0.076 SAM002643511_CEFOTAXIME_SODIUM_SALT 
4 28 -0.81 C04 sample 32790 44738 116770 103930 -0.964 -0.804 -0.271 -0.816 SAM002589994_LAMIVUDINE 
4 40 -0.52 D04 sample 41713 45044 137850 133460 -0.785 -0.799 0.17 -0.256 SAM002589958_Ondansetron 
4 52 1.89 E04 sample 192094 252051 175330 229280 2.216 2.239 0.952 1.56 SAM002589959_Betamethasone 
4 64 0.16 F04 sample 84710 115941 117590 160840 0.073 0.241 -0.253 0.263 SAM002589995_Celecoxib 










4 5 2.78 A05 sample 359924 233410 301700 227810 5.565 1.965 3.59 1.532 SAM002589960_Citalopram 
4 17 2.12 B05 sample 165508 245603 244660 257570 1.685 2.144 2.399 2.097 SAM002589961_Azithromycin 
4 29 2.66 C05 sample 237994 248414 299000 242570 3.132 2.185 3.534 1.812 SAM002589963_Lovastatin 
4 41 -0.18 D05 sample 62615 50056 129730 146970 -0.368 -0.726 0 0 SAM002589964_Aminoglutethimide 
4 53 -1.01 E05 sample 27992 50667 84170 85120 -1.059 -0.717 -0.951 -1.172 SAM002589965_Prozac 
4 65 -1.01 F05 sample 27503 60018 72180 96970 -1.069 -0.579 -1.201 -0.948 SAM002589966_FluniSOLIDe 
4 77 -0.39 G05 sample 81073 75848 100620 124580 0 -0.347 -0.608 -0.424 SAM002589967_Acyclovir 
4 89 0.68 H05 sample 155973 147478 161420 155150 1.495 0.704 0.662 0.155 SAM002589968_Etodolac 
4 6 -1.01 A06 sample 35296 43699 76100 88970 -0.914 -0.819 -1.12 -1.1 SAM002589969_Simvastatin 
4 18 -0.31 B06 sample 81409 90944 89500 120910 0.007 -0.126 -0.84 -0.494 SAM002589970_Rifabutin 
4 30 0.01 C06 sample 75420 127553 136250 137020 -0.113 0.412 0.136 -0.189 SAM002589971_Felodipine 
4 42 0.38 D06 sample 106132 101762 142460 184820 0.5 0.033 0.266 0.718 SAM002589972_Quinapril_hydrochloride 
4 54 0.12 E06 sample 92105 125934 130510 137280 0.22 0.388 0.016 -0.184 SAM002589973_Acitretin 
4 66 3.05 F06 sample 326004 266780 291080 290820 4.888 2.455 3.368 2.727 SAM002700173_Allegra 
4 78 0.39 G06 sample 93297 125384 148420 172120 0.244 0.38 0.39 0.477 SAM002700174_Fluorometholone 
4 90 -0.41 H06 sample 47275 99500 67460 139520 -0.674 0 -1.3 -0.141 SAM002700175_Sertraline 
4 7 -0.3 A07 sample 59590 77406 116830 144040 -0.429 -0.324 -0.269 -0.056 SAM002703129_CARBIDOPA 
4 19 NA B07 empty NA NA NA NA NA NA NA NA NA 
4 31 NA C07 empty NA NA NA NA NA NA NA NA NA 
4 43 NA D07 empty NA NA NA NA NA NA NA NA NA 
4 55 NA E07 empty NA NA NA NA NA NA NA NA NA 
4 67 NA F07 empty NA NA NA NA NA NA NA NA NA 
4 79 NA G07 empty NA NA NA NA NA NA NA NA NA 
4 91 NA H07 empty NA NA NA NA NA NA NA NA NA 
4 8 NA A08 empty NA NA NA NA NA NA NA NA NA 






4 32 NA C08 empty NA NA NA NA NA NA NA NA NA 
4 44 NA D08 empty NA NA NA NA NA NA NA NA NA 
4 56 NA E08 empty NA NA NA NA NA NA NA NA NA 
4 68 NA F08 empty NA NA NA NA NA NA NA NA NA 
4 80 NA G08 empty NA NA NA NA NA NA NA NA NA 
4 92 NA H08 empty NA NA NA NA NA NA NA NA NA 
4 9 NA A09 empty NA NA NA NA NA NA NA NA NA 
4 21 NA B09 empty NA NA NA NA NA NA NA NA NA 
4 33 NA C09 empty NA NA NA NA NA NA NA NA NA 
4 45 NA D09 empty NA NA NA NA NA NA NA NA NA 
4 57 NA E09 empty NA NA NA NA NA NA NA NA NA 
4 69 NA F09 empty NA NA NA NA NA NA NA NA NA 
4 81 NA G09 empty NA NA NA NA NA NA NA NA NA 
4 93 NA H09 empty NA NA NA NA NA NA NA NA NA 
4 10 NA A10 empty NA NA NA NA NA NA NA NA NA 
4 22 NA B10 empty NA NA NA NA NA NA NA NA NA 
4 34 NA C10 empty NA NA NA NA NA NA NA NA NA 
4 46 NA D10 empty NA NA NA NA NA NA NA NA NA 
4 58 NA E10 empty NA NA NA NA NA NA NA NA NA 
4 70 NA F10 empty NA NA NA NA NA NA NA NA NA 
4 82 NA G10 empty NA NA NA NA NA NA NA NA NA 
4 94 NA H10 empty NA NA NA NA NA NA NA NA NA 
4 11 NA A11 empty NA NA NA NA NA NA NA NA NA 
4 23 NA B11 empty NA NA NA NA NA NA NA NA NA 
4 35 NA C11 empty NA NA NA NA NA NA NA NA NA 









4 59 NA E11 empty NA NA NA NA NA NA NA NA NA 
4 71 NA F11 empty NA NA NA NA NA NA NA NA NA 
4 83 NA G11 empty NA NA NA NA NA NA NA NA NA 
4 95 NA H11 empty NA NA NA NA NA NA NA NA NA 
4 12 4.16 A12 
merbb4
-f 
368848 274820 424159 259030 5.743 2.573 6.146 2.124 control 
4 24 5.21 B12 
merbb4
-f 
514828 258300 511558 276370 8.656 2.33 7.971 2.453 control 





619190 443931 301880 34.902 7.627 6.559 2.937 control 
4 48 4.32 D12 
merbb4
-f 
400690 259490 390972 314660 6.378 2.348 5.454 3.179 control 
4 60 12.74 E12 bace-1 866471 692630 
110623
7 
664150 15.674 8.704 20.385 9.804 control 
4 72 13.51 F12 bace-1 
105208
6 
586870 994483 620440 19.378 7.152 18.052 8.976 control 







719600 63.954 13.532 19.906 10.855 control 






12.2   NCC 003 Screen Result 




























5 1 2.21 
A0
1 
baseline 109790 131590 126410 124180 3.056 2.916 1.496 0.296 control 
5 13 2.41 
B0
1 
baseline 117530 123790 146100 144740 3.514 2.489 2.335 1.002 control 
5 25 4.86 
C0
1 






dapt 72700 80330 61390 49510 0.858 0.114 -1.274 -2.266 control 
5 49 0.74 
E0
1 
dapt 118820 109040 86610 71800 3.591 1.683 -0.199 -1.501 control 
5 61 0.59 
F0
1 






tapi-1 81030 63050 81480 63860 1.352 -0.831 -0.418 -1.774 control 
5 85 0.88 
H0
1 






sample 74310 63690 71880 100680 0.954 -0.796 -0.827 -0.51 SAM001247063_Nalbuphine 
5 14 -0.6 
B0
2 






sample 46170 87640 57410 69630 -0.713 0.514 -1.444 -1.576 SAM001247069_Zacopride 
5 38 0.11 
D0
2 
sample 57340 94340 97800 109000 -0.052 0.88 0.277 -0.225 SAM001247068_SKF_83566 
5 50 0.53 
E0
2 
sample 41990 86430 133770 133570 -0.961 0.447 1.81 0.619 SAM001246964_3'-deoxydenosine 
5 62 0.29 
F0
2 
sample 60950 110850 88880 127960 0.162 1.782 -0.103 0.426 SAM001246965_AM_404 
5 74 0.35 
G0
2 
sample 62290 95200 102160 119040 0.242 0.927 0.463 0.12 
SAM001246962_PILOCARPINE_HYDROCHLO
RIDE 
5 86 0.53 
H0
2 
sample 69660 94620 100400 77860 0.678 0.895 0.388 -1.293 SAM001246963_NIFEDIPINE 
5 3 0.19 
A0
3 
sample 72140 84010 78230 117410 0.825 0.315 -0.556 0.064 SAM001246961_Flurbiprofen 
5 15 0.17 
B0
3 



























sample 40170 66430 100570 115210 -1.069 -0.646 0.395 -0.011 SAM001247059_Duloxetine 
5 63 0.78 
F0
3 




5 75 1.63 
G0
3 




5 87 2.09 
H0
3 
sample 51570 115110 142090 225790 -0.393 2.015 2.165 3.783 SAM001247039_PROGESTERONE 
5 4 0.82 
A0
4 
sample 86230 79030 128910 102290 1.66 0.043 1.603 -0.455 SAM001247033_FAMOTIDINE 
5 16 0.53 
B0
4 























5 64 0.88 
F0
4 





5 76 0.01 
G0
4 
sample 58100 79750 72490 116350 -0.007 0.082 -0.801 0.028 SAM001246969_Selegiline-hydrochloride 
5 88 0.63 
H0
4 
sample 67460 91110 91640 150490 0.548 0.703 0.015 1.199 SAM001246970_Capsaicin 
5 5 0.01 
A0
5 






sample 66310 69470 72200 111480 0.48 -0.48 -0.813 -0.139 SAM001246972_(Â±)-Vesamicol_hydrochloride 
5 29 0 
C0
5 












sample 1310 3810 27440 98350 -3.371 -4.069 -2.721 -0.59 SAM001247027_diphenylcyclopropenone 
5 65 0.29 
F0
5 








5 77 0.13 
G0
5 
sample 52080 59940 116080 133710 -0.363 -1.001 1.056 0.623 SAM001247051_Mesoridazine 
5 89 2.1 
H0
5 








sample 28650 48540 71320 107910 -1.751 -1.624 -0.851 -0.262 
SAM001247054_10H-Phenothiazine,_2-chloro-
10-[3-(4-methyl-1-piperazinyl)propyl-_[CAS] 
5 18 0.05 
B0
6 









sample 48240 88100 84370 89390 -0.591 0.539 -0.295 -0.898 SAM001247056_CLOTRIMAZOLE 
5 42 1.01 
D0
6 
sample 54510 87120 127510 172780 -0.219 0.485 1.543 1.964 SAM001246987_LORATADINE 
5 54 0.89 
E0
6 
sample 73960 91770 111140 162660 0.933 0.739 0.846 1.617 
SAM001247037_PHENELZINE_SULFATE_SAL
T 
5 66 0.9 
F0
6 
sample 70410 102460 116460 132580 0.723 1.324 1.072 0.585 SAM001246997_Riluzole 
5 78 0.12 
G0
6 
sample 47810 63800 111470 162110 -0.616 -0.79 0.86 1.598 SAM001247004_Naltrindole 
5 90 1.27 
H0
6 


















sample 44970 70930 42790 75970 -0.784 -0.4 -2.067 -1.358 SAM001246974_Cinanserin 
5 43 -1.2 
D0
7 




















sample 22970 31620 113510 176180 -2.088 -2.548 0.947 2.081 SAM001246995_Prazosin 
5 91 0.85 
H0
7 




















sample 41610 41070 41820 72440 -0.983 -2.032 -2.108 -1.479 SAM001246977_Fluvoxamine 












sample 29920 41250 74330 92210 -1.676 -2.022 -0.723 -0.801 SAM001247046_Fluoperazine 
5 68 0.86 
F0
8 
sample 64840 76680 122450 160050 0.393 -0.086 1.328 1.527 
SAM001247023_(+)-3-HYDROXY-N-
METHYLMORPHINAN_D-TARTRATE 
5 80 0.66 
G0
8 
sample 68740 81710 130100 135700 0.624 0.189 1.654 0.692 
SAM001247049_L-Ornithine,_N5-
[imino(methylamino)methyl]-[CAS] 
5 92 0.14 
H0
8 






sample 26470 34470 76590 90560 -1.88 -2.393 -0.626 -0.857 SAM001247038_Pizotyline 
5 21 0.04 
B0
9 






sample 47800 70780 58200 128900 -0.617 -0.408 -1.41 0.458 
SAM001247019_N,N'-DIACETYL-1,6-
DIAMINOHEXANE 
5 45 0.18 
D0
9 
sample 68250 87970 87410 100580 0.595 0.532 -0.165 -0.514 
SAM001247024_DIPHENHYDRAMINE-
HYDROCHLORIDE 
5 57 0.59 
E0
9 






sample 1320 2450 8020 2000 -3.37 -4.143 -3.548 -3.896 SAM001246980_Ifenprodil 
5 81 0.94 
G0
9 
sample 2690 86760 124710 163180 -3.289 0.465 1.424 1.635 
SAM001247028_TETRAETHYLTHIURAM_DIS
ULFIDE 
5 93 1.13 
H0
9 












sample 67800 78460 79320 95980 0.568 0.012 -0.51 -0.671 
SAM001247047_TRIPELENNAMINE_HYDRO
CHLORIDE 
5 34 0.14 
C1
0 
sample 71310 78030 91070 124140 0.776 -0.012 -0.009 0.295 
SAM001246996_Pyrazinecarboxamide,_3,5-
diamino-N-(aminoiminomethyl)-6-chloro-_[CAS] 
5 46 0.51 
D1
0 




5 58 1.43 
E1
0 


















5 94 1.1 
H1
0 

















sample 69530 80970 86700 99940 0.671 0.149 -0.196 -0.536 SAM001247018_LIDOCAINE 
5 35 0.09 
C1
1 
sample 61820 77460 97640 99290 0.214 -0.043 0.271 -0.558 SAM001246982_Indomethacin 
5 47 0.56 
D1
1 






sample 51850 61030 103970 93270 -0.377 -0.941 0.54 -0.764 SAM001246991_Paroxetine 
5 71 0.05 F11 sample 57680 83330 93490 115450 -0.031 0.278 0.094 -0.003 SAM001247031_Epigallocatechin_gallate 
5 83 0.81 
G1
1 
sample 69920 116130 113100 132440 0.694 2.071 0.929 0.58 
SAM001247020_5-Amino-2-hydroxy-
benzoic_acid 
5 95 0.15 
H1
1 
sample 46320 60960 114660 161000 -0.704 -0.945 0.996 1.56 
SAM001247025_Oxiranecarboxylic_acid,_2-[6-
(4-chlorophenoxy)hexyl]-,_ethyl_ester-_[CAS] 





72390 329830 60260 278430 0.84 13.751 -1.322 5.59 control 





134630 294470 118900 416900 4.527 11.819 1.176 10.341 control 





103660 311310 120430 349950 2.693 12.739 1.242 8.044 control 





99040 298690 109200 292730 2.419 12.049 0.763 6.08 control 
5 60 18.9 
E1
2 
























baseline 80283 85935 78350 78900 1.436 0.527 -0.944 -1.407 control 
6 13 0.63 
B0
1 
baseline 81529 108142 91640 84390 1.491 1.531 -0.238 -1.223 control 
6 25 0.18 
C0
1 









































sample 57119 73096 82100 120500 0.418 -0.054 -0.745 -0.011 SAM001246761_Cephalexin_monohydrate 
6 14 0.86 
B0
2 
sample 88761 73274 98410 168740 1.809 -0.046 0.123 1.607 SAM001246762_PIDOTIMOD 
6 26 0.5 
C0
2 












sample 49220 68022 60850 73060 0.07 -0.283 -1.875 -1.603 SAM001246751_nandrolone 
6 62 0.49 
F0
2 
sample 90875 71115 114390 121050 1.902 -0.143 0.973 0.007 SAM001246752_NIZATIDINE 
6 74 1.17 
G0
2 
sample 58121 75143 136620 176680 0.462 0.039 2.155 1.874 SAM001246753_5-FLUOROCYTOSINE 
6 86 1.15 
H0
2 
sample 70003 71783 151700 160060 0.984 -0.113 2.957 1.316 SAM001246754_Trileptal 
6 3 0.11 
A0
3 
sample 51289 75699 110340 120620 0.161 0.064 0.757 -0.007 SAM001246756_TROXIPIDE 
6 15 0.37 
B0
3 






sample 12772 29327 83600 96610 -1.532 -2.033 -0.665 -0.813 SAM001246645_AZELASTINE_HCl 
6 39 0.55 
D0
3 
sample 49087 93256 115040 127990 0.065 0.858 1.007 0.24 SAM001246759_TOCAINIDE 
6 51 0.31 
E0
3 
sample 54850 91097 86610 130020 0.318 0.76 -0.505 0.308 SAM001246760_TAXIFOLIN-(+/-) 
6 63 0.8 
F0
3 
sample 52335 74253 124800 162480 0.207 -0.002 1.526 1.397 SAM001246758_LEVOFLOXACIN 
6 75 1.23 
G0
3 
sample 46461 94991 146970 166300 -0.051 0.936 2.706 1.525 
SAM001246643_CEFATRIZINE_PROPYLENE_
GLYCOL 
6 87 0.17 
H0
3 
sample 15910 107407 88650 142770 -1.394 1.497 -0.397 0.736 SAM001246700_IDEBENONE 
6 4 0.53 
A0
4 
sample 65775 77635 114310 128710 0.798 0.151 0.968 0.264 SAM001246703_LEVOSULPIRIDE 
6 16 0.23 
B0
4 





























sample 63617 82063 79030 106610 0.703 0.352 -0.908 -0.477 
SAM001246631_ONDANSETRON-
HYDROCHLORIDE 
6 76 0.4 
G0
4 
sample 59300 107452 98200 129110 0.514 1.499 0.111 0.278 SAM001246694_LEVONORGESTREL 
6 88 0.89 
H0
4 












sample 31486 55428 109230 177750 -0.709 -0.853 0.698 1.909 SAM001246697_LAMOTRIGINE 
6 29 0.01 
C0
5 












sample 46149 67755 87940 115060 -0.065 -0.295 -0.434 -0.194 SAM001246638_ALFUZOSIN 
6 65 0.03 
F0
5 
sample 48953 75766 96070 115470 0.059 0.067 -0.002 -0.18 SAM001246639_Amisulpride 
6 77 -0.6 
G0
5 
sample 61859 67021 79600 94190 0.626 -0.328 -0.878 -0.894 SAM001246632_LOFEPRAMINE 
6 89 0.13 
H0
5 
sample 46350 195501 102130 89390 -0.056 5.48 0.32 -1.055 SAM001246688_PEROSPIRONE_HCl 
6 6 1.09 
A0
6 
























sample 18291 34245 93830 82100 -1.289 -1.81 -0.121 -1.299 SAM001246633_PAROXETINE 
6 66 0.25 
F0
6 
sample 64996 75009 72020 134870 0.764 0.033 -1.281 0.471 
SAM001246634_OLMESARTAN_MEDOXOMI
L 
6 78 1.75 
G0
6 
sample 76700 123606 143110 133480 1.279 2.23 2.5 0.424 SAM001246635_LOSARTAN_Potassium 
6 90 0.62 
H0
6 
sample 70181 79793 99660 152120 0.992 0.249 0.189 1.05 SAM001246636_TEMOZOLOMIDE 
6 7 1.15 
A0
7 
sample 23497 90964 125280 171750 -1.06 0.754 1.552 1.708 SAM001246682_Methyltestosterone 
6 19 0.32 
B0
7 











sample 36937 57208 78400 106590 -0.47 -0.772 -0.942 -0.478 SAM001246687_MECILLINAM 
6 43 -1.6 
D0
7 












sample 29661 41566 86680 103960 -0.789 -1.479 -0.501 -0.566 SAM001246679_ITRACONAZOLE 
6 79 0.23 
G0
7 
sample 72651 81485 98680 95850 1.101 0.325 0.137 -0.838 SAM001246674_CEFPODOXIME_PROXETIL 
6 91 0.29 
H0
7 
sample 62949 82352 100300 74460 0.674 0.365 0.223 -1.556 SAM001246680_Buflomedil_HCl 
6 8 0.16 
A0
8 




























sample 45905 71516 87860 88820 -0.075 -0.125 -0.439 -1.074 SAM001246618_BISOPROLOL_FUMARATE 
6 68 0.42 
F0
8 
sample 61036 183507 100990 124630 0.59 4.938 0.26 0.127 SAM001246623_EZETIMIBE 
6 80 0.1 
G0
8 






sample 1847 2092 740 970 -2.012 -3.264 -5.073 -4.021 SAM001246676_IDARUBICIN_HCl 
6 9 1 
A0
9 
sample 25856 55784 168210 205390 -0.957 -0.836 3.836 2.837 SAM001246685_FLUBENDAZOLE 
6 21 0.33 
B0
9 














sample 19804 61236 68890 124990 -1.223 -0.59 -1.448 0.139 SAM001246748_CLARITHROMYCIN 
6 57 -0.5 
E0
9 
sample 22496 76634 111220 80330 -1.104 0.106 0.804 -1.359 SAM001246750_ARIPIPRAZOLE 
6 69 0.72 
F0
9 
sample 90341 108609 94190 93360 1.878 1.552 -0.102 -0.922 SAM001246747_TRIMEBUTINE_MALEATE 
6 81 0.04 
G0
9 
sample 41922 124096 96140 123340 -0.25 2.252 0.002 0.084 SAM001246746_Mestanolone 
6 93 1.38 
H0
9 






6 10 1.03 
A1
0 
sample 75543 106339 111610 125820 1.228 1.449 0.825 0.167 SAM001246720_PICEID 
6 22 0.16 
B1
0 














sample 51089 67956 89680 105390 0.153 -0.286 -0.342 -0.518 SAM001246721_NATEGLINIDE 
6 58 1.16 
E1
0 
sample 36158 100042 129170 155310 -0.504 1.164 1.759 1.157 SAM001246722_MEGESTROL_ACETATE 
6 70 0.27 
F1
0 
sample 46083 82152 100640 129710 -0.067 0.356 0.241 0.298 SAM001246728_ORMETOPRIM 
6 82 1.03 
G1
0 
sample 44035 64752 149010 186840 -0.158 -0.431 2.814 2.214 SAM001246738_ZILEUTON 
6 94 0.42 
H1
0 
sample 40319 74409 117280 145550 -0.321 0.006 1.126 0.829 SAM001246729_STAVUDINE 
6 11 0.22 
A1
1 
sample 54583 61458 112210 124610 0.306 -0.58 0.857 0.127 SAM001246730_Gabexate-mesylate 
6 23 0.62 
B1
1 
sample 72161 125342 99100 114770 1.079 2.308 0.159 -0.203 SAM001246724_OXICONAZOLE_NITRATE 
6 35 0 
C1
1 
sample 50221 90719 78560 117450 0.114 0.743 -0.933 -0.114 SAM001246731_KITASAMYCIN 
6 47 0.05 
D1
1 
sample 61347 97550 86660 93020 0.604 1.052 -0.502 -0.933 SAM001246732_FAMCICLOVIR 
6 59 0.18 
E1
1 
sample 62971 76789 86030 128180 0.675 0.113 -0.536 0.246 SAM001246725_Sotalol hydrochloride 






sample 21094 24120 89480 110470 -1.166 -2.268 -0.352 -0.348 SAM001246778_TAXIFOLIN-(+) 
6 95 0.08 
H1
1 
sample 73652 84867 84640 111180 1.145 0.478 -0.61 -0.324 SAM001246782_ALOSETRON_HCl 













313233 329860 199128 391880 11.677 11.554 5.48 9.093 control 





191718 280360 225362 325230 6.335 9.316 6.876 6.857 control 


































bace-1 759595 637420 682672 825390 31.301 25.459 31.201 23.637 control 
7 1 0.06 
A0
1 
baseline 43130 67590 66600 70910 0.011 0.167 0.105 -0.191 control 
7 13 0.18 
B0
1 
baseline 54040 54040 79450 60010 0.94 -0.477 0.838 -0.619 control 
7 25 0.37 
C0
1 












dapt 31670 51100 26280 46130 -0.964 -0.617 -2.195 -1.164 control 
7 61 -1 
F0
1 












tapi-1 42860 45320 40920 34820 -0.012 -0.892 -1.36 -1.608 control 
7 2 0.72 
A0
2 
sample 63600 70530 58070 104800 1.753 0.306 -0.382 1.14 
SAM001246723_BUPROPION_HYDROCHLOR
IDE 
7 14 7.4 
B0
2 
sample 218380 239530 178140 157850 14.926 8.336 6.467 3.222 SAM001246718_IRSOGLADINE_MALEATE 
7 26 0.23 
C0
2 






sample 43370 46540 69550 57740 0.031 -0.834 0.273 -0.708 
SAM001246739_BENPROPERINE_PHOSPHAT
E 
7 50 0.7 
E0
2 
sample 61400 73960 62450 99660 1.566 0.469 -0.132 0.938 SAM001246740_PHENPROBAMATE 
7 62 0.43 
F0
2 
sample 50540 106730 65770 81260 0.642 2.026 0.057 0.216 
SAM001246743_MEMANTINE_HYDROCHLO
RIDE 
7 74 0.61 
G0
2 
sample 54970 82690 70720 79460 1.019 0.884 0.34 0.145 SAM001246736_Carvedilol 
7 86 1.87 
H0
2 
sample 62260 108180 103580 104140 1.639 2.095 2.214 1.114 SAM001246741_LOMIFYLLINE 
7 3 0.22 
A0
3 
sample 64980 63540 69200 80590 1.871 -0.026 0.253 0.189 SAM001246742_PAZUFLOXACIN 
7 15 0.77 
B0
3 
sample 52850 78780 82440 87970 0.838 0.698 1.008 0.479 SAM001246745_MIGLITOL 
7 27 1.71 
C0
3 
sample 69440 113540 85330 101800 2.25 2.35 1.173 1.022 SAM001246737_TRANILAST 
7 39 0.3 
D0
3 






7 51 0.32 
E0
3 












sample 53520 54520 55940 60420 0.895 -0.454 -0.503 -0.603 SAM001246655_NELFINAVIR_MESYLATE 
7 87 0.34 
H0
3 






sample 2960 4690 17570 16990 -3.408 -2.822 -2.692 -2.308 SAM001246651_TOPOTECAN_HCL 
7 16 0.28 
B0
4 






sample 12120 30930 49000 46620 -2.628 -1.575 -0.899 -1.144 SAM001246540_PRAMIPEXOLE_HCl 
7 40 -0.1 
D0
4 
























sample 39380 60530 69870 72370 -0.308 -0.169 0.291 -0.133 SAM001246603_VALDECOXIB 
7 5 0.6 
A0
5 
sample 31700 55400 117790 116960 -0.962 -0.413 3.025 1.617 SAM001246658_NAFTOPIDIL 
7 17 0.91 
B0
5 
sample 31970 68700 108430 116530 -0.939 0.219 2.491 1.6 SAM001246662_Nobiletin 
7 29 0.2 
C0
5 
sample 35400 86170 69460 79320 -0.647 1.049 0.268 0.139 SAM001246541_FINASTERIDE 
7 41 0.09 
D0
5 
























sample 51250 56170 71060 66310 0.702 -0.376 0.359 -0.371 SAM001246665_FENOLDOPAM_MESYLATE 
7 6 1.73 
A0
6 
sample 36510 95110 99430 144250 -0.552 1.474 1.977 2.689 SAM001246610_ROSIGLITAZONE_MALEATE 
7 18 0.5 
B0
6 






7 30 0.8 
C0
6 


















sample 17350 43450 47350 73680 -2.183 -0.98 -0.993 -0.082 SAM001246666_Sertraline 
7 78 1.09 
G0
6 






sample 910 830 1620 2790 -3.582 -3.006 -3.602 -2.865 
SAM001246559_EPIRUBICIN_HYDROCHLOR
IDE 
7 7 0.86 
A0
7 
sample 20960 73200 87480 115440 -1.876 0.433 1.296 1.557 SAM001246612_BICALUTAMIDE 
7 19 1.26 
B0
7 
sample 46280 77780 97540 152560 0.279 0.651 1.869 3.015 SAM001246672_BENIDIPINE_HCl 
7 31 0.95 
C0
7 
























sample 1540 700 950 700 -3.529 -3.012 -3.64 -2.947 SAM001246553_TRIPTOLIDE 
7 91 -0.9 
H0
7 
sample 48360 74790 8010 18240 0.456 0.509 -3.237 -2.259 SAM001246608_ROSIGLITAZONE_HCl 
7 8 0.68 
A0
8 
sample 46650 81650 83760 89110 0.311 0.835 1.083 0.524 SAM001246561_FTORAFUR 
7 20 0.56 
B0
8 
sample 44870 84310 67510 126990 0.159 0.961 0.157 2.011 SAM001246769_OLIGOMYCIN_C 
7 32 1.27 
C0
8 
sample 42830 92000 136920 106600 -0.014 1.326 4.116 1.21 SAM001246712_BENAZEPRIL_HCl 
7 44 0.38 
D0
8 
sample 46030 70420 72920 90880 0.258 0.301 0.465 0.593 SAM001246765_Oxymetholone 
7 56 -0.6 
E0
8 
sample 18380 48530 56590 63880 -2.095 -0.739 -0.466 -0.467 SAM001246714_IPRIFLAVONE 
7 68 0.14 
F0
8 
sample 49430 62610 57480 84470 0.547 -0.07 -0.416 0.342 SAM001246770_OXAPROZIN 
7 80 -1.3 
G0
8 

















sample 24780 35080 62660 69260 -1.551 -1.378 -0.12 -0.256 SAM001246767_Isoquercitrin 
7 21 0.05 
B0
9 
sample 37730 55770 93170 88620 -0.449 -0.395 1.62 0.504 SAM001246763_FLUMAZENIL 
7 33 0.65 
C0
9 












sample 11540 25650 31740 51010 -2.678 -1.826 -1.884 -0.972 SAM001246589_RIFABUTIN 
7 69 0.69 
F0
9 








sample 41530 53160 53100 60000 -0.125 -0.519 -0.665 -0.619 SAM001246586_TADALAFIL 
7 93 0.03 
H0
9 














sample 44730 57060 47710 52570 0.147 -0.334 -0.973 -0.911 SAM001246764_MOXONIDINE_HCl 
7 34 0.18 
C1
0 
sample 43040 59520 109900 84980 0.003 -0.217 2.574 0.362 SAM001246711_Nitrazepam 
7 46 0.34 
D1
0 
sample 51410 68190 73430 68400 0.716 0.195 0.494 -0.289 SAM001246571_PEFLOXACIN_MESYLATE 
7 58 0.74 
E1
0 
sample 56130 62930 95440 85150 1.117 -0.055 1.75 0.368 SAM001246572_VENLAFAXINE_HCl 
7 70 1.16 
F1
0 
sample 57520 86840 76050 107900 1.236 1.081 0.644 1.261 
SAM001246591_PANTOPRAZOLE_SODIUM_S
ALT 
7 82 0.21 
G1
0 








sample 38110 64630 58940 38440 -0.416 0.026 -0.332 -1.466 SAM001246588_INDINAVIR_SULPHATE 
7 11 -0.1 
A1
1 
sample 39490 60710 70930 74820 -0.299 -0.16 0.352 -0.037 SAM001246585_MIDAZOLAM_HCl 
7 23 0.94 
B1
1 
sample 54810 82490 90040 77040 1.005 0.875 1.442 0.05 SAM001246582_LAMIVUDINE 
7 35 0.29 
C1
1 
sample 49250 75400 65710 63100 0.532 0.538 0.054 -0.497 
SAM001246564_PROCARBAZINE_HYDROCH
LORIDE 
7 47 0.25 
D1
1 
















7 83 0.01 
G1
1 
sample 45010 68730 49370 72140 0.171 0.221 -0.878 -0.143 SAM001246576_TROPISETRON_HCl 
7 95 0.29 
H1
1 
sample 50390 73920 59820 78420 0.629 0.467 -0.282 0.104 SAM001246534_Ranolazine_dihydrochloride 





86100 264180 111990 349000 3.668 9.508 2.694 10.727 control 





80730 390430 148630 284930 3.211 15.507 4.784 8.212 control 





119350 289000 104350 306660 6.498 10.687 2.258 9.065 control 









































baseline 82491 78654 70150 91170 1.644 0.428 -1.14 -0.542 control 
8 25 0.45 
C0
1 






dapt 31941 50694 51440 58190 -1.001 -0.745 -1.848 -1.632 control 
8 49 -1.4 
E0
1 


















tapi-1 35922 36156 91410 77770 -0.793 -1.355 -0.335 -0.985 control 
8 2 5.21 
A0
2 
sample 154947 187285 245690 199450 5.435 4.985 5.503 3.037 SAM001246531_NITRENDIPINE 
8 14 0.54 
B0
2 
sample 68511 79014 90180 126550 0.912 0.443 -0.382 0.627 SAM001246578_SAQUINAVIR_MESYLATE 
8 26 0.65 
C0
2 












8 50 0.99 
E0
2 
sample 101911 92219 126340 121420 2.66 0.997 0.987 0.458 SAM001246574_EXEMESTANE 
8 62 0.72 
F0
2 
sample 75429 109658 96770 112370 1.274 1.729 -0.132 0.159 SAM001246708_NITAZOXANIDE 
8 74 0.57 
G0
2 
sample 62152 91048 114880 113610 0.58 0.948 0.553 0.2 SAM001246536_Diazepam 
8 86 0.75 
H0
2 








sample 71214 60477 86790 102660 1.054 -0.334 -0.51 -0.162 SAM001246528_RUTIN 
8 15 0.52 
B0
3 
sample 58387 61089 122090 127730 0.383 -0.309 0.826 0.666 SAM001246580_PENCICLOVIR 
8 27 -0.6 
C0
3 
sample 46335 76222 69700 79030 -0.248 0.326 -1.157 -0.943 SAM001246772_CALCITRIOL 
8 39 0.84 
D0
3 
sample 68799 123457 120230 127470 0.928 2.308 0.755 0.658 SAM001246532_DIPHENOXYLATE 
8 51 0.21 
E0
3 
sample 72583 84455 93450 98490 1.126 0.671 -0.258 -0.3 SAM001247005_Felbamate 
8 63 0.54 
F0
3 






sample 56261 63359 75840 104830 0.271 -0.214 -0.924 -0.091 SAM001247011_Pentoxifylline 
8 87 0.32 
H0
3 
sample 68421 96777 93090 93790 0.908 1.188 -0.271 -0.456 SAM001246596_Ketorolac-tromethamine 
8 4 0.06 
A0
4 
sample 43921 47019 113290 125700 -0.374 -0.899 0.493 0.599 SAM001246783_RITONAVIR 
8 16 0.39 
B0
4 






sample 57900 63863 97320 107620 0.357 -0.192 -0.111 0.002 SAM001246624_LINEZOLID 
8 40 -0.4 
D0
4 
sample 52532 56477 92320 77650 0.076 -0.502 -0.301 -0.989 SAM001246727_LOMERIZINE_DiHCl 
8 52 0.15 
E0
4 












sample 42660 51505 62600 77850 -0.44 -0.711 -1.425 -0.982 SAM001246546_REPAGLINIDE 
8 88 0.38 
H0
4 
sample 45992 104830 115220 113610 -0.266 1.526 0.566 0.2 SAM001246555_Ethylestrenol 
8 5 0.44 
A0
5 
sample 34697 86887 114840 117210 -0.857 0.773 0.552 0.319 SAM001246605_PTEROSTILBENE 
8 17 0 
B0
5 











sample 43921 72763 64270 76140 -0.374 0.181 -1.362 -1.039 
SAM001246556_DEXBROMPHENIRAMINE_M
ALEATE 
8 41 0.31 
D0
5 






sample 37615 42263 99890 82150 -0.704 -1.098 -0.014 -0.84 SAM001246606_TEGASEROD_MALEATE 
8 65 -0.6 
F0
5 












sample 49181 72078 86040 86680 -0.099 0.152 -0.538 -0.691 SAM001246599_Citalopram-hydrobromide 
8 6 1.01 
A0
6 
sample 66620 114756 109780 143870 0.814 1.943 0.36 1.2 SAM001246558_TICLOPIDINE_HCl 
8 18 0.35 
B0
6 
sample 72619 100002 77080 94640 1.127 1.324 -0.877 -0.427 SAM001246594_LOXOPROFEN_SODIUM 
8 30 0.02 
C0
6 












sample 37922 69142 95960 79990 -0.688 0.029 -0.163 -0.912 SAM001246584_ISRADIPINE 
8 66 0.09 
F0
6 
sample 64026 82221 89850 74890 0.678 0.578 -0.394 -1.08 SAM001246581_VALSARTAN 
8 78 0.15 
G0
6 





































































sample 36715 85049 83130 119530 -0.751 0.696 -0.648 0.395 SAM001246615_RIZATRIPTAN_BENZOATE 
8 20 0.58 
B0
8 
sample 67538 119890 86310 116680 0.862 2.158 -0.528 0.301 SAM001246620_RIFAPENTINE 
8 32 0.36 
C0
8 
sample 60783 73628 125580 101710 0.508 0.217 0.958 -0.194 
SAM001246630_LOTEPREDNOL_ETABONAT
E 
8 44 0.66 
D0
8 


















sample 20537 24825 101710 121770 -1.598 -1.83 0.055 0.469 SAM001246701_NICORANDIL 
8 92 0.07 
H0
8 






sample 44641 61954 99410 107390 -0.337 -0.272 -0.032 -0.006 SAM001246542_ITOPRIDE_HCl 
8 21 -0.7 
B0
9 































8 81 0.15 
G0
9 





8 93 1.34 
H0
9 




8 10 2.09 
A1
0 
sample 55234 72421 223550 227680 0.218 0.167 4.665 3.97 
SAM001247078_Acetamide,_2-amino-N-(1-
methyl-1,2-diphenylethyl)-,_(+/-)-_[CAS] 
8 22 0.34 
B1
0 
sample 38876 45128 150410 147150 -0.638 -0.978 1.897 1.308 SAM001247080_Altanserin 
8 34 0.66 
C1
0 
sample 46857 88850 115680 129610 -0.221 0.856 0.583 0.729 SAM001247084_Betaxolol-hydrochloride 
8 46 2.29 
D1
0 






8 58 1.54 
E1
0 
sample 66223 82509 160930 228190 0.793 0.59 2.296 3.987 SAM001247082_Azasetron 
8 70 1.21 
F1
0 
sample 65106 100938 128020 161510 0.734 1.363 1.05 1.783 SAM001247087_GR_89696 
8 82 1.66 
G1
0 




8 94 2.01 
H1
0 
sample 48965 64728 211110 232320 -0.11 -0.156 4.194 4.124 SAM001246872_DIAZOXIDE 
8 11 0.12 
A1
1 
sample 38246 41110 174340 135390 -0.671 -1.147 2.803 0.92 SAM001246886_2-CHLOROADENOSINE 
8 23 1.51 
B1
1 






sample 44353 48100 78480 102840 -0.352 -0.854 -0.824 -0.156 
SAM001246914_1,1-DIMETHYL-4-
PHENYLPIPERAZINIUM_IODIDE 
8 47 0.63 
D1
1 
sample 49830 49541 135460 162460 -0.065 -0.793 1.332 1.814 SAM001246893_PIRENPERONE 
8 59 0.01 
E1
1 
sample 33580 56856 113730 172760 -0.915 -0.486 0.51 2.155 SAM001246866_MESTRANOL 
8 71 0.33 F11 sample 53379 50658 125340 124010 0.121 -0.746 0.949 0.543 
SAM001246867_2-(2-
AMINOETHYL)PYRIDINE 
8 83 1.36 
G1
1 
sample 53901 44785 193500 185310 0.148 -0.993 3.528 2.57 
SAM001246868_BENACTYZINE_HYDROCHL
ORIDE 
8 95 0.22 
H1
1 
sample 32535 50983 131270 181460 -0.97 -0.733 1.173 2.442 SAM001246870_DICHLOROACETIC_ACID 





169053 351630 234538 248680 6.174 11.879 5.081 4.664 control 





210812 269810 152624 229070 8.359 8.447 1.981 4.016 control 





211353 233740 179970 274350 8.387 6.934 3.016 5.513 control 



































baseline 49310 46560 48910 81040 0.15 -1.101 -0.509 -0.383 control 







9 25 0.57 
C0
1 
baseline 69620 72760 81290 96410 1.348 0.167 0.977 -0.014 control 
9 37 -1.2 
D0
1 
























tapi-1 46170 58330 44540 54320 -0.035 -0.531 -0.71 -1.024 control 
9 2 3.41 
A0
2 












sample 46460 75090 40900 77970 -0.018 0.28 -0.877 -0.456 SAM001246784_GOSERELIN_ACETATE 
9 38 0.79 
D0
2 
sample 77150 123490 55560 82280 1.791 2.622 -0.204 -0.353 SAM001246678_SECOISOLARICIRESINOL 
9 50 0.36 
E0
2 
sample 59400 81460 62940 72910 0.745 0.588 0.135 -0.578 SAM001246796_RALTITREXED 
9 62 0.12 
F0
2 
sample 44160 76060 73570 93630 -0.154 0.327 0.623 -0.08 
SAM001246792_DOXAPRAM_HYDROCHLOR
IDE 
9 74 0.24 
G0
2 






sample 34350 66610 119080 90430 -0.732 -0.131 2.712 -0.157 SAM001246865_Brucine 
9 3 0.18 
A0
3 












sample 17680 40590 21880 50300 -1.715 -1.39 -1.75 -1.121 SAM001246791_PALONOSETRON_HCl 
9 39 0.25 
D0
3 
sample 74660 83220 40360 89630 1.645 0.673 -0.902 -0.176 SAM001246874_NAPROXEN_SODIUM 
9 51 0.52 
E0
3 
sample 87450 100290 47080 77800 2.399 1.5 -0.593 -0.46 
SAM001246875_MEPIVACAINE_HYDROCHL
ORIDE 
9 63 1.11 
F0
3 




9 75 1.34 
G0
3 






9 87 0.86 
H0
3 
























sample 49130 69970 46890 77790 0.139 0.032 -0.602 -0.461 SAM001246894_3-PYRIDINEMETHANOL 
9 52 0.31 
E0
4 
sample 55400 67070 62520 125070 0.509 -0.108 0.115 0.675 SAM001246979_Haloperidol 
9 64 0.59 
F0
4 
sample 66460 78370 49140 128170 1.161 0.439 -0.499 0.749 SAM001247042_Stiripentol 
9 76 0.52 
G0
4 
sample 56230 103260 70390 90000 0.558 1.643 0.477 -0.167 SAM001247034_Fluperlapine 
9 88 0.8 
H0
4 
sample 62080 83610 127540 125980 0.903 0.692 3.1 0.696 SAM001246887_OXYPHENONIUM_BROMIDE 
9 5 -0.3 
A0
5 












sample 49200 46310 67480 80940 0.144 -1.113 0.343 -0.385 SAM001246912_XANTHINOL_NICOTINATE 
9 41 0.11 
D0
5 












sample 45120 62890 60830 107170 -0.097 -0.311 0.038 0.245 SAM001246871_118-71-8 
9 77 0.37 
G0
5 
sample 43820 63880 86070 135300 -0.174 -0.263 1.196 0.92 SAM001246854_6-AMINOINDAZOLE 
9 89 1.12 
H0
5 




































9 66 0.21 
F0
6 
sample 51900 56760 74950 102190 0.303 -0.607 0.686 0.125 SAM001246524_ROPIVACAINE_HCl 
9 78 0.29 
G0
6 
sample 52830 59970 64720 164960 0.358 -0.452 0.216 1.632 SAM001246525_ANASTROZOLE 
9 90 0.45 
H0
6 






sample 27100 55030 58660 97200 -1.159 -0.691 -0.062 0.005 SAM001246906_MEDROXYPROGESTERONE 
9 19 -0.5 
B0
7 






sample 47920 53100 85080 22240 0.068 -0.785 1.151 -1.795 SAM001246908_7-NITROINDAZOLE 
9 43 0.03 
D0
7 
sample 45080 90530 51760 103600 -0.099 1.027 -0.378 0.159 SAM001246909_5-Methoxytryptamine 
9 55 0.23 
E0
7 






sample 35040 42030 29870 46160 -0.691 -1.32 -1.383 -1.22 
SAM001246526_2-CHLORO-2'-
DEOXYADENOSINE 
9 79 0.06 
G0
7 
sample 56310 71970 58160 96520 0.563 0.129 -0.085 -0.011 SAM001246527_GRANISETRON_HCl 
9 91 0.19 
H0
7 












sample 37770 70060 59120 87580 -0.53 0.036 -0.041 -0.226 SAM001246885_DESOXIMETASONE 
9 32 0.33 
C0
8 
sample 45370 49080 103450 127570 -0.082 -0.979 1.994 0.735 
SAM001246557_DEXCHLORPHENIRAMINE_
MALEATE 
9 44 0.21 
D0
8 
sample 52360 88600 57020 100940 0.33 0.934 -0.137 0.095 
SAM001247088_Guanidine,_N-cyano-N'-(1,1-
dimethylpropyl)-N''-3-pyridinyl-_[CAS] 
9 56 0.21 
E0
8 
sample 48220 93860 62840 109220 0.086 1.188 0.13 0.294 SAM001247090_L-694,247 
9 68 0.64 
F0
8 
sample 35330 58950 99010 193410 -0.674 -0.501 1.79 2.316 SAM001247081_AM-251 
9 80 0.64 
G0
8 
sample 48870 69900 85150 172770 0.124 0.029 1.154 1.82 SAM001247089_HTMT 
9 92 1.72 
H0
8 


























9 33 0.09 
C0
9 
sample 36380 50180 77430 134670 -0.612 -0.926 0.8 0.905 SAM001246898_Beclomethasone 
9 45 1.03 
D0
9 
sample 66320 109470 74450 134460 1.153 1.944 0.663 0.9 SAM001246900_OMEPRAZOLE 
9 57 0.12 
E0
9 
sample 35790 80630 53250 120020 -0.647 0.548 -0.31 0.553 SAM001246842_DOLASETRON_MESYLATE 
9 69 3.04 
F0
9 


















sample 41040 58770 73130 63460 -0.338 -0.51 0.602 -0.805 SAM001246847_Tramadol 
9 22 0.04 
B1
0 
sample 77580 76380 54410 66830 1.817 0.342 -0.257 -0.724 SAM001246815_CHLORDIAZEPOXIDE 
9 34 0.06 
C1
0 
sample 47070 77880 48530 101180 0.018 0.415 -0.527 0.101 SAM001246816_CEFIXIME_TRIHYDRATE 
9 46 0.17 
D1
0 






sample 34980 65320 52690 143960 -0.695 -0.193 -0.336 1.128 SAM001246820_LOFEXIDINE_HCl 
9 70 0.83 
F1
0 
sample 64570 83160 70360 138350 1.05 0.67 0.475 0.993 SAM001246804_BALSALAZIDE 
9 82 0.71 
G1
0 






sample 7770 15770 19270 63690 -2.299 -2.591 -1.87 -0.799 SAM001246803_ITAVASTATIN_Ca 
9 11 0.47 
A1
1 






sample 1540 16420 17010 38930 -2.666 -2.56 -1.973 -1.394 SAM001246883_Cyproheptadine-hydrochloride 
9 35 -2.7 
C1
1 






sample 57810 75470 46260 58780 0.651 0.298 -0.631 -0.917 SAM001246879_CORTICOSTERONE 
9 59 0.23 
E1
1 
sample 61870 67480 49510 120190 0.891 -0.089 -0.482 0.557 SAM001246821_VECURONIUM_BROMIDE 
9 71 0.09 F11 sample 65890 68930 49650 105630 1.128 -0.018 -0.475 0.208 SAM001246801_TIBOLONE 
9 83 0.39 
G1
1 
sample 51230 87330 57060 118840 0.263 0.872 -0.135 0.525 SAM001246860_NICOTINAMIDE 
9 95 0.97 
H1
1 











83480 237070 89330 207530 2.165 8.12 1.346 2.655 control 





100540 208370 104300 197670 3.171 6.731 2.033 2.418 control 





88400 165660 107590 156320 2.455 4.664 2.184 1.425 control 





81190 163740 96990 220190 2.03 4.571 1.698 2.959 control 
9 60 8.29 
E1
2 












bace-1 227650 608040 281300 573400 10.665 26.076 10.157 11.44 control 
9 96 11.7 
H1
2 
bace-1 271870 543840 259070 518690 13.272 22.969 9.137 10.126 control 
10 1 1.68 
A0
1 
baseline 71250 78430 111480 112490 2.869 1.635 1.733 1.295 control 
10 13 2.71 
B0
1 
baseline 121210 97190 140740 139820 6.244 2.683 2.737 2.119 control 
10 25 4.45 
C0
1 


















dapt 27830 34430 42530 27180 -0.064 -0.824 -0.633 -1.279 control 
10 73 0.02 
G0
1 
tapi-1 39720 64180 40590 46110 0.739 0.839 -0.7 -0.708 control 
10 85 1.44 
H0
1 


















sample 38080 42250 41490 53370 0.628 -0.387 -0.669 -0.489 SAM001246648_LACIDIPINE 
10 38 -0.4 
D0
2 
sample 24870 35500 45490 66470 -0.264 -0.764 -0.531 -0.094 SAM001246659_MIRTAZAPINE 
10 50 0.12 
E0
2 

















sample 8830 43400 39470 40370 -1.348 -0.322 -0.738 -0.881 SAM001246705_AMLODIPINE_BASE 
10 86 0.66 
H0
2 












sample 17710 34010 30290 26190 -0.748 -0.847 -1.053 -1.309 
SAM001246598_IRINOTECAN_HCl_)trihydrate
) 
10 27 0.36 
C0
3 










10 51 0.53 
E0
3 














sample 7580 9120 5070 6520 -1.432 -2.238 -1.918 -1.902 SAM001246880_Etoposide 
10 87 1.4 
H0
3 
sample 40630 83790 86020 177600 0.8 1.935 0.859 3.259 SAM001247105_Sibutramine 
10 4 0.2 
A0
4 












sample 25460 44930 41150 59470 -0.224 -0.237 -0.68 -0.305 SAM001246592_SIBUTRAMINE_HCl 
10 40 0.1 
D0
4 
sample 21980 48570 67510 99450 -0.459 -0.034 0.224 0.901 SAM001246833_Lorazepam 
10 52 0.22 
E0
4 





10 64 1.45 
F0
4 








sample 23860 39990 58580 37870 -0.332 -0.513 -0.082 -0.956 
SAM001246646_AMIODARONE_HYDROCHL
ORIDE 
10 88 0.15 
H0
4 
sample 39450 37990 69970 69110 0.721 -0.625 0.309 -0.014 SAM001246644_mevastatin 
10 5 0.49 
A0
5 
sample 35740 58850 75590 58350 0.47 0.541 0.502 -0.339 SAM001246622_IMATINIB_MESYLATE 
10 17 -0.2 
B0
5 
sample 29590 43600 58510 55680 0.055 -0.311 -0.085 -0.419 SAM001247102_Metylperon 
10 29 -0.1 
C0
5 











sample 25950 42570 40270 46330 -0.191 -0.369 -0.711 -0.701 SAM001247070_PERGOLIDE MESYLATE 
10 53 -0.8 
E0
5 
sample 16870 33400 37690 55020 -0.805 -0.881 -0.799 -0.439 SAM001246793_ATRACURIUM_BESYLATE 
10 65 0 
F0
5 
sample 27350 65740 60650 70040 -0.097 0.926 -0.011 0.014 SAM001246799_ARTEMETHER 
10 77 0.97 
G0
5 
sample 47890 58730 82000 110230 1.291 0.534 0.722 1.226 SAM001247071_EBSELEN 
10 89 0.77 
H0
5 






sample 22210 26580 33540 62610 -0.444 -1.262 -0.941 -0.21 SAM001246805_TELITHROMYCIN 
10 18 0.71 
B0
6 
sample 27970 44840 121290 118360 -0.055 -0.242 2.07 1.472 SAM001247065_CCPA 
10 30 0.48 
C0
6 
sample 23850 66260 61090 112350 -0.333 0.955 0.004 1.29 SAM001247067_PD_81723 
10 42 0.53 
D0
6 
sample 31620 61660 71530 111220 0.192 0.698 0.362 1.256 SAM001246590_Stanozolol 
10 54 0.86 
E0
6 
sample 29710 56180 103430 113450 0.063 0.392 1.457 1.323 SAM001246641_Zaleplon 
10 66 0.78 
F0
6 
sample 41810 64010 82160 74000 0.88 0.829 0.727 0.133 SAM001246840_Prostaglandin_E1 
10 78 1.41 
G0
6 
sample 37740 71920 106010 141540 0.605 1.271 1.545 2.171 SAM001246921_Testosterone 
10 90 2.32 
H0
6 
sample 49080 96810 124020 151900 1.371 2.662 2.163 2.483 
SAM001246922_DEHYDROEPIANDROSTERO
NE 
10 7 0.11 
A0
7 
sample 40380 59850 49950 49360 0.784 0.597 -0.378 -0.61 SAM001247099_SDM25N 
10 19 0.46 
B0
7 















sample 5850 21530 53940 96420 -1.549 -1.545 -0.241 0.81 SAM001247096_Salmeterol 
10 55 0.36 
E0
7 
sample 26880 53180 75710 120670 -0.128 0.224 0.506 1.541 SAM001247097_SB_205607 
10 67 1.58 
F0
7 
sample 61260 64620 97370 132640 2.194 0.863 1.249 1.902 SAM001247098_R(+)-SCH-23390_hydrochloride 
10 79 NA 
G0
7 
empty NA NA NA NA NA NA NA NA NA 
10 91 NA 
H0
7 
empty NA NA NA NA NA NA NA NA NA 







10 20 NA 
B0
8 
empty NA NA NA NA NA NA NA NA NA 
10 32 NA 
C0
8 
empty NA NA NA NA NA NA NA NA NA 
10 44 NA 
D0
8 
empty NA NA NA NA NA NA NA NA NA 
10 56 NA 
E0
8 
empty NA NA NA NA NA NA NA NA NA 
10 68 NA 
F0
8 
empty NA NA NA NA NA NA NA NA NA 
10 80 NA 
G0
8 
empty NA NA NA NA NA NA NA NA NA 
10 92 NA 
H0
8 
empty NA NA NA NA NA NA NA NA NA 
10 9 NA 
A0
9 
empty NA NA NA NA NA NA NA NA NA 
10 21 NA 
B0
9 
empty NA NA NA NA NA NA NA NA NA 
10 33 NA 
C0
9 
empty NA NA NA NA NA NA NA NA NA 
10 45 NA 
D0
9 
empty NA NA NA NA NA NA NA NA NA 
10 57 NA 
E0
9 
empty NA NA NA NA NA NA NA NA NA 
10 69 NA 
F0
9 
empty NA NA NA NA NA NA NA NA NA 
10 81 NA 
G0
9 
empty NA NA NA NA NA NA NA NA NA 
10 93 NA 
H0
9 
empty NA NA NA NA NA NA NA NA NA 
10 10 NA 
A1
0 
empty NA NA NA NA NA NA NA NA NA 
10 22 NA 
B1
0 
empty NA NA NA NA NA NA NA NA NA 
10 34 NA 
C1
0 
empty NA NA NA NA NA NA NA NA NA 
10 46 NA 
D1
0 
empty NA NA NA NA NA NA NA NA NA 
10 58 NA 
E1
0 
empty NA NA NA NA NA NA NA NA NA 
10 70 NA 
F1
0 






10 82 NA 
G1
0 
empty NA NA NA NA NA NA NA NA NA 
10 94 NA 
H1
0 
empty NA NA NA NA NA NA NA NA NA 
10 11 NA 
A1
1 
empty NA NA NA NA NA NA NA NA NA 
10 23 NA 
B1
1 
empty NA NA NA NA NA NA NA NA NA 
10 35 NA 
C1
1 
empty NA NA NA NA NA NA NA NA NA 
10 47 NA 
D1
1 
empty NA NA NA NA NA NA NA NA NA 
10 59 NA 
E1
1 
empty NA NA NA NA NA NA NA NA NA 
10 71 NA F11 empty NA NA NA NA NA NA NA NA NA 
10 83 NA 
G1
1 
empty NA NA NA NA NA NA NA NA NA 
10 95 NA 
H1
1 
empty NA NA NA NA NA NA NA NA NA 





98850 277940 77020 258730 4.733 12.784 0.551 5.706 control 





128870 346170 105900 325750 6.761 16.597 1.542 7.728 control 





126230 304460 138100 388750 6.583 14.266 2.647 9.628 control 
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